{"questions": [{"id": "5a67a049b750ff4455000007", "body": "Does echinacea increase anaphylaxis risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9507713", "http://www.ncbi.nlm.nih.gov/pubmed/11814277", "http://www.ncbi.nlm.nih.gov/pubmed/28731887", "http://www.ncbi.nlm.nih.gov/pubmed/18831749", "http://www.ncbi.nlm.nih.gov/pubmed/17085774", "http://www.ncbi.nlm.nih.gov/pubmed/25784510", "http://www.ncbi.nlm.nih.gov/pubmed/23024696", "http://www.ncbi.nlm.nih.gov/pubmed/26895223", "http://www.ncbi.nlm.nih.gov/pubmed/26633727", "http://www.ncbi.nlm.nih.gov/pubmed/21923308"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 33, "text": "Echinacea-associated anaphylaxis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9507713"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "A woman with atopy experienced anaphylaxis after taking, among other dietary supplements, a commercial extract of echinacea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9507713"}, {"offsetInBeginSection": 556, "offsetInEndSection": 700, "text": "Patients with atopy should be cautioned about the risk of developing life-threatening reactions to complementary medicines, including echinacea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9507713"}, {"offsetInBeginSection": 196, "offsetInEndSection": 305, "text": "Recent reports have highlighted the risk of allergic reactions to complementary medicines in atopic patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814277"}, {"offsetInBeginSection": 305, "offsetInEndSection": 423, "text": "OBJECTIVE: To determine the characteristics of adverse reactions linked to use of the popular herbal remedy echinacea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814277"}, {"offsetInBeginSection": 1155, "offsetInEndSection": 1280, "text": "Two patients suffered anaphylaxis and a third had an acute asthma attack 10 minutes after their first ever dose of echinacea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814277"}, {"offsetInBeginSection": 1281, "offsetInEndSection": 1482, "text": "The fourth patient suffered recurrent episodes of mild asthma each time echinacea was ingested, and the fifth developed a maculopapular rash within 2 days of ingestion which recurred when rechallenged.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814277"}, {"offsetInBeginSection": 1715, "offsetInEndSection": 1859, "text": "There were 26 cases suggestive of possible immunoglobulin E-mediated hypersensitivity (4 anaphylaxis, 12 acute asthma, 10 urticaria/angioedema).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814277"}, {"offsetInBeginSection": 2461, "offsetInEndSection": 2648, "text": "The possibility that cross-reactivity between echinacea and other environmental allergens may trigger allergic reactions in \"echinacea-na\u00efve\" subjects is supported by the Australian data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814277"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Risk of anaphylaxis in complementary and alternative medicine.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28731887"}]}, {"id": "58e8a2fc3e8b6dc87c00000c", "body": "Do cephalopods use RNA editing less frequently than other species?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29048557", "http://www.ncbi.nlm.nih.gov/pubmed/28388405", "http://www.ncbi.nlm.nih.gov/pubmed/28855414", "http://www.ncbi.nlm.nih.gov/pubmed/8939811", "http://www.ncbi.nlm.nih.gov/pubmed/22044752", "http://www.ncbi.nlm.nih.gov/pubmed/25347917", "http://www.ncbi.nlm.nih.gov/pubmed/26169954", "http://www.ncbi.nlm.nih.gov/pubmed/18567816", "http://www.ncbi.nlm.nih.gov/pubmed/8467802", "http://www.ncbi.nlm.nih.gov/pubmed/2480644"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Linkage of A-to-I RNA editing in metazoans and the impact on genome evolution.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The adenosine-to-inosine (A-to-I) RNA editomes have been systematically characterized in various metazoan species, and many editing sites were found in clusters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557"}, {"offsetInBeginSection": 278, "offsetInEndSection": 491, "text": "By adopting a method originally designed to detect linkage disequilibrium of DNA mutations, we examined the editomes of ten metazoan species and detected extensive linkage of editing in Drosophila and cephalopods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1304, "text": "This present study also suggests that linkage of editing should be considered in elucidating the functional consequences of RNA editing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557"}, {"offsetInBeginSection": 179, "offsetInEndSection": 313, "text": "Recent reports suggesting increased levels of RNA editing in squids thus raise the question of the nature and effects of these events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388405"}, {"offsetInBeginSection": 314, "offsetInEndSection": 475, "text": "We here show that RNA editing is particularly common in behaviorally sophisticated coleoid cephalopods, with tens of\u00a0thousands of evolutionarily conserved sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388405"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1074, "text": "This trade-off between genome evolution and transcriptome plasticity highlights the importance of RNA recoding as a strategy for diversifying proteins, particularly those associated with neural function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388405"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Nuclear and mitochondrial RNA editing systems have opposite effects on protein diversity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28855414"}, {"offsetInBeginSection": 781, "offsetInEndSection": 930, "text": "Here, phylogenetic comparisons were used to determine whether RNA editing generally restores ancestral protein sequences or creates derived variants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28855414"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1100, "text": "Unlike in mitochondrial systems, RNA editing in metazoan and fungal nuclear transcripts overwhelmingly leads to novel sequences not found in inferred ancestral proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28855414"}]}, {"id": "5a6a3335b750ff4455000025", "body": "Which algorithm is available for computing minimal absent words using external memory?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28407038", "http://www.ncbi.nlm.nih.gov/pubmed/25526884", "http://www.ncbi.nlm.nih.gov/pubmed/22974263", "http://www.ncbi.nlm.nih.gov/pubmed/19426495", "http://www.ncbi.nlm.nih.gov/pubmed/18366790", "http://www.ncbi.nlm.nih.gov/pubmed/28293277", "http://www.ncbi.nlm.nih.gov/pubmed/21386877", "http://www.ncbi.nlm.nih.gov/pubmed/22220210", "http://www.ncbi.nlm.nih.gov/pubmed/27004958", "http://www.ncbi.nlm.nih.gov/pubmed/26953874"], "snippets": [{"offsetInBeginSection": 2, "offsetInEndSection": 57, "text": "MAW: computing minimal absent words in external memory.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Motivation: The biological significance of minimal absent words has been investigated in genomes of organisms from all domains of life.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 136, "offsetInEndSection": 231, "text": "For instance, three minimal absent words of the human genome were found in Ebola virus genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 232, "offsetInEndSection": 399, "text": "There exists an O(n) -time and O(n) -space algorithm for computing all minimal absent words of a sequence of length n on a fixed-sized alphabet based on suffix arrays.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 531, "offsetInEndSection": 740, "text": "Such memory requirements are a significant hurdle to the computation of minimal absent words in large datasets.Results: We present emMAW, the first external-memory algorithm for computing minimal absent words.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 741, "offsetInEndSection": 810, "text": "A free open-source implementation of our algorithm is made available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 811, "offsetInEndSection": 916, "text": "This allows for computation of minimal absent words on far bigger data sets than was previously possible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1066, "text": "Our implementation requires less than 3\u2009h on a standard workstation to process the full human genome when as little as 1\u2009GB of RAM is made available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 1067, "offsetInEndSection": 1616, "text": "We stress that our implementation, despite making use of external memory, is fast; indeed, even on relatively smaller datasets when enough RAM is available to hold all necessary data structures, it is less than two times slower than state-of-the-art internal-memory implementations.Availability and implementation: https://github.com/solonas13/maw (free software under the terms of the GNU GPL).Contact: alice.heliou@lix.polytechnique.fr or solon.pissis@kcl.ac.uk.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Linear-time computation of minimal absent words using suffix array.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25526884"}]}, {"id": "5a7357e63b9d13c708000001", "body": "Is there an RNAi drug being developed to treat amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23432579", "http://www.ncbi.nlm.nih.gov/pubmed/27033334", "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "http://www.ncbi.nlm.nih.gov/pubmed/19495687", "http://www.ncbi.nlm.nih.gov/pubmed/26458571", "http://www.ncbi.nlm.nih.gov/pubmed/28430919", "http://www.ncbi.nlm.nih.gov/pubmed/20307511", "http://www.ncbi.nlm.nih.gov/pubmed/17456035", "http://www.ncbi.nlm.nih.gov/pubmed/25670385", "http://www.ncbi.nlm.nih.gov/pubmed/20024842"], "snippets": [{"offsetInBeginSection": 828, "offsetInEndSection": 976, "text": "But there are also reports on clinical trials in asthma, hypercholesterolemia and genetic diseases such as inherited skin disorders and amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432579"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 115, "offsetInEndSection": 246, "text": "RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 566, "offsetInEndSection": 676, "text": "To test this hypothesis, TTR-targeting siRNAs were evaluated in a murine model of hereditary ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1286, "text": "Together, the data presented herein support the therapeutic hypothesis behind TTR lowering and highlight the potential of RNAi in the treatment of patients afflicted with ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707"}, {"offsetInBeginSection": 323, "offsetInEndSection": 434, "text": "The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707"}, {"offsetInBeginSection": 1302, "offsetInEndSection": 1464, "text": "Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707"}, {"offsetInBeginSection": 378, "offsetInEndSection": 497, "text": "Given this ability, RNAi silencing strategies have been developed to inhibit viral genes and replication in host cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19495687"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1242, "text": "These findings suggest that RNAi-based drugs may offer breakthrough technology to protect and treat humans and animals from viral infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19495687"}]}, {"id": "5a87d73861bb38fb2400000b", "body": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21998885", "http://www.ncbi.nlm.nih.gov/pubmed/20621236", "http://www.ncbi.nlm.nih.gov/pubmed/24916866", "http://www.ncbi.nlm.nih.gov/pubmed/24739945", "http://www.ncbi.nlm.nih.gov/pubmed/26238868", "http://www.ncbi.nlm.nih.gov/pubmed/26341328", "http://www.ncbi.nlm.nih.gov/pubmed/28782647", "http://www.ncbi.nlm.nih.gov/pubmed/27533048", "http://www.ncbi.nlm.nih.gov/pubmed/28169013", "http://www.ncbi.nlm.nih.gov/pubmed/28989415"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Progress toward developing a carbohydrate-conjugate vaccine against Clostridium difficile ribotype 027: synthesis of the cell-surface polysaccharide PS-I repeating unit.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998885"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Clostridium difficile strain ribotype 027 is a hypervirulent pathogen that is responsible for recent, severe outbreaks of serious nosocomial infections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998885"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Infection due to C. difficile ribotype 078: first report of cases in the Republic of Ireland.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Clostridium difficile is an important healthcare-associated pathogen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}, {"offsetInBeginSection": 70, "offsetInEndSection": 174, "text": "Hypervirulent strains such as those belonging to ribotype 027 have been widely reported in recent years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}, {"offsetInBeginSection": 175, "offsetInEndSection": 344, "text": "A second strain associated with hypervirulence is ribotype 078 and the prevalence of Clostridium difficile infection (CDI) due to this ribotype appears to be increasing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}, {"offsetInBeginSection": 345, "offsetInEndSection": 516, "text": "This report describes an outbreak, in which 15cases of CDI due to ribotype 078 were detected in an Irish hospital and from a nursing home in the hospital's catchment area.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}, {"offsetInBeginSection": 517, "offsetInEndSection": 604, "text": "C. difficile ribotype 078 accounted for 15% of total isolates submitted for ribotyping.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Occurrence of Clostridium difficile infections due to PCR ribotype 027 in Bucharest, Romania.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916866"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "INTRODUCTION: Little is known about prevailing ribotypes of Clostridium difficile infection in Romania where CDI is not a mandatory notifiable disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916866"}]}, {"id": "5a67a550b750ff4455000009", "body": "Is there an association between carcinoid syndrome and mitral valve disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11568027", "http://www.ncbi.nlm.nih.gov/pubmed/7453210", "http://www.ncbi.nlm.nih.gov/pubmed/21316509", "http://www.ncbi.nlm.nih.gov/pubmed/26564596", "http://www.ncbi.nlm.nih.gov/pubmed/14626739", "http://www.ncbi.nlm.nih.gov/pubmed/7236050", "http://www.ncbi.nlm.nih.gov/pubmed/22364692", "http://www.ncbi.nlm.nih.gov/pubmed/27278349", "http://www.ncbi.nlm.nih.gov/pubmed/24812331", "http://www.ncbi.nlm.nih.gov/pubmed/146456"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Surgical management of left-sided carcinoid heart disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "BACKGROUND: Carcinoid involvement of left-sided heart valves has been reported in patients with a patent foramen ovale, carcinoid tumor of the lung, and active carcinoid syndrome with high levels of serotonin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 210, "offsetInEndSection": 378, "text": "The present study details the clinical features and surgical management of patients with carcinoid heart disease affecting both left- and right-sided valves.METHODS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 379, "offsetInEndSection": 542, "text": "RESULTS: Eleven patients (7 men, 4 women) with symptomatic carcinoid heart disease underwent surgery for left- and right-sided valve disease between 1989 and 1999.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 690, "offsetInEndSection": 793, "text": "Of 11 patients, 5 (45%) had a patent foramen ovale; 1 of these also had a primary lung carcinoid tumor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 794, "offsetInEndSection": 1053, "text": "Surgery included tricuspid valve replacement in all patients, pulmonary valve replacement in 3 and valvectomy in 7, mitral valve replacement in 6 and repair in 1, aortic valve replacement in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1108, "text": "One myocardial metastatic carcinoid tumor was removed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 1313, "offsetInEndSection": 1464, "text": "CONCLUSIONS: Carcinoid heart disease may affect left- and right-sided valves and occurred without intracardiac shunting in 55% of this surgical series.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 1575, "offsetInEndSection": 1700, "text": "Cardiac surgery should be considered for select patients with carcinoid heart disease affecting left- and right-sided valves.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Porcine heterograft valve replacement in carcinoid heart disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7453210"}]}, {"id": "58eb99f3eda5a57672000009", "body": "Do origins of replication close to yeast centromeres fire early or late?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15294892", "http://www.ncbi.nlm.nih.gov/pubmed/18093330", "http://www.ncbi.nlm.nih.gov/pubmed/9783589", "http://www.ncbi.nlm.nih.gov/pubmed/22589733", "http://www.ncbi.nlm.nih.gov/pubmed/17304213", "http://www.ncbi.nlm.nih.gov/pubmed/22081599", "http://www.ncbi.nlm.nih.gov/pubmed/20865002", "http://www.ncbi.nlm.nih.gov/pubmed/20808889", "http://www.ncbi.nlm.nih.gov/pubmed/22081107", "http://www.ncbi.nlm.nih.gov/pubmed/12167157"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Enforcement of late replication origin firing by clusters of short G-rich DNA sequences.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Previous studies in budding yeast suggested that the default firing time of most DNA replication origins is early in S phase and that origins can be forced to fire later by proximity to certain cis-acting sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 275, "offsetInEndSection": 382, "text": "We have attempted to characterize cis-acting sequences that affect replication timing in the fission yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 383, "offsetInEndSection": 475, "text": "We identified a stretch of 200 bp that was sufficient to compel nearby origins to fire late.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 476, "offsetInEndSection": 620, "text": "The 200-bp stretch was able to force an origin to fire late whether adjacent to the origin or approximately 800 bp away in opposite orientation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 621, "offsetInEndSection": 724, "text": "The stretch contains a cluster of three close matches to a G-rich, 10-bp late consensus sequence (LCS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 725, "offsetInEndSection": 853, "text": "The three LCS elements cooperate with each other and with other sequences within the 200-bp stretch to enforce late replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 854, "offsetInEndSection": 1011, "text": "Although only a few origins that fire in very late S phase have been identified in fission yeast, all of them are located close to a cluster of LCS elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294892"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Checkpoint independence of most DNA replication origins in fission yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18093330"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "BACKGROUND: In budding yeast, the replication checkpoint slows progress through S phase by inhibiting replication origin firing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18093330"}]}, {"id": "5a6d0727b750ff445500002b", "body": "Is there any role of 5hmC in T-cell development and differentiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25071199", "http://www.ncbi.nlm.nih.gov/pubmed/27252783", "http://www.ncbi.nlm.nih.gov/pubmed/22956496", "http://www.ncbi.nlm.nih.gov/pubmed/27346350", "http://www.ncbi.nlm.nih.gov/pubmed/26363184", "http://www.ncbi.nlm.nih.gov/pubmed/26115768", "http://www.ncbi.nlm.nih.gov/pubmed/21750410", "http://www.ncbi.nlm.nih.gov/pubmed/25200796", "http://www.ncbi.nlm.nih.gov/pubmed/24615693", "http://www.ncbi.nlm.nih.gov/pubmed/23958281"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Dissecting the dynamic changes of 5-hydroxymethylcytosine in T-cell development and differentiation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199"}, {"offsetInBeginSection": 173, "offsetInEndSection": 319, "text": "We have mapped 5-hydroxymethylcytosine (5hmC) at different stages of T-cell development in the thymus and T-cell differentiation in the periphery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199"}, {"offsetInBeginSection": 786, "offsetInEndSection": 927, "text": "Our data constitute a valuable resource that will facilitate detailed analysis of the role of 5hmC in T-cell development and differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "BACKGROUND: Hematopoietic stem cell renewal and differentiation are regulated through epigenetic processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 108, "offsetInEndSection": 306, "text": "The conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC) by ten-eleven-translocation enzymes provides new insights into the epigenetic regulation of gene expression during development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 307, "offsetInEndSection": 394, "text": "Here, we studied the potential gene regulatory role of 5hmC during human hematopoiesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 394, "offsetInEndSection": 590, "text": "RESULTS: We used reduced representation of 5-hydroxymethylcytosine profiling (RRHP) to characterize 5hmC distribution in CD34+ cells, CD4+ T cells, CD19+ B cells, CD14+ monocytes and granulocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 799, "offsetInEndSection": 906, "text": "In CD34+ cells, 5hmC primes for the expression of genes regulating myeloid and lymphoid lineage commitment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 907, "offsetInEndSection": 1075, "text": "Throughout blood cell differentiation, intragenic 5hmC is maintained at genes that are highly expressed and required for acquisition of the mature blood cell phenotype.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}]}, {"id": "5a74a4be0384be9551000004", "body": "Are there RNAi approaches considered for the treatment of kidney injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20588055", "http://www.ncbi.nlm.nih.gov/pubmed/27009268", "http://www.ncbi.nlm.nih.gov/pubmed/20217562", "http://www.ncbi.nlm.nih.gov/pubmed/27253415", "http://www.ncbi.nlm.nih.gov/pubmed/23627598", "http://www.ncbi.nlm.nih.gov/pubmed/27867451", "http://www.ncbi.nlm.nih.gov/pubmed/23968852", "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "http://www.ncbi.nlm.nih.gov/pubmed/24090239", "http://www.ncbi.nlm.nih.gov/pubmed/23035592"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Knockdown of Cyclophilin D Gene by RNAi Protects Rat from Ischemia/ Reperfusion-Induced Renal Injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 11, "offsetInEndSection": 127, "text": "AIMS: Mitochondrial permeability transition has a critical role in ischemia/reperfusion (I/R)-induced kidney injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 379, "offsetInEndSection": 455, "text": "Much evidence shows that CypD plays an important role in I/R-induced injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 455, "offsetInEndSection": 644, "text": "METHODS: To evaluate the role of CypD following I/R renal injury, we tested the hypothesis that knockdown of CypD gene by RNA interference (RNAi) protects rat from I/R-induced renal injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 644, "offsetInEndSection": 771, "text": "RESULTS: Our data show that knockdown of CypD by RNAi protects normal rat kidney cell line from hypoxia-induced necrotic death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1027, "text": "Both pathologic and biochemical analyses show that knockdown of CypD by RNAi protects rat kidney from I/R-induced renal injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1147, "text": "CONCLUSION: Our study provides the evidence that CypD may be a potential target for protecting I/R-induced renal injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268"}, {"offsetInBeginSection": 278, "offsetInEndSection": 487, "text": "Herein, we describe ammonium-functionalized carbon nanotube (fCNT)-mediated transport of siRNA selectively and with high efficiency to renal proximal tubule cells in animal models of acute kidney injury (AKI).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268"}, {"offsetInBeginSection": 1281, "offsetInEndSection": 1461, "text": "The rapid and kidney-specific pharmacokinetic profile of fCNT in primates was comparable to what was observed in mice and suggests that this approach is amenable for use in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268"}]}, {"id": "5a87e95461bb38fb2400000c", "body": "Which is the transcriptome of RNA polymerase III?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20413673", "http://www.ncbi.nlm.nih.gov/pubmed/17977614", "http://www.ncbi.nlm.nih.gov/pubmed/21417954", "http://www.ncbi.nlm.nih.gov/pubmed/20418882", "http://www.ncbi.nlm.nih.gov/pubmed/24564208", "http://www.ncbi.nlm.nih.gov/pubmed/28228471", "http://www.ncbi.nlm.nih.gov/pubmed/14634212", "http://www.ncbi.nlm.nih.gov/pubmed/27506977", "http://www.ncbi.nlm.nih.gov/pubmed/16166643", "http://www.ncbi.nlm.nih.gov/pubmed/15121834"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Defining the RNA polymerase III transcriptome: Genome-wide localization of the RNA polymerase III transcription machinery in human cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Our view of the RNA polymerase III (Pol III) transcription machinery in mammalian cells arises mostly from studies of the RN5S (5S) gene, the Ad2 VAI gene, and the RNU6 (U6) gene, as paradigms for genes with type 1, 2, and 3 promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 236, "offsetInEndSection": 343, "text": "Recruitment of Pol III onto these genes requires prior binding of well-characterized transcription factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 344, "offsetInEndSection": 548, "text": "Technical limitations in dealing with repeated genomic units, typically found at mammalian Pol III genes, have so far hampered genome-wide studies of the Pol III transcription machinery and transcriptome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 549, "offsetInEndSection": 627, "text": "We have localized, genome-wide, Pol III and some of its transcription factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 628, "offsetInEndSection": 782, "text": "Our results reveal broad usage of the known Pol III transcription machinery and define a minimal Pol III transcriptome in dividing IMR90hTert fibroblasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 783, "offsetInEndSection": 975, "text": "This transcriptome consists of some 500 actively transcribed genes including a few dozen candidate novel genes, of which we confirmed nine as Pol III transcription units by additional methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1214, "text": "It does not contain any of the microRNA genes previously described as transcribed by Pol III, but reveals two other microRNA genes, MIR886 (hsa-mir-886) and MIR1975 (RNY5, hY5, hsa-mir-1975), which are genuine Pol III transcription units.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "The expanding RNA polymerase III transcriptome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977614"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "The role of RNA polymerase (Pol) III in eukaryotic transcription is commonly thought of as being restricted to a small set of highly expressed, housekeeping non-protein-coding (nc)RNA genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977614"}]}, {"id": "5a67a72fb750ff445500000a", "body": "Is propranolol used for treatment of infantile hemangioma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24346925", "http://www.ncbi.nlm.nih.gov/pubmed/21385205", "http://www.ncbi.nlm.nih.gov/pubmed/23519547", "http://www.ncbi.nlm.nih.gov/pubmed/25535459", "http://www.ncbi.nlm.nih.gov/pubmed/24352207", "http://www.ncbi.nlm.nih.gov/pubmed/24505868", "http://www.ncbi.nlm.nih.gov/pubmed/26400030", "http://www.ncbi.nlm.nih.gov/pubmed/22503260", "http://www.ncbi.nlm.nih.gov/pubmed/22299307", "http://www.ncbi.nlm.nih.gov/pubmed/21402978"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Propranolol for treatment of infantile hemangiomas.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346925"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Infantile hemangioma is the most common vascular tumor in early childhood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346925"}, {"offsetInBeginSection": 75, "offsetInEndSection": 181, "text": "Propranolol has been successfully used recently in a limited number of children with Infantile hemangioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346925"}, {"offsetInBeginSection": 182, "offsetInEndSection": 315, "text": "We present 6 cases of Infantile hemangioma, at a single dermatological center, which responded to oral propranolol with good results.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346925"}, {"offsetInBeginSection": 0, "offsetInEndSection": 38, "text": "Propranolol for infantile hemangiomas.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Propranolol has been used successfully in a limited number of children with infantile hemangiomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}, {"offsetInBeginSection": 99, "offsetInEndSection": 218, "text": "This multicenter retrospective study describes the efficacy and adverse effects of propranolol in infantile hemangioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}, {"offsetInBeginSection": 219, "offsetInEndSection": 342, "text": "Seventy-one infants with infantile hemangiomas were treated with oral propranolol, 1 mg/kg/12 hours, for at least 12 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}, {"offsetInBeginSection": 343, "offsetInEndSection": 563, "text": "A photograph based severity scoring assessment was performed by five observers to evaluate efficacy, utilizing a scoring system of 10 as the original infantile hemangioma before treatment and 0 as completely normal skin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}, {"offsetInBeginSection": 636, "offsetInEndSection": 723, "text": "Propranolol was a rapid and effective treatment for infantile hemangiomas at 4 weeks (p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}]}, {"id": "58ede257eda5a57672000010", "body": "What is the genetic basis of the Delayed Sleep-Phase Syndrome (DSPS)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8255922", "http://www.ncbi.nlm.nih.gov/pubmed/23250347", "http://www.ncbi.nlm.nih.gov/pubmed/17964201", "http://www.ncbi.nlm.nih.gov/pubmed/18571740", "http://www.ncbi.nlm.nih.gov/pubmed/14592284", "http://www.ncbi.nlm.nih.gov/pubmed/10875562", "http://www.ncbi.nlm.nih.gov/pubmed/11306557", "http://www.ncbi.nlm.nih.gov/pubmed/16295212", "http://www.ncbi.nlm.nih.gov/pubmed/11186112", "http://www.ncbi.nlm.nih.gov/pubmed/11763990"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "In human delayed sleep-phase syndrome (DSPS), sleep onset and wake times occur far later than normal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 102, "offsetInEndSection": 196, "text": "In the population, DSPS may be an important contributor to complaints of sleep onset insomnia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 197, "offsetInEndSection": 372, "text": "We previously reported an animal model of DSPS in laboratory rats in which the onset of nocturnal activity is delayed by several hours [negative phase angle difference (PAD)].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 830, "offsetInEndSection": 950, "text": "This effect of melatonin on the phase angle of entrained rats is consistent with its effects on delayed sleep in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1031, "text": "It is likely, therefore, that S20098 may be of use to ameliorate DSPS in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Total sleep deprivation study in delayed sleep-phase syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23250347"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Delayed sleep-phase syndrome (DSPS) is characterized by delayed sleep onset against the desired clock time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23250347"}, {"offsetInBeginSection": 212, "offsetInEndSection": 327, "text": "We report the finding of sleep studies after 24 h total sleep deprivation (TSD) in a 28-year-old DSPS male patient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23250347"}, {"offsetInBeginSection": 328, "offsetInEndSection": 446, "text": "He had characteristics of mild chronic DSPS, which may have been precipitated by his frequent night shift assignments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23250347"}]}, {"id": "5a6d0b2db750ff445500002d", "body": "Which factors drive replisome disassembly during DNA replication termination and mitosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28368371", "http://www.ncbi.nlm.nih.gov/pubmed/25342805", "http://www.ncbi.nlm.nih.gov/pubmed/28235849", "http://www.ncbi.nlm.nih.gov/pubmed/25835602", "http://www.ncbi.nlm.nih.gov/pubmed/28537574", "http://www.ncbi.nlm.nih.gov/pubmed/26322582", "http://www.ncbi.nlm.nih.gov/pubmed/27086594", "http://www.ncbi.nlm.nih.gov/pubmed/26255844", "http://www.ncbi.nlm.nih.gov/pubmed/15916609", "http://www.ncbi.nlm.nih.gov/pubmed/28092263"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Replisome disassembly is the final step of DNA replication in eukaryotes, involving the ubiquitylation and CDC48-dependent dissolution of the CMG helicase (CDC45-MCM-GINS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368371"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Polyubiquitylation drives replisome disassembly at the termination of DNA replication.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342805"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Resolution of replication forks during termination of DNA replication is essential for accurate duplication of eukaryotic genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342805"}, {"offsetInBeginSection": 529, "offsetInEndSection": 653, "text": "The Mcm7 subunit is the only component of the active helicase that we find polyubiquitylated during replication termination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342805"}, {"offsetInBeginSection": 764, "offsetInEndSection": 891, "text": "Altogether, our data provide insight into the mechanism of replisome disassembly during eukaryotic DNA replication termination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342805"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A key event during eukaryotic replication termination is the removal of the CMG helicase from chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28235849"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Termination of DNA replication forks: \"Breaking up is hard to do\".", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25835602"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "To ensure duplication of the entire genome, eukaryotic DNA replication initiates from thousands of replication origins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25835602"}, {"offsetInBeginSection": 222, "offsetInEndSection": 358, "text": "During replication fork termination forks converge, the replisomes disassemble and topoisomerase II resolves the daughter DNA molecules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25835602"}, {"offsetInBeginSection": 484, "offsetInEndSection": 593, "text": "Our recent findings shed light onto the mechanism of replisome disassembly upon replication fork termination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25835602"}]}, {"id": "5a75fec383b0d9ea6600000b", "body": "Can the CEP290 gene mutations be targeted by AAV-mediated gene therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28109959", "http://www.ncbi.nlm.nih.gov/pubmed/28679290", "http://www.ncbi.nlm.nih.gov/pubmed/10775597", "http://www.ncbi.nlm.nih.gov/pubmed/15960597", "http://www.ncbi.nlm.nih.gov/pubmed/21257638", "http://www.ncbi.nlm.nih.gov/pubmed/9282169", "http://www.ncbi.nlm.nih.gov/pubmed/17724218", "http://www.ncbi.nlm.nih.gov/pubmed/24807808", "http://www.ncbi.nlm.nih.gov/pubmed/26325627", "http://www.ncbi.nlm.nih.gov/pubmed/22142163"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "As the most common subtype of Leber congenital amaurosis (LCA), LCA10 is a severe retinal dystrophy caused by mutations in the CEP290 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109959"}, {"offsetInBeginSection": 140, "offsetInEndSection": 277, "text": "The most frequent mutation found in patients with LCA10 is a deep intronic mutation in CEP290 that generates a cryptic splice donor site.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109959"}, {"offsetInBeginSection": 278, "offsetInEndSection": 396, "text": "The large size of the CEP290 gene prevents its use in adeno-associated virus (AAV)-mediated gene augmentation therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109959"}, {"offsetInBeginSection": 397, "offsetInEndSection": 651, "text": "Here, we show that targeted genomic deletion using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system represents a promising therapeutic approach for the treatment of patients with LCA10 bearing the CEP290 splice mutation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109959"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1055, "text": "In addition, we demonstrated that a dual AAV system could effectively delete an intronic fragment of the Cep290 gene in the mouse retina.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109959"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28679290"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Design and packaging of adeno-associated virus gene targeting vectors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10775597"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "Adeno-associated virus (AAV) vectors can transduce cells by several mechanisms, including (i) gene addition by chromosomal integration or episomal transgene expression or (ii) gene targeting by modification of homologous chromosomal sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10775597"}, {"offsetInBeginSection": 366, "offsetInEndSection": 563, "text": "In this study, we used retroviral vectors to introduce mutant alkaline phosphatase reporter genes into normal human cells and subsequently corrected these mutations with AAV gene targeting vectors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10775597"}, {"offsetInBeginSection": 564, "offsetInEndSection": 775, "text": "We find that increasing the length of homology between the AAV vector and the target locus improves gene correction rates, as does positioning the mutation to be corrected in the center of the AAV vector genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10775597"}]}, {"id": "5a87ea1861bb38fb2400000d", "body": "What is a coligo?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24531370", "http://www.ncbi.nlm.nih.gov/pubmed/25764216", "http://www.ncbi.nlm.nih.gov/pubmed/27593562"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "New insights into the promoterless transcription of DNA coligo templates by RNA polymerase III.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}, {"offsetInBeginSection": 450, "offsetInEndSection": 611, "text": "By using immunoprecipitated RNA polymerase III we now report corroborating evidence that this enzyme is the sole polymerase responsible for coligo transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}, {"offsetInBeginSection": 612, "offsetInEndSection": 774, "text": "The immobilized polymerase enabled experiments showing that coligo transcripts can be formed through transcription termination without subsequent 3' end trimming.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1124, "text": "The results show that unpaired nucleotides in the coligo stem facilitate circumtranscription, but also that internal loops and bulges should be kept small to avoid secondary transcription initiation sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "New insights into the promoterless transcription of DNA coligo templates by RNA polymerase III.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764216"}, {"offsetInBeginSection": 450, "offsetInEndSection": 611, "text": "By using immunoprecipitated RNA polymerase III we now report corroborating evidence that this enzyme is the sole polymerase responsible for coligo transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764216"}, {"offsetInBeginSection": 612, "offsetInEndSection": 774, "text": "The immobilized polymerase enabled experiments showing that coligo transcripts can be formed through transcription termination without subsequent 3' end trimming.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764216"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1124, "text": "The results show that unpaired nucleotides in the coligo stem facilitate circumtranscription, but also that internal loops and bulges should be kept small to avoid secondary transcription initiation sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764216"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "RNA polymerase III initiation on coligo DNA templates containing loops of variable sequence, size and nucleotide chemistry.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}, {"offsetInBeginSection": 160, "offsetInEndSection": 347, "text": "Here we randomized the 12-nucleotide larger loop (L-loop) of a well characterized coligo and found unexpectedly that in vitro transcription by FLAG-Pol III was not significantly affected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}]}, {"id": "5a67b2f7b750ff445500000f", "body": "Which type of urinary incontinence is diagnosed with the Q tip test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25966437", "http://www.ncbi.nlm.nih.gov/pubmed/3056562", "http://www.ncbi.nlm.nih.gov/pubmed/10423870", "http://www.ncbi.nlm.nih.gov/pubmed/18214136", "http://www.ncbi.nlm.nih.gov/pubmed/15195034", "http://www.ncbi.nlm.nih.gov/pubmed/3585870", "http://www.ncbi.nlm.nih.gov/pubmed/20141914", "http://www.ncbi.nlm.nih.gov/pubmed/8729187", "http://www.ncbi.nlm.nih.gov/pubmed/3368164", "http://www.ncbi.nlm.nih.gov/pubmed/3945436"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Comparison of TVT and TOT on urethral mobility and surgical outcomes in stress urinary incontinence with hypermobile urethra.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "OBJECTIVE: To compare the change of urethral mobility after midurethral sling procedures in stress urinary incontinence with hypermobile urethra and assess these findings with surgical outcomes.STUDY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 200, "offsetInEndSection": 398, "text": "DESIGN: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 399, "offsetInEndSection": 460, "text": "Preoperatively, urethral mobility was measured by Q tip test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 631, "offsetInEndSection": 715, "text": "Six months postoperatively, Q tip test and quality of life assessment were repeated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1129, "text": "In both TOT and TVT groups, postoperative Q tip test values, IIQ-7 and UDI-6 scores were statistically reduced when compared with preoperative values.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 1130, "offsetInEndSection": 1263, "text": "Postoperative Q tip test value in TVT group was significantly smaller than in TOT group [25\u00b0(15-45\u00b0) and 20\u00b0 (15-45\u00b0), respectively].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1402, "text": "When we compared the Q-tip test value, IIQ-7 and UDI-6 scores changes, there were no statistically significant changes between the groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Transrectal ultrasound versus cystography in the evaluation of anatomical stress urinary incontinence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3056562"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Thirty-two female patients with clinical and urodynamic findings of genuine stress urinary incontinence were evaluated before and 6 months after surgery for stress urinary incontinence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3056562"}]}, {"id": "58edf567eda5a57672000011", "body": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22833514", "http://www.ncbi.nlm.nih.gov/pubmed/22759512", "http://www.ncbi.nlm.nih.gov/pubmed/19487478", "http://www.ncbi.nlm.nih.gov/pubmed/22544737", "http://www.ncbi.nlm.nih.gov/pubmed/24939385", "http://www.ncbi.nlm.nih.gov/pubmed/19795912", "http://www.ncbi.nlm.nih.gov/pubmed/20630871", "http://www.ncbi.nlm.nih.gov/pubmed/19577518", "http://www.ncbi.nlm.nih.gov/pubmed/21602344", "http://www.ncbi.nlm.nih.gov/pubmed/22719925"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "The Mycobacterium DosR regulon structure and diversity revealed by comparative genomic analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), which claims approximately two million people annually, remains a global health concern.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 152, "offsetInEndSection": 313, "text": "The non-replicating or dormancy like state of this pathogen which is impervious to anti-tuberculosis drugs is widely recognized as the culprit for this scenario.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 314, "offsetInEndSection": 438, "text": "The dormancy survival regulator (DosR) regulon, composed of 48 co-regulated genes, is held as essential for Mtb persistence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 439, "offsetInEndSection": 614, "text": "The DosR regulon is regulated by a two-component regulatory system consisting of two sensor kinases-DosS (Rv3132c) and DosT (Rv2027c), and a response regulator DosR (Rv3133c).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 615, "offsetInEndSection": 694, "text": "The underlying regulatory mechanism of DosR regulon expression is very complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 755, "offsetInEndSection": 827, "text": "The DosR regulon enables the pathogen to persist during lengthy hypoxia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1012, "text": "Comparative genomic analysis demonstrated that the DosR regulon is widely distributed among the mycobacterial genomes, ranging from the pathogenic strains to the environmental strains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 1013, "offsetInEndSection": 1181, "text": "In-depth studies on the DosR response should provide insights into its role in TB latency in vivo and shape new measures to combat this exceeding recalcitrant pathogen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "In silico analysis of DosR regulon proteins of Mycobacterium tuberculosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759512"}]}, {"id": "5a6d1143b750ff445500002e", "body": "List the partners of budding yeast Cdc48 that are important for disassembly of ubiquitylated CMG helicase at the end of chromosome replication", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28355556", "http://www.ncbi.nlm.nih.gov/pubmed/25342810", "http://www.ncbi.nlm.nih.gov/pubmed/26255844", "http://www.ncbi.nlm.nih.gov/pubmed/28235849", "http://www.ncbi.nlm.nih.gov/pubmed/28368371", "http://www.ncbi.nlm.nih.gov/pubmed/24307213", "http://www.ncbi.nlm.nih.gov/pubmed/16103218", "http://www.ncbi.nlm.nih.gov/pubmed/22285032", "http://www.ncbi.nlm.nih.gov/pubmed/22718908", "http://www.ncbi.nlm.nih.gov/pubmed/24121501"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Ufd1-Npl4 Recruit Cdc48 for Disassembly of Ubiquitylated CMG Helicase at the End of Chromosome Replication.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "Disassembly of the Cdc45-MCM-GINS (CMG) DNA helicase is the key regulated step during DNA replication termination in eukaryotes, involving ubiquitylation of the Mcm7 helicase subunit, leading to a disassembly process that requires the Cdc48 \"segregase\".", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 254, "offsetInEndSection": 425, "text": "Here, we employ a screen to identify partners of budding yeast Cdc48 that are important for disassembly of ubiquitylated CMG helicase at the end of chromosome replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 426, "offsetInEndSection": 522, "text": "We demonstrate that the ubiquitin-binding Ufd1-Npl4 complex recruits Cdc48 to ubiquitylated CMG.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 749, "offsetInEndSection": 988, "text": "Mutation of K29 abrogates in\u00a0vitro recruitment of Ufd1-Npl4-Cdc48 to the CMG helicase, supporting a model whereby Ufd1-Npl4 recruits Cdc48 to ubiquitylated CMG at the end of chromosome replication, thereby driving the disassembly reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Cdc48 and a ubiquitin ligase drive disassembly of the CMG helicase at the end of DNA replication.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Chromosome replication is initiated by a universal mechanism in eukaryotic cells, involving the assembly and activation at replication origins of the CMG (Cdc45-MCM-GINS) DNA helicase, which is essential for the progression of replication forks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}, {"offsetInBeginSection": 246, "offsetInEndSection": 380, "text": "Disassembly of CMG is likely to be a key regulated step at the end of chromosome replication, but the mechanism was unknown until now.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}, {"offsetInBeginSection": 381, "offsetInEndSection": 548, "text": "Here we show that the ubiquitin ligase known as SCF(Dia2) promotes ubiquitylation of CMG during the final stages of chromosome replication in Saccharomyces cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}, {"offsetInBeginSection": 549, "offsetInEndSection": 653, "text": "The Cdc48/p97 segregase then associates with ubiquitylated CMG, leading rapidly to helicase disassembly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}]}, {"id": "5a76039b83b0d9ea66000010", "body": "What are jakinibs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26994322", "http://www.ncbi.nlm.nih.gov/pubmed/29104284", "http://www.ncbi.nlm.nih.gov/pubmed/28255960", "http://www.ncbi.nlm.nih.gov/pubmed/22819198", "http://www.ncbi.nlm.nih.gov/pubmed/26633291", "http://www.ncbi.nlm.nih.gov/pubmed/27821272", "http://www.ncbi.nlm.nih.gov/pubmed/28323260"], "snippets": [{"offsetInBeginSection": 698, "offsetInEndSection": 870, "text": "Given these promising findings, Jakinibs are expected to represent the next generation compounds for treating RA, and a number of Jakinibs are currently in clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26994322"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1060, "text": "Jakinibs can differ substantially in their selectivity against JAKs; tofacitinib and baricitinib target multiple JAKs, whereas the most recently developed Jakinibs target only a single JAK.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26994322"}, {"offsetInBeginSection": 138, "offsetInEndSection": 467, "text": "Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-molecule inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104284"}, {"offsetInBeginSection": 468, "offsetInEndSection": 662, "text": "Building on the clinical success of first-generation jakinibs, second-generation compounds that claim to be more selective are currently undergoing development and proceeding to clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104284"}, {"offsetInBeginSection": 663, "offsetInEndSection": 865, "text": "However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104284"}, {"offsetInBeginSection": 866, "offsetInEndSection": 1102, "text": "This Review discusses the biology of jakinibs from a translational perspective, focusing on recent insights from clinical trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104284"}, {"offsetInBeginSection": 930, "offsetInEndSection": 1021, "text": "Many other Jakinibs are in preclinical development or in various phases of clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255960"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1345, "text": "The safety and clinical efficacy of the Jakinibs are reviewed, starting with the FDA-approved Jakinib tofacitinib, and continuing on to next-generation Jakinibs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255960"}, {"offsetInBeginSection": 587, "offsetInEndSection": 735, "text": "Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacological agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819198"}, {"offsetInBeginSection": 1044, "offsetInEndSection": 1191, "text": "Jakinibs are currently being investigated for a number of new indications, and second-generation selective Jakinibs are being developed and tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633291"}]}, {"id": "5a87efa961bb38fb2400000e", "body": "Are mutations in the nf1 gene associated with memory?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24334617", "http://www.ncbi.nlm.nih.gov/pubmed/25788518", "http://www.ncbi.nlm.nih.gov/pubmed/9639526", "http://www.ncbi.nlm.nih.gov/pubmed/12707950", "http://www.ncbi.nlm.nih.gov/pubmed/23047742", "http://www.ncbi.nlm.nih.gov/pubmed/8528106", "http://www.ncbi.nlm.nih.gov/pubmed/19475561", "http://www.ncbi.nlm.nih.gov/pubmed/25403449", "http://www.ncbi.nlm.nih.gov/pubmed/22207399", "http://www.ncbi.nlm.nih.gov/pubmed/22869071"], "snippets": [{"offsetInBeginSection": 279, "offsetInEndSection": 461, "text": "Individuals with Legius syndrome have multiple CALMs with or without freckling, but they do not show the typical NF1-associated tumors such as neurofibromas or optic pathway gliomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24334617"}, {"offsetInBeginSection": 680, "offsetInEndSection": 882, "text": "The SPRED1 gene was identified in 2001 and codes for a protein that downregulates the RAS-mitogen activated protein kinase (RAS-MAPK) pathway; as does neurofibromin, the protein encoded by the NF1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24334617"}, {"offsetInBeginSection": 1118, "offsetInEndSection": 1370, "text": "Mice with homozygous knockout of the Spred1 gene show learning deficits and decreased synaptic plasticity in hippocampal neurons similar to those seen in Nf1 heterozygous mice, underlining the importance of the RAS-MAPK pathway for learning and memory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24334617"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Neurofibromatosis type 1 (NF1) is a common autosomal dominant neurologic condition characterized by significant clinical heterogeneity, ranging from malignant cancers to cognitive deficits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}, {"offsetInBeginSection": 372, "offsetInEndSection": 510, "text": "The purpose of this study was to define the impact of the germline NF1 gene mutation on brain neurofibromin function relevant to learning.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}, {"offsetInBeginSection": 511, "offsetInEndSection": 743, "text": "Herein, we employ human NF1-patient primary skin fibroblasts, induced pluripotent stem cells and derivative neural progenitor cells (NPCs) to demonstrate that NF1 germline mutations have dramatic effects on neurofibromin expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1211, "text": "Additionally, we leveraged two complementary Nf1 genetically-engineered mouse strains in which hippocampal-based learning and memory is DA-dependent to establish that neuronal DA levels and signaling as well as mouse spatial learning are controlled in an Nf1 gene dose-dependent manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Juvenile myelomonocytic leukemia (JMML) is a pediatric myelodysplastic syndrome that is associated with neurofibromatosis, type 1 (NF1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9639526"}, {"offsetInBeginSection": 137, "offsetInEndSection": 309, "text": "The NF1 tumor suppressor gene encodes neurofibromin, which regulates the growth of immature myeloid cells by accelerating guanosine triphosphate hydrolysis on Ras proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9639526"}, {"offsetInBeginSection": 310, "offsetInEndSection": 458, "text": "The purpose of this study was to determine if the NF1 gene was involved in the pathogenesis of JMML in children without a clinical diagnosis of NF1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9639526"}]}, {"id": "5a68f2bab750ff4455000017", "body": "Is tretinoin effective for photoaging?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9703125", "http://www.ncbi.nlm.nih.gov/pubmed/25141855", "http://www.ncbi.nlm.nih.gov/pubmed/9486677", "http://www.ncbi.nlm.nih.gov/pubmed/10790815", "http://www.ncbi.nlm.nih.gov/pubmed/22538278", "http://www.ncbi.nlm.nih.gov/pubmed/2186790", "http://www.ncbi.nlm.nih.gov/pubmed/8435921", "http://www.ncbi.nlm.nih.gov/pubmed/8785463", "http://www.ncbi.nlm.nih.gov/pubmed/3534016", "http://www.ncbi.nlm.nih.gov/pubmed/28293257"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Photoaging therapy with topical tretinoin: an evidence-based analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Topical tretinoin is established as an effective treatment for photoaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 262, "offsetInEndSection": 437, "text": "Most of the misinformation about tretinoin has been perpetuated from the early days of the drug, when its efficacy for treating the effects of photoaging was still in dispute.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 438, "offsetInEndSection": 633, "text": "Significant advances in clinical and basic research in this area have dispelled much of the confusion, clearing the way for an evidence-based medical approach to tretinoin therapy for photoaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 634, "offsetInEndSection": 781, "text": "This review summarizes recent relevant advances in tretinoin therapy to guide physicians in treating patients with this safe and effective hormone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 782, "offsetInEndSection": 865, "text": "To date, tretinoin remains the only therapeutic agent proved to repair photodamage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Is tretinoin still a key agent for photoaging management?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25141855"}, {"offsetInBeginSection": 38, "offsetInEndSection": 220, "text": "REVIEW: This review focuses on the UV radiation effects on skin, emphasizing the photoaging process, and the photoprotection conferred by tretinoin (all-trans retinoic acid or ATRA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25141855"}, {"offsetInBeginSection": 221, "offsetInEndSection": 296, "text": "Tretinoin is still the best tested retinoid to reverse photoaged skin.MAJOR", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25141855"}, {"offsetInBeginSection": 297, "offsetInEndSection": 403, "text": "CONCLUSIONS: Tretinoin can be used for photoaging treatment or combined treatment by different mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25141855"}]}, {"id": "58edfaf4eda5a57672000012", "body": "What is the function of the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22439727", "http://www.ncbi.nlm.nih.gov/pubmed/22833514", "http://www.ncbi.nlm.nih.gov/pubmed/22544737", "http://www.ncbi.nlm.nih.gov/pubmed/25535276", "http://www.ncbi.nlm.nih.gov/pubmed/12446625", "http://www.ncbi.nlm.nih.gov/pubmed/22372912", "http://www.ncbi.nlm.nih.gov/pubmed/28255560", "http://www.ncbi.nlm.nih.gov/pubmed/19795912", "http://www.ncbi.nlm.nih.gov/pubmed/19487478", "http://www.ncbi.nlm.nih.gov/pubmed/22759512"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439727"}, {"offsetInBeginSection": 204, "offsetInEndSection": 390, "text": "To develop drugs that effectively eradicate latent infection and shorten treatment duration, the pathophysiology of the causative agent Mycobacterium tuberculosis needs to be understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439727"}, {"offsetInBeginSection": 693, "offsetInEndSection": 841, "text": "Here, we summarize what we have learnt since the discovery of the master regulator of dormancy, DosR, and the key gaps in our knowledge that remain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439727"}, {"offsetInBeginSection": 842, "offsetInEndSection": 944, "text": "Furthermore, we discuss a possible wider clinical relevance of DosR for 'nontuberculous mycobacteria'.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439727"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "The Mycobacterium DosR regulon structure and diversity revealed by comparative genomic analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), which claims approximately two million people annually, remains a global health concern.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 152, "offsetInEndSection": 313, "text": "The non-replicating or dormancy like state of this pathogen which is impervious to anti-tuberculosis drugs is widely recognized as the culprit for this scenario.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 314, "offsetInEndSection": 438, "text": "The dormancy survival regulator (DosR) regulon, composed of 48 co-regulated genes, is held as essential for Mtb persistence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 439, "offsetInEndSection": 614, "text": "The DosR regulon is regulated by a two-component regulatory system consisting of two sensor kinases-DosS (Rv3132c) and DosT (Rv2027c), and a response regulator DosR (Rv3133c).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1012, "text": "Comparative genomic analysis demonstrated that the DosR regulon is widely distributed among the mycobacterial genomes, ranging from the pathogenic strains to the environmental strains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}]}, {"id": "5a6d217eb750ff4455000034", "body": "Are there ultraconserved genomic regions in the budding yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028909", "http://www.ncbi.nlm.nih.gov/pubmed/23349633", "http://www.ncbi.nlm.nih.gov/pubmed/2118998", "http://www.ncbi.nlm.nih.gov/pubmed/20436919", "http://www.ncbi.nlm.nih.gov/pubmed/28348222", "http://www.ncbi.nlm.nih.gov/pubmed/15899965", "http://www.ncbi.nlm.nih.gov/pubmed/17072884", "http://www.ncbi.nlm.nih.gov/pubmed/25213602", "http://www.ncbi.nlm.nih.gov/pubmed/17785203", "http://www.ncbi.nlm.nih.gov/pubmed/23079418"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The systematic analysis of ultraconserved genomic regions in the budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028909"}, {"offsetInBeginSection": 341, "offsetInEndSection": 816, "text": "Here, we present a systematic study of ultraconserved genomic regions in the budding yeast based on the publicly available genome sequences, in order to reveal their relationship with the adaptability or fitness advantages of the budding yeast.Results: Our results indicate that, in addition to some fundamental biological functions, the UCSs play an important role in the adaptation of S. cerevisiae to the acidic environment, which is backed up by the previous observation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028909"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Centromere-like regions in the budding yeast genome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349633"}, {"offsetInBeginSection": 810, "offsetInEndSection": 867, "text": "CLR sequences are conserved among related budding yeasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349633"}, {"offsetInBeginSection": 868, "offsetInEndSection": 1011, "text": "Many genomic features characteristic of CLRs are also associated with these conserved homologous sequences from closely related budding yeasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349633"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Drosophila scaffold-attached regions bind nuclear scaffolds and can function as ARS elements in both budding and fission yeasts.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2118998"}, {"offsetInBeginSection": 293, "offsetInEndSection": 375, "text": "Here, we extend these observations to the fission yeast Schizosaccharomyces pombe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2118998"}, {"offsetInBeginSection": 685, "offsetInEndSection": 882, "text": "Two of the Drosophila SARs have autonomously replicating sequence activity in budding yeast, and three function in fission yeast, while four flanking non-SAR sequences are totally inactive in both.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2118998"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "What influences DNA replication rate in budding yeast?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20436919"}, {"offsetInBeginSection": 605, "offsetInEndSection": 737, "text": "FINDINGS: Here, we aimed at quantifying to which extent sequence properties contribute to the DNA replication time in budding yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20436919"}]}, {"id": "5a7610af83b0d9ea6600001a", "body": "Which Janus kinase does decernotinib target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26230873", "http://www.ncbi.nlm.nih.gov/pubmed/25762693", "http://www.ncbi.nlm.nih.gov/pubmed/27253519", "http://www.ncbi.nlm.nih.gov/pubmed/28790974", "http://www.ncbi.nlm.nih.gov/pubmed/27298338", "http://www.ncbi.nlm.nih.gov/pubmed/28765121", "http://www.ncbi.nlm.nih.gov/pubmed/28158411", "http://www.ncbi.nlm.nih.gov/pubmed/23301855", "http://www.ncbi.nlm.nih.gov/pubmed/26994322", "http://www.ncbi.nlm.nih.gov/pubmed/24326567"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26230873"}, {"offsetInBeginSection": 148, "offsetInEndSection": 423, "text": "Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26230873"}, {"offsetInBeginSection": 424, "offsetInEndSection": 594, "text": "We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26230873"}, {"offsetInBeginSection": 812, "offsetInEndSection": 1030, "text": "Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26230873"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Cytokines, growth factors, and other chemical messengers rely on a class of intracellular nonreceptor tyrosine kinases known as Janus kinases (JAKs) to rapidly transduce intracellular signals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27253519"}, {"offsetInBeginSection": 226, "offsetInEndSection": 348, "text": "Janus kinase (JAK) inhibitors are oral synthetic DMARDs that inhibit the non-receptor tyrosine kinase family Janus kinase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27253519"}, {"offsetInBeginSection": 631, "offsetInEndSection": 761, "text": "Results of three JAK inhibitors (baricitinib, decernotinib, and peficitinib) in phase III are consistent with that of tofacitinib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27253519"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790974"}]}, {"id": "5a87fd0561bb38fb24000010", "body": "Is autophagy modulated in a circadian fashion?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20833224", "http://www.ncbi.nlm.nih.gov/pubmed/24328814", "http://www.ncbi.nlm.nih.gov/pubmed/26674859", "http://www.ncbi.nlm.nih.gov/pubmed/23707790", "http://www.ncbi.nlm.nih.gov/pubmed/24751357", "http://www.ncbi.nlm.nih.gov/pubmed/26671266", "http://www.ncbi.nlm.nih.gov/pubmed/28625127", "http://www.ncbi.nlm.nih.gov/pubmed/22520961", "http://www.ncbi.nlm.nih.gov/pubmed/19377293", "http://www.ncbi.nlm.nih.gov/pubmed/23750326"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Glucocorticoids and circadian clock control of cell proliferation: at the interface between three dynamic systems.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The circadian clock, an endogenous timekeeper that regulates daily rhythms of physiology, also influences the dynamic release of glucocorticoids.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 146, "offsetInEndSection": 257, "text": "The release of glucocorticoids is characteristically pulsatile and is further modulated in a circadian fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 258, "offsetInEndSection": 460, "text": "A circadian pacemaker in the brain regulates daily rhythms of hypothalamic-pituitary-adrenal axis and autonomic nervous system activity that both influence glucocorticoid release from the adrenal gland.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 461, "offsetInEndSection": 580, "text": "This systemic regulation interacts with rhythms in the adrenal gland itself that are driven by its own circadian clock.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 808, "offsetInEndSection": 948, "text": "Cell proliferation is also under circadian control, and recent evidence suggests that this regulation may involve glucocorticoid signalling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1141, "text": "Here, we review the dynamic processes participating in the interplay between the circadian clock, glucocorticoids and cell proliferation, and we discuss the potential implications for therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "The biological clock modulates the human cortisol response in a multiplicative fashion.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328814"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Human cortisol levels follow a clear circadian rhythm.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328814"}, {"offsetInBeginSection": 55, "offsetInEndSection": 178, "text": "We investigated the contribution of alternation of sleep and wakefulness and the circadian clock, using forced desynchrony.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328814"}]}, {"id": "5a68ff52b750ff445500001c", "body": "Which tendons are affected in the Dequervain's tenosynovitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28765477", "http://www.ncbi.nlm.nih.gov/pubmed/871301", "http://www.ncbi.nlm.nih.gov/pubmed/10595881", "http://www.ncbi.nlm.nih.gov/pubmed/26752490", "http://www.ncbi.nlm.nih.gov/pubmed/4038032", "http://www.ncbi.nlm.nih.gov/pubmed/24822827", "http://www.ncbi.nlm.nih.gov/pubmed/3488531", "http://www.ncbi.nlm.nih.gov/pubmed/14507508", "http://www.ncbi.nlm.nih.gov/pubmed/11831123", "http://www.ncbi.nlm.nih.gov/pubmed/26007263"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Triggering of the abductor pollicis longus in association with deQuervain's tenosynovitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "DeQuervain's tenosynovitis is a common cause of radial-sided wrist pain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}, {"offsetInBeginSection": 73, "offsetInEndSection": 233, "text": "Symptoms result from a narrow first dorsal compartment and associated tendinosis of the enclosed extensor pollicis brevis and/or abductor pollicis longus (APL).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}, {"offsetInBeginSection": 612, "offsetInEndSection": 761, "text": "Intraoperatively, after supernumerary tendons were identified and addressed, the APL was at risk for subluxation over a prominent fibroosseous ridge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}, {"offsetInBeginSection": 762, "offsetInEndSection": 868, "text": "Routine first dorsal compartment release alone may have failed to address all of this patient's pathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Hand flexor tenosynovitis in rheumatoid arthritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/871301"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Tenosynovitis of one or more flexor tendons of the hand (mean 3.1 tendons per patient) was noted in 55% of 100 patients with rheumatoid arthritis (RA) examined periodically during a mean period of 5 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/871301"}, {"offsetInBeginSection": 206, "offsetInEndSection": 351, "text": "The third flexor tendon was involved most frequently (71% of patients), followed by the second (62%), fourth (53%), fifth (27%), and first (13%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/871301"}, {"offsetInBeginSection": 352, "offsetInEndSection": 999, "text": "Patients with flexor tendonitis (FT) had a significantly higher prevalence of rheumatoid nodules (56% vs 33%), carpal tunnel syndrome (47% vs 13%), wrist extensor tenosynovitis (47% vs 9%), and elbow epicondylitis (22% vs 7%) than patients without FT. Dupuytren's contracture, DeQuervain's tenovaginitis, flexor carpi radialis and ulnaris tendonitis, and Achilles tendonitis were found exclusively in patients with FT. A control group of 50 non-RA patients with FT had statistically fewer diseased tendons per patient (mean 1.5) and a different digital distribution, the thumb being affected more frequently (P less than 0.05) than in RA patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/871301"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Intersection syndrome is a condition that should be differentiated from DeQuervain's stenosing tenosynovitis, as there are many subtle differences in treatment and prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10595881"}]}, {"id": "58ee1cafeda5a57672000014", "body": "Are TAD boundaries in Drosophila depleted in highly-expressed genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26518482", "http://www.ncbi.nlm.nih.gov/pubmed/28388407", "http://www.ncbi.nlm.nih.gov/pubmed/28282436", "http://www.ncbi.nlm.nih.gov/pubmed/26748519", "http://www.ncbi.nlm.nih.gov/pubmed/27111891", "http://www.ncbi.nlm.nih.gov/pubmed/25818644", "http://www.ncbi.nlm.nih.gov/pubmed/27210764", "http://www.ncbi.nlm.nih.gov/pubmed/26431028", "http://www.ncbi.nlm.nih.gov/pubmed/29077530", "http://www.ncbi.nlm.nih.gov/pubmed/28408976"], "snippets": [{"offsetInBeginSection": 449, "offsetInEndSection": 624, "text": "To explore principles of TAD folding in Drosophila melanogaster, we performed Hi-C and poly(A)(+) RNA-seq in four cell lines of various origins (S2, Kc167, DmBG3-c2, and OSC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482"}, {"offsetInBeginSection": 625, "offsetInEndSection": 881, "text": "Contrary to previous studies, we find that regions between TADs (i.e., the inter-TADs and TAD boundaries) in Drosophila are only weakly enriched with the insulator protein dCTCF, while another insulator protein Su(Hw) is preferentially present within TADs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482"}, {"offsetInBeginSection": 882, "offsetInEndSection": 989, "text": "However, Drosophila inter-TADs harbor active chromatin and constitutively transcribed (housekeeping) genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482"}, {"offsetInBeginSection": 990, "offsetInEndSection": 1129, "text": "Accordingly, we find that binding of insulator proteins dCTCF and Su(Hw) predicts TAD boundaries much worse than active chromatin marks do.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482"}, {"offsetInBeginSection": 449, "offsetInEndSection": 551, "text": "Early expressed genes serve as nucleation sites for topologically associating domain (TAD) boundaries.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388407"}, {"offsetInBeginSection": 753, "offsetInEndSection": 914, "text": "However, the appearance of TAD boundaries is independent of transcription and requires the transcription factor Zelda for locus-specific TAD boundary insulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388407"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Regions of very low H3K27me3 partition the Drosophila genome into topological domains.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282436"}, {"offsetInBeginSection": 232, "offsetInEndSection": 356, "text": "However, the mechanisms that partition the genome into TADs and the nature of domain boundaries are still poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282436"}, {"offsetInBeginSection": 357, "offsetInEndSection": 489, "text": "We have investigated boundary regions in the Drosophila genome and find that they can be identified as domains of very low H3K27me3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282436"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1316, "text": "However, rather than being clustered at the borders of these domains, these proteins bind throughout the H3K27me3-depleted regions and are much more strongly associated with the transcription start sites of housekeeping genes than with the H3K27me3 domain boundaries.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282436"}]}, {"id": "5a6d23ccb750ff4455000035", "body": "Does TUC.338 inhibit colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27914101", "http://www.ncbi.nlm.nih.gov/pubmed/28599453", "http://www.ncbi.nlm.nih.gov/pubmed/27878301", "http://www.ncbi.nlm.nih.gov/pubmed/27637778", "http://www.ncbi.nlm.nih.gov/pubmed/21187392", "http://www.ncbi.nlm.nih.gov/pubmed/19240162", "http://www.ncbi.nlm.nih.gov/pubmed/27793031", "http://www.ncbi.nlm.nih.gov/pubmed/26617747", "http://www.ncbi.nlm.nih.gov/pubmed/24468585", "http://www.ncbi.nlm.nih.gov/pubmed/25996664"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "TUC.338 promotes invasion and metastasis in colorectal cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 441, "offsetInEndSection": 512, "text": "Until now, the role of TUC.338 in colorectal cancers remains undefined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 513, "offsetInEndSection": 701, "text": "This study revealed that TUC.338 is significantly up-regulated in colorectal cancers (CRC) tissue and CRC cell lines, and the up-regulated TUC.338 is associated with lymph node metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 702, "offsetInEndSection": 846, "text": "Transfection with small interfering RNA (siRNA) markedly inhibited cell migration and invasion in SW480 and HCT116 colorectal cancer cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 847, "offsetInEndSection": 1038, "text": "TIMP-1 was demonstrated to be negatively regulated by TUC.338 at the posttranscriptional level, via a specific target site within the 3' untranslated region by dual-luciferase reporter assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1144, "text": "The expression of TIMP-1 was also observed to inversely correlate with TUC.338 expression in CRC tissues.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 1145, "offsetInEndSection": 1293, "text": "Over-expression of TIMP-1 with migRI-TIMP-1-GFP inhibited CRC cell migration and invasion and down-regulates MMP9, resembling that of TUC.338-siRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 1294, "offsetInEndSection": 1453, "text": "Thus, these findings suggested that TUC.338 acts as a novel oncogene by targeting the TIMP-1 gene thus promoting colorectal cancer cell migration and invasion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "TUC338 promotes cell migration and invasion by targeting TIMP1 in cervical cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28599453"}, {"offsetInBeginSection": 770, "offsetInEndSection": 915, "text": "Transfection with small interfering RNA (siRNA) against TUC338 could markedly inhibit cell migration and invasion in HeLa and C33A CC cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28599453"}]}, {"id": "5a76122383b0d9ea6600001c", "body": "What is oclacitinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24495176", "http://www.ncbi.nlm.nih.gov/pubmed/25940959", "http://www.ncbi.nlm.nih.gov/pubmed/23829933", "http://www.ncbi.nlm.nih.gov/pubmed/28513001", "http://www.ncbi.nlm.nih.gov/pubmed/25496303", "http://www.ncbi.nlm.nih.gov/pubmed/27847179", "http://www.ncbi.nlm.nih.gov/pubmed/25688708", "http://www.ncbi.nlm.nih.gov/pubmed/24581322", "http://www.ncbi.nlm.nih.gov/pubmed/25109820", "http://www.ncbi.nlm.nih.gov/pubmed/28920784"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495176"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1434, "text": "These results demonstrate that oclacitinib is a targeted therapy that selectively inhibits JAK1-dependent cytokines involved in allergy, inflammation, and pruritus and suggests these are the mechanisms by which oclacitinib effectively controls clinical signs associated with allergic skin disease in dogs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495176"}, {"offsetInBeginSection": 239, "offsetInEndSection": 396, "text": "OBJECTIVES: To evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940959"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23829933"}, {"offsetInBeginSection": 245, "offsetInEndSection": 439, "text": "OBJECTIVES: We aimed to evaluate the safety and efficacy of oclacitinib for the control of pruritus associated with allergic dermatitis in a randomized, double-blinded, placebo-controlled trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23829933"}, {"offsetInBeginSection": 259, "offsetInEndSection": 404, "text": "OBJECTIVE: Prospective study to evaluate the frequency of UTI and subclinical bacteriuria in dogs with allergic dermatitis receiving oclacitinib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28513001"}, {"offsetInBeginSection": 1394, "offsetInEndSection": 1600, "text": "IMPORTANCE: These findings indicate that bacteriuria is not an expected adverse effect in dogs treated with oclacitinib without a prior history of UTI or predisposing condition during this treatment period.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28513001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496303"}, {"offsetInBeginSection": 240, "offsetInEndSection": 443, "text": "OBJECTIVES: To evaluate the efficacy and safety of oclacitinib, in comparison to ciclosporin, for the control of AD in a blinded, randomized clinical trial, incorporating a noninferiority test at day 28.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496303"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27847179"}]}, {"id": "5a882b5761bb38fb24000013", "body": "List the four most important interferonopathies", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27325888", "http://www.ncbi.nlm.nih.gov/pubmed/29093484", "http://www.ncbi.nlm.nih.gov/pubmed/26744186", "http://www.ncbi.nlm.nih.gov/pubmed/25998914", "http://www.ncbi.nlm.nih.gov/pubmed/26052098", "http://www.ncbi.nlm.nih.gov/pubmed/27821552", "http://www.ncbi.nlm.nih.gov/pubmed/26397019", "http://www.ncbi.nlm.nih.gov/pubmed/26363997", "http://www.ncbi.nlm.nih.gov/pubmed/25463593", "http://www.ncbi.nlm.nih.gov/pubmed/27260006"], "snippets": [{"offsetInBeginSection": 885, "offsetInEndSection": 1000, "text": "These findings add USP18 deficiency to the list of genetic disorders collectively termed type I interferonopathies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325888"}, {"offsetInBeginSection": 992, "offsetInEndSection": 1149, "text": "IL-6, MCP-1, IL-22, TNF-\u03b1) and pronounced complement consumption, resembling changes seen in type I interferonopathies and other autoinflammatory conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093484"}, {"offsetInBeginSection": 0, "offsetInEndSection": 27, "text": "[Type I interferonopathies.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744186"}, {"offsetInBeginSection": 235, "offsetInEndSection": 432, "text": "Genetic defects that result in an inadequate activation of the type I interferon system can cause a group of inflammatory disorders, which are collectively referred to as type I interferonopathies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Type I interferonopathies--an expanding disease spectrum of immunodysregulation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998914"}, {"offsetInBeginSection": 445, "offsetInEndSection": 657, "text": "While their phenotypic spectrum is broad, ranging from severe neurological impairment to mild cutaneous disease, systemic autoinflammation, and autoimmunity are commonly shared signs of type I interferonopathies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998914"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Aicardi-Gouti\u00e8res syndrome and the type I interferonopathies.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26052098"}, {"offsetInBeginSection": 391, "offsetInEndSection": 571, "text": "Here, we discuss the molecular and cellular basis of the interferonopathies, their categorization, future treatment strategies and the insights they provide into normal physiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26052098"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821552"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Fine-tuning of type I IFN-signaling in microglia--implications for homeostasis, CNS autoimmunity and interferonopathies.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26397019"}]}, {"id": "5a6f8baeb750ff4455000057", "body": "What is the purpose of the FRAX scale?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22492479", "http://www.ncbi.nlm.nih.gov/pubmed/22630782", "http://www.ncbi.nlm.nih.gov/pubmed/21198706", "http://www.ncbi.nlm.nih.gov/pubmed/25771422", "http://www.ncbi.nlm.nih.gov/pubmed/27163858", "http://www.ncbi.nlm.nih.gov/pubmed/28013446", "http://www.ncbi.nlm.nih.gov/pubmed/3953643", "http://www.ncbi.nlm.nih.gov/pubmed/20959961", "http://www.ncbi.nlm.nih.gov/pubmed/8825884", "http://www.ncbi.nlm.nih.gov/pubmed/7942998"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The WHO Fracture Risk Assessment Tool (FRAX; http://www.shef.ac.uk/FRAX) estimates the 10-year probability of major osteoporotic fracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 139, "offsetInEndSection": 280, "text": "Clodronate and bazedoxifene reduced nonvertebral and clinical fracture more effectively on a relative scale in women with higher FRAX scores.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 281, "offsetInEndSection": 415, "text": "We used data from the Fracture Intervention Trial (FIT) to evaluate the interaction between FRAX score and treatment with alendronate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 710, "offsetInEndSection": 901, "text": "We used Poisson regression models to assess the interaction between alendronate and FRAX score on the risk of nonvertebral, clinical, major osteoporotic, and radiographic vertebral fractures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 1289, "offsetInEndSection": 1442, "text": "However, there was no evidence of an interaction between alendronate and FRAX score with FN BMD for risk of nonvertebral fracture (interaction p\u2009=\u20090.61).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 1443, "offsetInEndSection": 1529, "text": "The absolute benefit of alendronate was greatest among women with highest FRAX scores.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 1530, "offsetInEndSection": 1689, "text": "Results were similar for clinical fractures, major osteoporotic fractures, and radiographic vertebral fractures and whether or not FRAX scores included FN BMD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 1690, "offsetInEndSection": 1904, "text": "Among this cohort of women with low bone mass there was no significant interaction between FRAX score and alendronate for nonvertebral, clinical or major osteoporotic fractures, or radiographic vertebral fractures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 1905, "offsetInEndSection": 2006, "text": "These results suggest that the effect of alendronate on a relative scale does not vary by FRAX score.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}]}, {"id": "58ee217feda5a57672000015", "body": "How are topologically associating domains (TAD) associated with replication timing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25409831", "http://www.ncbi.nlm.nih.gov/pubmed/28348222", "http://www.ncbi.nlm.nih.gov/pubmed/25995270", "http://www.ncbi.nlm.nih.gov/pubmed/28977529", "http://www.ncbi.nlm.nih.gov/pubmed/23832846", "http://www.ncbi.nlm.nih.gov/pubmed/26590169", "http://www.ncbi.nlm.nih.gov/pubmed/27669308", "http://www.ncbi.nlm.nih.gov/pubmed/27312344", "http://www.ncbi.nlm.nih.gov/pubmed/26150425", "http://www.ncbi.nlm.nih.gov/pubmed/26558551"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Topologically associating domains are stable units of replication-timing regulation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Eukaryotic chromosomes replicate in a temporal order known as the replication-timing program.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 94, "offsetInEndSection": 443, "text": "In mammals, replication timing is cell-type-specific with at least half the genome switching replication timing during development, primarily in units of 400-800 kilobases ('replication domains'), whose positions are preserved in different cell types, conserved between species, and appear to confine long-range effects of chromosome rearrangements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 444, "offsetInEndSection": 719, "text": "Early and late replication correlate, respectively, with open and closed three-dimensional chromatin compartments identified by high-resolution chromosome conformation capture (Hi-C), and, to a lesser extent, late replication correlates with lamina-associated domains (LADs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 720, "offsetInEndSection": 956, "text": "Recent Hi-C mapping has unveiled substructure within chromatin compartments called topologically associating domains (TADs) that are largely conserved in their positions between cell types and are similar in size to replication domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 1091, "offsetInEndSection": 1220, "text": "Moreover, attempts to reconcile TADs and LADs to replication-timing data have not revealed a common, underlying domain structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1398, "text": "Here we localize boundaries of replication domains to the early-replicating border of replication-timing transitions and map their positions in 18 human and 13 mouse cell types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 1399, "offsetInEndSection": 1699, "text": "We demonstrate that, collectively, replication domain boundaries share a near one-to-one correlation with TAD boundaries, whereas within a cell type, adjacent TADs that replicate at similar times obscure replication domain boundaries, largely accounting for the previously reported lack of alignment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 1700, "offsetInEndSection": 2063, "text": "Moreover, cell-type-specific replication timing of TADs partitions the genome into two large-scale sub-nuclear compartments revealing that replication-timing transitions are indistinguishable from late-replicating regions in chromatin composition and lamina association and accounting for the reduced correlation of replication timing to LADs and heterochromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 2064, "offsetInEndSection": 2284, "text": "Our results reconcile cell-type-specific sub-nuclear compartmentalization and replication timing with developmentally stable structural domains and offer a unified model for large-scale chromosome structure and function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}]}, {"id": "5a6e2b1bb750ff445500003e", "body": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28961763", "http://www.ncbi.nlm.nih.gov/pubmed/27239475", "http://www.ncbi.nlm.nih.gov/pubmed/24222209", "http://www.ncbi.nlm.nih.gov/pubmed/25677125", "http://www.ncbi.nlm.nih.gov/pubmed/28088185", "http://www.ncbi.nlm.nih.gov/pubmed/26374744", "http://www.ncbi.nlm.nih.gov/pubmed/28134831", "http://www.ncbi.nlm.nih.gov/pubmed/26576536", "http://www.ncbi.nlm.nih.gov/pubmed/23297033", "http://www.ncbi.nlm.nih.gov/pubmed/24979058"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "psygenet2r: a R/Bioconductor package for the analysis of psychiatric disease genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 82, "offsetInEndSection": 220, "text": "Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 221, "offsetInEndSection": 514, "text": "PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts.Results: We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 515, "offsetInEndSection": 764, "text": "The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 765, "offsetInEndSection": 1107, "text": "Psygenet2r is especially suited for network medicine analysis of psychiatric disorders.Availability: The package is implemented in R and is available under MIT license from Bioconductor ( http://bioconductor.org/packages/release/bioc/html/psygenet2r.html ).Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Guitar: An R/Bioconductor Package for Gene Annotation Guided Transcriptomic Analysis of RNA-Related Genomic Features.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239475"}, {"offsetInBeginSection": 492, "offsetInEndSection": 668, "text": "We developed here an open source Guitar R/Bioconductor package for sketching the transcriptomic view of RNA-related biological features represented by genome based coordinates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239475"}, {"offsetInBeginSection": 1181, "offsetInEndSection": 1317, "text": "The newly developed Guitar R/Bioconductor package achieves stable performance on the data tested and revealed novel biological insights.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239475"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "tRanslatome: an R/Bioconductor package to portray translational control.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24222209"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "UNLABELLED: High-throughput technologies have led to an explosion of genomic data available for automated analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24222209"}]}, {"id": "5a7626989e632bc066000001", "body": "Has ruxolitinib received FDA approval?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23985569", "http://www.ncbi.nlm.nih.gov/pubmed/24766055", "http://www.ncbi.nlm.nih.gov/pubmed/22544377", "http://www.ncbi.nlm.nih.gov/pubmed/28277287", "http://www.ncbi.nlm.nih.gov/pubmed/26056473", "http://www.ncbi.nlm.nih.gov/pubmed/27069082", "http://www.ncbi.nlm.nih.gov/pubmed/23977767", "http://www.ncbi.nlm.nih.gov/pubmed/24083419", "http://www.ncbi.nlm.nih.gov/pubmed/18077994", "http://www.ncbi.nlm.nih.gov/pubmed/28869184"], "snippets": [{"offsetInBeginSection": 356, "offsetInEndSection": 484, "text": "With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23985569"}, {"offsetInBeginSection": 226, "offsetInEndSection": 310, "text": "Only one JAK1/JAK2 inhibitor has gained FDA approval for treatment of myelofibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24766055"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1141, "text": "Resultant research in targeting the JAK/STAT pathway led to the approval of ruxolitinib, a JAK1/JAK2 inhibitor with activity in MPNs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24766055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 366, "text": "On November 16, 2011, the U.S. Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544377"}, {"offsetInBeginSection": 367, "offsetInEndSection": 599, "text": "This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544377"}, {"offsetInBeginSection": 258, "offsetInEndSection": 434, "text": "The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28277287"}, {"offsetInBeginSection": 417, "offsetInEndSection": 614, "text": "The goal of this work is to critically analyze data supporting use of ruxolitinib in the clinical settings approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056473"}, {"offsetInBeginSection": 615, "offsetInEndSection": 786, "text": "We systematically reviewed the literature and analyzed the risk of biases in the two randomized studies (COMFORT I and COMFORT II) on which FDA and EMA approval was based.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056473"}, {"offsetInBeginSection": 0, "offsetInEndSection": 486, "text": "PURPOSE: To review the use of patient-reported outcome (PRO) data in medical product labeling granted by the US Food and Drug Administration (FDA) for new molecular entities and biologic license applications by the FDA Office of Hematology and Oncology Products (OHOP) between January 2010 and December 2014, to elucidate challenges faced by OHOP for approving PRO labeling, and to understand challenges faced by drug manufacturers to include PRO end points in oncology clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069082"}, {"offsetInBeginSection": 486, "offsetInEndSection": 652, "text": "METHODS: FDA Drug Approval Reports by Month were reviewed to obtain the number of new molecular entities and biologic license applications approved from 2010 to 2014.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069082"}]}, {"id": "5a88370c61bb38fb24000014", "body": "What is the function of the gene MDA5?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21185857", "http://www.ncbi.nlm.nih.gov/pubmed/29069650", "http://www.ncbi.nlm.nih.gov/pubmed/26260315", "http://www.ncbi.nlm.nih.gov/pubmed/17977974", "http://www.ncbi.nlm.nih.gov/pubmed/19324880", "http://www.ncbi.nlm.nih.gov/pubmed/21881126", "http://www.ncbi.nlm.nih.gov/pubmed/25008915", "http://www.ncbi.nlm.nih.gov/pubmed/22797917", "http://www.ncbi.nlm.nih.gov/pubmed/24939427", "http://www.ncbi.nlm.nih.gov/pubmed/16116171"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Characterization and antiviral function of a cytosolic sensor gene, MDA5, in Japanese flounder, Paralichthys olivaceus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21185857"}, {"offsetInBeginSection": 155, "offsetInEndSection": 322, "text": "The receptor encoded by melanoma differentiation-associated gene 5 (MDA5), an RLR, recognizes viral RNA in the cytoplasm and enhances antiviral response in host cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21185857"}, {"offsetInBeginSection": 970, "offsetInEndSection": 1071, "text": "These results suggest that Japanese flounder MDA5 is involved in the induction of antiviral response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21185857"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Melanoma differentiation-associated gene 5 (MDA5) is a pattern recognition receptor that recognizes cytoplasmic viral double-stranded RNA (dsRNA) and initiates rapid innate antiviral responses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}, {"offsetInBeginSection": 472, "offsetInEndSection": 616, "text": "The conformational switch of MDA5 causes antiviral defense, but excessive activation of the MDA5-MAVS pathway may result in autoimmune diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}, {"offsetInBeginSection": 617, "offsetInEndSection": 685, "text": "The regulatory mechanisms of MDA5 activation remain largely unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}, {"offsetInBeginSection": 686, "offsetInEndSection": 808, "text": "By yeast 2-hybrid, we identified DNAJB1, a member of the HSP40 (heat shock protein 40) family, as an MDA5-binding protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}, {"offsetInBeginSection": 1290, "offsetInEndSection": 1363, "text": "HSP70 inhibitor also enhanced the IFN-inducing function of MDA5 and MAVS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Melanoma differentiation-associated gene 5 (MDA5) is a member of retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) family which can initiate type I IFN expression in response to RNA virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26260315"}, {"offsetInBeginSection": 208, "offsetInEndSection": 435, "text": "In this study, we constructed six mutants of Ctenopharyngodon idella MDA5 (CiMAD5) overexpression plasmids and generated stable transfected C. idella kidney (CIK) cell lines to study the function of different domains of CiMAD5.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26260315"}]}, {"id": "5a70de5199e2c3af26000005", "body": "Is scuba diving safe during pregnancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17000494", "http://www.ncbi.nlm.nih.gov/pubmed/11777528", "http://www.ncbi.nlm.nih.gov/pubmed/12808399", "http://www.ncbi.nlm.nih.gov/pubmed/12053898", "http://www.ncbi.nlm.nih.gov/pubmed/7423656", "http://www.ncbi.nlm.nih.gov/pubmed/20086738", "http://www.ncbi.nlm.nih.gov/pubmed/8888455", "http://www.ncbi.nlm.nih.gov/pubmed/7789850", "http://www.ncbi.nlm.nih.gov/pubmed/1624782", "http://www.ncbi.nlm.nih.gov/pubmed/10416137"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Scuba diving and pregnancy: can we determine safe limits?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 348, "offsetInEndSection": 406, "text": "Latest gestational age reported while diving was 35 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 407, "offsetInEndSection": 511, "text": "One respondent reported 92 dives during a single pregnancy, with two dives to 65 m in the 1st trimester.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 616, "offsetInEndSection": 776, "text": "Overall, the women did not conduct enough dives per pregnancy, therefore no significant correlation between diving and fetal abnormalities could be established.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 777, "offsetInEndSection": 907, "text": "These data indicate women are increasingly observing the diving industry recommendation and refraining from diving while pregnant.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1012, "text": "Field studies are not likely to be useful, or the way forward, for future diving and pregnancy research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 1013, "offsetInEndSection": 1159, "text": "Differences in placental circulation between humans and other animals limit the applicability of animal research for pregnancy and diving studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1253, "text": "It is unlikely that the effect of scuba diving on the unborn human fetus will be established.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000494"}, {"offsetInBeginSection": 262, "offsetInEndSection": 530, "text": "Generally, participation in a wide range of recreational activities appears to be safe during pregnancy; however, each sport should be reviewed individually for its potential risk, and activities with a high risk of abdominal trauma should be avoided during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11777528"}, {"offsetInBeginSection": 531, "offsetInEndSection": 678, "text": "Scuba diving also should be avoided throughout pregnancy because the fetus is at an increased risk for decompression sickness during this activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11777528"}]}, {"id": "58ee2515eda5a57672000016", "body": "Which individuals show preferential colonization of the Prevotellaceae bacteria in their guts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23692388", "http://www.ncbi.nlm.nih.gov/pubmed/26637604", "http://www.ncbi.nlm.nih.gov/pubmed/28553195", "http://www.ncbi.nlm.nih.gov/pubmed/25284151", "http://www.ncbi.nlm.nih.gov/pubmed/28625783", "http://www.ncbi.nlm.nih.gov/pubmed/18836026", "http://www.ncbi.nlm.nih.gov/pubmed/28628661", "http://www.ncbi.nlm.nih.gov/pubmed/17233730", "http://www.ncbi.nlm.nih.gov/pubmed/7620812", "http://www.ncbi.nlm.nih.gov/pubmed/16233108"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Insect guts present distinctive environments for microbial colonization, and bacteria in the gut potentially provide many beneficial services to their hosts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692388"}, {"offsetInBeginSection": 248, "offsetInEndSection": 407, "text": "Most insect guts contain relatively few microbial species as compared to mammalian guts, but some insects harbor large gut communities of specialized bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692388"}, {"offsetInBeginSection": 656, "offsetInEndSection": 806, "text": "One obstacle to the evolution of intimate associations with gut microorganisms is the lack of dependable transmission routes between host individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692388"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Oxygen Affects Gut Bacterial Colonization and Metabolic Activities in a Gnotobiotic Cockroach Model.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 371, "offsetInEndSection": 555, "text": "We established the cockroach Shelfordella lateralis as a gnotobiotic model and inoculated germfree nymphs with two bacterial strains isolated from the guts of conventional cockroaches.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 1235, "offsetInEndSection": 1404, "text": "The pure cultures formed the typical products of mixed-acid or butyrate fermentation, whereas the guts of gnotobiotic cockroaches accumulated mostly lactate and acetate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 1405, "offsetInEndSection": 1619, "text": "Similar shifts toward more-oxidized products were observed when the pure cultures were exposed to oxygen, which corroborated the strong effects of oxygen on the metabolic fluxes previously observed in termite guts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 1620, "offsetInEndSection": 1865, "text": "Oxygen microsensor profiles of the guts of germfree, gnotobiotic, and conventional cockroaches indicated that both gut tissue and microbiota contribute to oxygen consumption and suggest that the oxygen status influences the colonization success.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 290, "offsetInEndSection": 461, "text": "The aim of this work was to provide an overview of the bacteria colonizing the gut of wild-caught fishes and to determine whether some bacterial species can be pathogenic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28553195"}, {"offsetInBeginSection": 698, "offsetInEndSection": 853, "text": "The potential pathogenicity of isolated bacteria was investigated using fruit fly (Drosophila melanogaster) and zebrafish (Danio rerio) as model organisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28553195"}]}, {"id": "5a6e3299b750ff4455000040", "body": "What is the main focus of the CVE R/Bioconductor package?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28545463", "http://www.ncbi.nlm.nih.gov/pubmed/21937664", "http://www.ncbi.nlm.nih.gov/pubmed/15824474", "http://www.ncbi.nlm.nih.gov/pubmed/25246429", "http://www.ncbi.nlm.nih.gov/pubmed/26803161", "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "http://www.ncbi.nlm.nih.gov/pubmed/28575171", "http://www.ncbi.nlm.nih.gov/pubmed/27646783", "http://www.ncbi.nlm.nih.gov/pubmed/24700319", "http://www.ncbi.nlm.nih.gov/pubmed/23709494"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "CVE: an R package for interactive variant prioritisation in precision oncology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545463"}, {"offsetInBeginSection": 97, "offsetInEndSection": 233, "text": "To support this development, we present the Cancer Variant Explorer (CVE), an R package with an interactive Shiny web browser interface.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545463"}, {"offsetInBeginSection": 641, "offsetInEndSection": 766, "text": "CONCLUSIONS: The CVE package allows interactive variant prioritisation to expedite the analysis of cancer sequencing studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545463"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1152, "text": "The CVE package is available via Bioconductor ( http://bioconductor.org/packages/CVE/ ).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545463"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expert-curated datasets from GEO.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937664"}, {"offsetInBeginSection": 340, "offsetInEndSection": 568, "text": "The inSilicoDb R/Bioconductor package is a command-line front-end to the InSilico DB, a web-based database currently containing 86 104 expert-curated human Affymetrix expression profiles compiled from 1937 GEO repository series.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937664"}, {"offsetInBeginSection": 569, "offsetInEndSection": 765, "text": "The use of this package builds on the Bioconductor project's focus on reproducibility by enabling a clear workflow in which not only analysis, but also the retrieval of verified data is supported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937664"}, {"offsetInBeginSection": 872, "offsetInEndSection": 918, "text": "The main outcome measure was incidence of CVE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824474"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Rcpi: R/Bioconductor package to generate various descriptors of proteins, compounds and their interactions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25246429"}, {"offsetInBeginSection": 282, "offsetInEndSection": 561, "text": "To solve this problem, we developed a freely available R/Bioconductor package, called Compound-Protein Interaction with R (Rcpi), for complex molecular representation from drugs, proteins and more complex interactions, including protein-protein and compound-protein interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25246429"}]}, {"id": "5a7726989e632bc06600000c", "body": "Does deflazacort have more side effects than prednisone?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16244521", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/8329416", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/8241229", "http://www.ncbi.nlm.nih.gov/pubmed/8356936", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/7194867", "http://www.ncbi.nlm.nih.gov/pubmed/22115006", "http://www.ncbi.nlm.nih.gov/pubmed/11038071"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "OBJECTIVE: To determine and compare the long-term effects of prednisone and deflazacort on the functional status of children with Duchenne muscular dystrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244521"}, {"offsetInBeginSection": 321, "offsetInEndSection": 414, "text": "Eighteen had been treated with prednisone, 12 with deflazacort, and 19 had no drug treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244521"}, {"offsetInBeginSection": 509, "offsetInEndSection": 635, "text": "Lower and upper limb motor functions, pulmonary function, prevalence of surgery for scoliosis, and side effects were compared.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244521"}, {"offsetInBeginSection": 882, "offsetInEndSection": 991, "text": "CONCLUSIONS: Prednisone and deflazacort have a significant beneficial effect on slowing the disease progress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244521"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "We randomized 18 Duchenne muscular dystrophy (DMD) boys whose age ranged from 5.2 to 14.6 years (mean, 7.3 years) for treatment with either deflazacort (0.9 mg/kg/day) or prednisone (0.75 mg/kg/day) on the basis of age and functional score at the onset of treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1055, "text": "At 9 months, the average weight increase with respect to baseline value was 5% (2 kg) in the deflazacort group but 18% in the prednisone group (P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Preliminary experience with deflazacort, a new synthetic steroid with fewer undesirable side effects, in heart transplant patients.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8329416"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Prednisone is widely used by most heart transplant units, despite its frequent side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8329416"}, {"offsetInBeginSection": 93, "offsetInEndSection": 210, "text": "Deflazacort, a new oral synthetic steroid with fewer side effects, has not been studied in heart transplant patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8329416"}]}, {"id": "5a885daa61bb38fb24000018", "body": "Which is the conserved motif of DEAD box proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7689221", "http://www.ncbi.nlm.nih.gov/pubmed/23523990", "http://www.ncbi.nlm.nih.gov/pubmed/9371600", "http://www.ncbi.nlm.nih.gov/pubmed/8253085", "http://www.ncbi.nlm.nih.gov/pubmed/1900936", "http://www.ncbi.nlm.nih.gov/pubmed/10727850", "http://www.ncbi.nlm.nih.gov/pubmed/8144024", "http://www.ncbi.nlm.nih.gov/pubmed/8948440", "http://www.ncbi.nlm.nih.gov/pubmed/26709771", "http://www.ncbi.nlm.nih.gov/pubmed/28559293"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Amplification of a DEAD box protein gene in retinoblastoma cell lines.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689221"}, {"offsetInBeginSection": 0, "offsetInEndSection": 299, "text": "DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp, are putative RNA helicases implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689221"}, {"offsetInBeginSection": 463, "offsetInEndSection": 700, "text": "Here, we report that the mRNA encoding a DEAD box protein, designated HuDBP-RB, is present at elevated levels in two of six retinoblastoma (RB) cell lines tested and is preferentially expressed in fetal tissues of neuroectodermal origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689221"}, {"offsetInBeginSection": 701, "offsetInEndSection": 976, "text": "It is not possible to classify HuDBP-RB as a member of any of the DEAD box protein subgroups identified to date since the regions of amino acid similarity between HuDBP-RB and other DEAD box proteins are restricted to the conserved motifs found in all members of this family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689221"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "The DEAD box proteins DDX5 (p68) and DDX17 (p72): multi-tasking transcriptional regulators.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "Members of the DEAD box family of RNA helicases, which are characterised by the presence of twelve conserved motifs (including the signature D-E-A-D motif) within a structurally conserved 'helicase' core, are involved in all aspects of RNA metabolism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 252, "offsetInEndSection": 437, "text": "Apart from unwinding RNA duplexes, which established these proteins as RNA helicases, DEAD box proteins have been shown to also catalyse RNA annealing and to displace proteins from RNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 438, "offsetInEndSection": 721, "text": "DEAD box proteins generally act as components of large multi-protein complexes and it is thought that interactions, via their divergent N- and C-terminal extensions, with other factors in the complexes may be responsible for the many different functions attributed to these proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 722, "offsetInEndSection": 920, "text": "In addition to their established crucial roles in the manipulation of RNA structure, it is becoming increasingly clear that several members of the DEAD box family act as regulators of transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "The carboxyl-terminal three-fourths of the hepatitis C virus (HCV) NS3 protein has been shown to possess an RNA helicase activity, typical of members of the DEAD box family of RNA helicases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371600"}]}, {"id": "5a7237672dc08e987e000008", "body": "Which drug can be reversed with idarucizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27224445", "http://www.ncbi.nlm.nih.gov/pubmed/28479184", "http://www.ncbi.nlm.nih.gov/pubmed/27575900", "http://www.ncbi.nlm.nih.gov/pubmed/25567155", "http://www.ncbi.nlm.nih.gov/pubmed/25899749", "http://www.ncbi.nlm.nih.gov/pubmed/27568285", "http://www.ncbi.nlm.nih.gov/pubmed/27697436", "http://www.ncbi.nlm.nih.gov/pubmed/28416406", "http://www.ncbi.nlm.nih.gov/pubmed/28695019", "http://www.ncbi.nlm.nih.gov/pubmed/27920714"], "snippets": [{"offsetInBeginSection": 194, "offsetInEndSection": 328, "text": "The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27224445"}, {"offsetInBeginSection": 554, "offsetInEndSection": 711, "text": "DETAILS: We describe the use of idarucizumab in the management of a 68-year-old woman who was taking dabigatran 150\u2009mg twice daily and ingested 125 capsules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27224445"}, {"offsetInBeginSection": 1234, "offsetInEndSection": 1352, "text": "DISCUSSION: This case highlights the potential use of idarucizumab for the management of massive dabigatran overdoses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27224445"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "INTRODUCTION: Idarucizumab is a reversal agent for dabigatran etexilate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 73, "offsetInEndSection": 254, "text": "By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 254, "offsetInEndSection": 375, "text": "PATIENT: We describe our experience with idarucizumab in a 71-year-old male patient pretreated with dabigatran etexilate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 453, "offsetInEndSection": 571, "text": "METHOD: Dabigatran etexilate was antagonized with idarucizumab, approximately 2.5 hours after the patient's last dose.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 572, "offsetInEndSection": 662, "text": "Immediately after the infusion of idarucizumab, the patient received thrombolytic therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 967, "offsetInEndSection": 1055, "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}]}, {"id": "58f89eb270f9fc6f0f00001a", "body": "What is the genetic basis of Ohdo syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7519949", "http://www.ncbi.nlm.nih.gov/pubmed/18798845", "http://www.ncbi.nlm.nih.gov/pubmed/26338144", "http://www.ncbi.nlm.nih.gov/pubmed/23395478", "http://www.ncbi.nlm.nih.gov/pubmed/12868473", "http://www.ncbi.nlm.nih.gov/pubmed/9605288", "http://www.ncbi.nlm.nih.gov/pubmed/9546834", "http://www.ncbi.nlm.nih.gov/pubmed/15127758", "http://www.ncbi.nlm.nih.gov/pubmed/9184251", "http://www.ncbi.nlm.nih.gov/pubmed/16700052"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Blepharophimosis, ptosis and mental retardation: further delineation of Ohdo syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519949"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "The Ohdo syndrome is characterized by blepharophimosis, ptosis, abnormal ears, and mental retardation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519949"}, {"offsetInBeginSection": 103, "offsetInEndSection": 214, "text": "This report describes a child with the Ohdo syndrome who, in addition, has microcephaly and growth retardation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519949"}, {"offsetInBeginSection": 215, "offsetInEndSection": 315, "text": "Her phenotype probably represents variable expression or genetic heterogeneity of the Ohdo syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519949"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "A clinical and genetic study of the Say/Barber/Biesecker/Young-Simpson type of Ohdo syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798845"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "We report a series of eight patients with the Say/Barber/Biesecker/Young-Simpson (SBBYS) type of Ohdo syndrome, which is the largest cohort described to date.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798845"}, {"offsetInBeginSection": 159, "offsetInEndSection": 364, "text": "We expand on the type, frequency and severity of the clinical characteristics in this condition; comment on the natural history of Ohdo syndrome and further refine previously published diagnostic criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798845"}, {"offsetInBeginSection": 502, "offsetInEndSection": 686, "text": "It remains possible that this rare condition is heterogeneous and therefore caution must be undertaken during counselling until the underlying genetic mechanism(s) is (are) identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798845"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Beyond Ohdo syndrome: A familial missense mutation broadens the MED12 spectrum.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338144"}, {"offsetInBeginSection": 181, "offsetInEndSection": 315, "text": "There are many genetic and non-genetic causes of ID; X-linked forms are identifiable through their characteristic inheritance pattern.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338144"}]}, {"id": "5a6e472ab750ff4455000048", "body": "What is the function of the TMEM132 genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29088312", "http://www.ncbi.nlm.nih.gov/pubmed/20795330", "http://www.ncbi.nlm.nih.gov/pubmed/12569411", "http://www.ncbi.nlm.nih.gov/pubmed/19947983", "http://www.ncbi.nlm.nih.gov/pubmed/15965245", "http://www.ncbi.nlm.nih.gov/pubmed/26661787", "http://www.ncbi.nlm.nih.gov/pubmed/8173323", "http://www.ncbi.nlm.nih.gov/pubmed/17888165", "http://www.ncbi.nlm.nih.gov/pubmed/16500932", "http://www.ncbi.nlm.nih.gov/pubmed/7579525"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Summary: The molecular functions of TMEM132 genes remain poorly understood and under-investigated despite their mutations associated with non-syndromic hearing loss, panic disorder and cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088312"}, {"offsetInBeginSection": 193, "offsetInEndSection": 323, "text": "Here we show the full domain architecture of human TMEM132 family proteins solved using in-depth sequence and structural analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088312"}, {"offsetInBeginSection": 511, "offsetInEndSection": 708, "text": "The extra-cellular portions of TMEM132 proteins contain five conserved domains including three tandem immunoglobulin domains, and a cohesin domain homologue, the first such domain found in animals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088312"}, {"offsetInBeginSection": 709, "offsetInEndSection": 996, "text": "These findings strongly predict a cellular adhesion function for TMEM132 family, connecting the extracellular medium with the intracellular actin cytoskeleton.Contact: Luis.Sanchez-Pulido@igmm.ed.ac.uk.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088312"}, {"offsetInBeginSection": 21, "offsetInEndSection": 59, "text": "What is the function of the Hox genes?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 0, "offsetInEndSection": 38, "text": "What is the function of the Hox genes?", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 82, "offsetInEndSection": 292, "text": "Indeed, the answer seems so obvious that several authors have spoken of 'the Hox function' about some of the Hox genes, namely Hox3/zen and Hox6/ftz that seem to have lost it during the evolution of Arthropods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 293, "offsetInEndSection": 374, "text": "What these authors meant is that these genes have lost their 'homeotic' function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 375, "offsetInEndSection": 473, "text": "Indeed, 'homeotic' refers to a functional property that is so often associated with the Hox genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 474, "offsetInEndSection": 565, "text": "However, the word 'Hox' should not be used to refer to a function, but to a group of genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}]}, {"id": "5a774240faa1ab7d2e000003", "body": "What is the relationship of fyn kinase and tau?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27193083", "http://www.ncbi.nlm.nih.gov/pubmed/11826099", "http://www.ncbi.nlm.nih.gov/pubmed/23805846", "http://www.ncbi.nlm.nih.gov/pubmed/19115405", "http://www.ncbi.nlm.nih.gov/pubmed/16115884", "http://www.ncbi.nlm.nih.gov/pubmed/21741124", "http://www.ncbi.nlm.nih.gov/pubmed/9930729", "http://www.ncbi.nlm.nih.gov/pubmed/21269457", "http://www.ncbi.nlm.nih.gov/pubmed/21228179", "http://www.ncbi.nlm.nih.gov/pubmed/15708437"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by neuropathological deposits of amyloid plaques and neurofibrillary tangles comprised of \u03b2-amyloid and tau protein, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 214, "offsetInEndSection": 305, "text": "In AD, tau becomes abnormally phosphorylated and aggregates to form intracellular deposits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 391, "offsetInEndSection": 554, "text": "Recent studies have suggested that the presence of tau at synapses may indicate a role in neuronal signalling, which could be disrupted in pathological conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 555, "offsetInEndSection": 752, "text": "The non-receptor-associated tyrosine kinase fyn is located at the dendrite in neurons, where it was recently shown to interact with tau to stabilise receptor complexes at the post-synaptic density.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 753, "offsetInEndSection": 869, "text": "Fyn also co-localises with tau in a proportion of neurons containing tau tangles in AD and fyn is also a tau kinase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 870, "offsetInEndSection": 933, "text": "Hence, tau-fyn interactions could play a pathogenic role in AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 934, "offsetInEndSection": 1157, "text": "Here we report the identification of critical proline residues, Pro213, Pro216, and Pro219, located within the fifth and sixth Pro-X-X-Pro motifs in the proline-rich region of tau, that are important for its binding to fyn.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 1158, "offsetInEndSection": 1357, "text": "These residues in tau are flanked by numerous phosphorylation sites and therefore we investigated the relationship between fyn and the degree of tau phosphorylation in human post-mortem brain tissue.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}, {"offsetInBeginSection": 1358, "offsetInEndSection": 1434, "text": "We found no difference in the amount of fyn present in control and AD brain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193083"}]}, {"id": "5a8866958cb19eca6b000003", "body": "Are neurexins localized at pre-synapses?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27664583", "http://www.ncbi.nlm.nih.gov/pubmed/17360903", "http://www.ncbi.nlm.nih.gov/pubmed/22262843", "http://www.ncbi.nlm.nih.gov/pubmed/26785044", "http://www.ncbi.nlm.nih.gov/pubmed/15620359", "http://www.ncbi.nlm.nih.gov/pubmed/12796785", "http://www.ncbi.nlm.nih.gov/pubmed/1621094", "http://www.ncbi.nlm.nih.gov/pubmed/28220838", "http://www.ncbi.nlm.nih.gov/pubmed/20471353", "http://www.ncbi.nlm.nih.gov/pubmed/23576952"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Neurexins and neuroligins are two distinct families of single-pass transmembrane proteins localized at pre- and postsynapses, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583"}, {"offsetInBeginSection": 489, "offsetInEndSection": 690, "text": "In this review, we summarize the structure and basic synaptic function of neurexins and neuroligins, followed by behaviors and synaptic phenotypes of knock-in and knock-out mouse of these family genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583"}, {"offsetInBeginSection": 691, "offsetInEndSection": 856, "text": "From the studies of these mice, it turns out that the effects of neurexins and neuroligins are amazingly neural circuit dependent, even within the same brain region.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583"}, {"offsetInBeginSection": 857, "offsetInEndSection": 951, "text": "In addition, neurexins and neuroligins are commonly involved in the endocannabinoid signaling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Silencing of neuroligin function by postsynaptic neurexins.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 126, "offsetInEndSection": 330, "text": "Synaptic adhesion molecules are thought to play an important role in synaptogenesis, and several trans-synaptic adhesion systems that promote the formation and maturation of synapses have been identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 331, "offsetInEndSection": 479, "text": "The neuroligin-neurexin complex is a heterophilic adhesion system that promotes assembly and maturation of synapses through bidirectional signaling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 480, "offsetInEndSection": 600, "text": "In this protein complex, postsynaptic neuroligins are thought to interact trans-synaptically with presynaptic neurexins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 677, "offsetInEndSection": 836, "text": "Using immunoelectron microscopy, we found that endogenous neurexins and epitope-tagged neurexin-1beta are localized to axons and presynaptic terminals in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 837, "offsetInEndSection": 907, "text": "Unexpectedly, neurexins are also abundant in the postsynaptic density.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}]}, {"id": "5a7238d32dc08e987e000009", "body": "Which two cotransporters are inhibited by sotagliflozin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28899222", "http://www.ncbi.nlm.nih.gov/pubmed/26049551", "http://www.ncbi.nlm.nih.gov/pubmed/28811850", "http://www.ncbi.nlm.nih.gov/pubmed/25759591", "http://www.ncbi.nlm.nih.gov/pubmed/28387957", "http://www.ncbi.nlm.nih.gov/pubmed/28872070", "http://www.ncbi.nlm.nih.gov/pubmed/26548423", "http://www.ncbi.nlm.nih.gov/pubmed/25690134", "http://www.ncbi.nlm.nih.gov/pubmed/26484403", "http://www.ncbi.nlm.nih.gov/pubmed/16446421"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222"}, {"offsetInBeginSection": 120, "offsetInEndSection": 306, "text": "We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222"}, {"offsetInBeginSection": 307, "offsetInEndSection": 595, "text": "Methods In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222"}, {"offsetInBeginSection": 920, "offsetInEndSection": 1112, "text": "Results A significantly larger proportion of patients in the sotagliflozin group than in the placebo group achieved the primary end point (200 of 699 patients [28.6%] vs. 107 of 703 [15.2%], P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "OBJECTIVE: To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.RESEARCH DESIGN AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551"}, {"offsetInBeginSection": 446, "offsetInEndSection": 967, "text": "RESULTS: In the sotagliflozin-treated group, the percent reduction from baseline in the primary end point of bolus insulin dose was 32.1% (P = 0.007), accompanied by lower mean daily glucose measured by continuous glucose monitoring (CGM) of 148.8 mg/dL (8.3 mmol/L) (P = 0.010) and a reduction of 0.55% (5.9 mmol/mol) (P = 0.002) in HbA1c compared with the placebo group that showed 6.4% reduction in bolus insulin dose, a mean daily glucose of 170.3 mg/dL (9.5 mmol/L), and a decrease of 0.06% (0.65 mmol/mol) in HbA1c.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551"}, {"offsetInBeginSection": 968, "offsetInEndSection": 1322, "text": "The percentage of time in target glucose range 70-180 mg/dL (3.9-10.0 mmol/L) increased from baseline with sotagliflozin compared with placebo, to 68.2% vs. 54.0% (P = 0.003), while the percentage of time in hyperglycemic range >180 mg/dL (10.0 mmol/L) decreased from baseline, to 25.0% vs. 40.2% (P = 0.002), for sotagliflozin and placebo, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1434, "text": "Body weight decreased (1.7 kg) with sotagliflozin compared with a 0.5 kg gain (P = 0.005) in the placebo group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551"}, {"offsetInBeginSection": 1434, "offsetInEndSection": 1664, "text": "CONCLUSIONS: As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850"}]}, {"id": "58f8a08370f9fc6f0f00001b", "body": "Which are the main manifestations of Ohdo syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15127758", "http://www.ncbi.nlm.nih.gov/pubmed/8279489", "http://www.ncbi.nlm.nih.gov/pubmed/23395478", "http://www.ncbi.nlm.nih.gov/pubmed/12868473", "http://www.ncbi.nlm.nih.gov/pubmed/7519949", "http://www.ncbi.nlm.nih.gov/pubmed/9546834", "http://www.ncbi.nlm.nih.gov/pubmed/18798845", "http://www.ncbi.nlm.nih.gov/pubmed/9184251", "http://www.ncbi.nlm.nih.gov/pubmed/16700052", "http://www.ncbi.nlm.nih.gov/pubmed/10631927"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Skeletal manifestations in Ohdo syndrome: a case with bilateral patella dislocations.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "We report a new case of Ohdo syndrome with bilateral patella dislocations where surgical intervention has been indicated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758"}, {"offsetInBeginSection": 122, "offsetInEndSection": 296, "text": "A review of the skeletal manifestations reported in the literature on Ohdo syndrome reveals that joint laxity and skeletal deformities are important aspects of the phenotype.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Two additional cases of the Ohdo blepharophimosis syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8279489"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Two additional cases of the Ohdo blepharophimosis syndrome are described and compared to the 5 patients previously reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8279489"}, {"offsetInBeginSection": 125, "offsetInEndSection": 262, "text": "Blepharophimosis, ptosis, dental hypoplasia, mental retardation, and deafness can be considered as common manifestations of the syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8279489"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Mutations in MED12 cause X-linked Ohdo syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Ohdo syndrome comprises a heterogeneous group of disorders characterized by intellectual disability (ID) and typical facial features, including blepharophimosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 162, "offsetInEndSection": 415, "text": "Clinically, these blepharophimosis-ID syndromes have been classified in five distinct subgroups, including the Maat-Kievit-Brunner (MKB) type, which, in contrast to the others, is characterized by X-linked inheritance and facial coarsening at older age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 416, "offsetInEndSection": 520, "text": "We performed exome sequencing in two families, each with two affected males with Ohdo syndrome MKB type.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}]}, {"id": "5a6e5df6b750ff445500004e", "body": "Describe GARLIC (GWAS-based Prediction Toolkit for Connecting Diseases and Cell Types)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28007912", "http://www.ncbi.nlm.nih.gov/pubmed/28302177", "http://www.ncbi.nlm.nih.gov/pubmed/26158728", "http://www.ncbi.nlm.nih.gov/pubmed/21382596", "http://www.ncbi.nlm.nih.gov/pubmed/24799394", "http://www.ncbi.nlm.nih.gov/pubmed/28240269", "http://www.ncbi.nlm.nih.gov/pubmed/19508241", "http://www.ncbi.nlm.nih.gov/pubmed/28036406", "http://www.ncbi.nlm.nih.gov/pubmed/28598966", "http://www.ncbi.nlm.nih.gov/pubmed/21536720"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "GARLIC: a bioinformatic toolkit for aetiologically connecting diseases and cell type-specific regulatory maps.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Genome-wide association studies (GWAS) have emerged as a powerful tool to uncover the genetic basis of human common diseases, which often show a complex, polygenic and multi-factorial aetiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007912"}, {"offsetInBeginSection": 522, "offsetInEndSection": 959, "text": "Based on emerging evidences suggesting that disease-associated SNPs are frequently found within cell type-specific regulatory sequences, here we present GARLIC (GWAS-based Prediction Toolkit for Connecting Diseases and Cell Types), a user-friendly, multi-purpose software with an associated database and online viewer that, using global maps of cis-regulatory elements, can aetiologically connect human diseases with relevant cell types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007912"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1312, "text": "Overall, GARLIC can satisfy several important needs within the field of medical genetics, thus potentially assisting in the ultimate goal of uncovering the elusive and complex genetic basis of common human disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "It remains challenging to predict regulatory variants in particular tissues or cell types due to highly context-specific gene regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302177"}, {"offsetInBeginSection": 138, "offsetInEndSection": 357, "text": "By connecting large-scale epigenomic profiles to expression quantitative trait loci (eQTLs) in a wide range of human tissues/cell types, we identify critical chromatin features that predict variant regulatory potential.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302177"}, {"offsetInBeginSection": 487, "offsetInEndSection": 597, "text": "Our method exhibits significant GWAS signal enrichment and is superior to existing cell type-specific methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302177"}, {"offsetInBeginSection": 598, "offsetInEndSection": 772, "text": "Furthermore, using phenotypically relevant epigenomes to weight the GWAS single-nucleotide polymorphisms, we improve the statistical power of the gene-based association test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302177"}, {"offsetInBeginSection": 471, "offsetInEndSection": 694, "text": "First we constructed a network with 18 node types--genes, diseases, tissues, pathophysiologies, and 14 MSigDB (molecular signatures database) collections--and 19 edge types from high-throughput publicly-available resources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158728"}, {"offsetInBeginSection": 695, "offsetInEndSection": 844, "text": "From this network composed of 40,343 nodes and 1,608,168 edges, we extracted features that describe the topology between specific genes and diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158728"}]}, {"id": "5a7d4721faa1ab7d2e000012", "body": "What does davunetide do to microtubules?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21902667", "http://www.ncbi.nlm.nih.gov/pubmed/23971871", "http://www.ncbi.nlm.nih.gov/pubmed/24210139", "http://www.ncbi.nlm.nih.gov/pubmed/21050875", "http://www.ncbi.nlm.nih.gov/pubmed/24873720", "http://www.ncbi.nlm.nih.gov/pubmed/22347799", "http://www.ncbi.nlm.nih.gov/pubmed/20417241", "http://www.ncbi.nlm.nih.gov/pubmed/24533805", "http://www.ncbi.nlm.nih.gov/pubmed/21524250", "http://www.ncbi.nlm.nih.gov/pubmed/25955282"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP (davunetide) toward clinical development with emphasis on microtubule protection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 205, "offsetInEndSection": 386, "text": "ADNP immunoreactivity was shown to occasionally decorate microtubules and ADNP silencing inhibited neurite outgrowth as measured by microtubule associated protein 2 (MAP2) labeling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 708, "offsetInEndSection": 949, "text": "NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1306, "text": "NAP (davunetide) protection against neurodegeneration has recently been shown to extend to katanin-related microtubule disruption under conditions of tau deficiencies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 162, "offsetInEndSection": 320, "text": "Davunetide has also been shown to prevent apoptosis or programmed-cell death in a range of in vitro and in vivo models by promoting microtubule stabilization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971871"}, {"offsetInBeginSection": 321, "offsetInEndSection": 626, "text": "Potential clinical uses of davunetide include neurodegenerative disorders such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or cognitive impairment in other diseases such as schizophrenia where microtubule structure and function is known to be impaired.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971871"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210139"}, {"offsetInBeginSection": 700, "offsetInEndSection": 851, "text": "Davunetide is a novel neuroprotective peptide that is thought to impact neuronal integrity and cell survival through the stabilization of microtubules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417241"}, {"offsetInBeginSection": 398, "offsetInEndSection": 557, "text": "Possible mechanisms of NAP actions include anti-inflammatory effect, antioxidant activity, inhibition of protein aggregation and interaction with microtubules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24533805"}]}, {"id": "5a886da58cb19eca6b000004", "body": "Has Cas9 gene editing the potential to correct inhereted hearing loss?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25987504", "http://www.ncbi.nlm.nih.gov/pubmed/26829318", "http://www.ncbi.nlm.nih.gov/pubmed/28195574", "http://www.ncbi.nlm.nih.gov/pubmed/27500183", "http://www.ncbi.nlm.nih.gov/pubmed/26817415", "http://www.ncbi.nlm.nih.gov/pubmed/28706995", "http://www.ncbi.nlm.nih.gov/pubmed/28758991", "http://www.ncbi.nlm.nih.gov/pubmed/28527117", "http://www.ncbi.nlm.nih.gov/pubmed/27494557", "http://www.ncbi.nlm.nih.gov/pubmed/27498021"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "The application of genome editing in studying hearing loss.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Targeted genome editing mediated by clustered, regularly interspaced, short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) technology has emerged as one of the most powerful tools to study gene functions, and with potential to treat genetic disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 472, "offsetInEndSection": 664, "text": "The simplicity and robustness of CRISPR/Cas9-directed genome editing in human cells and model organisms such as zebrafish, mice and primates make it a promising technology in hearing research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 665, "offsetInEndSection": 843, "text": "With CRISPR/Cas9 technology, functions of inner ear genes can be studied efficiently by the disruption of normal gene alleles through non-homologous-end-joining (NHEJ) mechanism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 844, "offsetInEndSection": 1025, "text": "For genetic hearing loss, CRISPR/Cas9 has potential to repair gene mutations by homology-directed-repair (HDR) or to disrupt dominant mutations by NHEJ, which could restore hearing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1361, "text": "Thus, application of CRISPR/Cas9 in hearing research will open up new avenues for understanding the pathology of genetic hearing loss and provide new routes in the development of treatment to restore hearing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1444, "text": "In this review, we describe major methodologies currently used for genome editing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1646, "text": "We will highlight applications of these technologies in studies of genetic disorders and discuss issues pertaining to applications of CRISPR/Cas9 in auditory systems implicated in genetic hearing loss.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "The combination of Cas9, guide RNA and repair template DNA can induce precise gene editing and the correction of genetic diseases in adult mammals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26829318"}, {"offsetInBeginSection": 792, "offsetInEndSection": 966, "text": "The efficiency of correction was >6% of hepatocytes after a single application, suggesting potential utility of Cas9-based therapeutic genome editing for a range of diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26829318"}]}, {"id": "5a7345792dc08e987e000019", "body": "Describe mechanism of action of Napabucasin.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28573435", "http://www.ncbi.nlm.nih.gov/pubmed/26899963", "http://www.ncbi.nlm.nih.gov/pubmed/11916069", "http://www.ncbi.nlm.nih.gov/pubmed/11563078", "http://www.ncbi.nlm.nih.gov/pubmed/6217819", "http://www.ncbi.nlm.nih.gov/pubmed/22174430", "http://www.ncbi.nlm.nih.gov/pubmed/22664071", "http://www.ncbi.nlm.nih.gov/pubmed/28683005", "http://www.ncbi.nlm.nih.gov/pubmed/2464658", "http://www.ncbi.nlm.nih.gov/pubmed/23821284"], "snippets": [{"offsetInBeginSection": 835, "offsetInEndSection": 1063, "text": "The therapeutic potential of napabucasin was first reported in a preclinical study that demonstrated the potent anti-tumor and anti-metastatic activity of napabucasin in several different cancer types, both in vitro and in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28573435"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1227, "text": "In mouse models, napabucasin was effective both as a monotherapy and in combination with other agents; in particular, synergy was observed with paclitaxel in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28573435"}, {"offsetInBeginSection": 1457, "offsetInEndSection": 1608, "text": "Adverse events attributed to napabucasin have been predominantly mild, although some patients have experienced grade 3 gastrointestinal adverse events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28573435"}, {"offsetInBeginSection": 1609, "offsetInEndSection": 1735, "text": "More severe adverse events required reduced or discontinued dosing of napabucasin or medication to reverse or manage symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28573435"}, {"offsetInBeginSection": 1736, "offsetInEndSection": 1912, "text": "In conclusion, napabucasin may prove useful in targeting cancer stem cells, with the potential to suppress metastasis and prevent relapse in patients with varying cancer types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28573435"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899963"}, {"offsetInBeginSection": 271, "offsetInEndSection": 412, "text": "A small molecule, napabucasin (BBI608), recently have been identified with suppression of stemness-high cancer cells in a variety of cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899963"}, {"offsetInBeginSection": 413, "offsetInEndSection": 530, "text": "However, the effects of napabucasin on PCa cells as well as PrCSCs isolated from PCa cells have not yet been defined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899963"}, {"offsetInBeginSection": 531, "offsetInEndSection": 713, "text": "The effect of napabucasin on PCa cells in cell proliferation, colony formation, and cell migration in vitro were measured by MTS, colony formation assay, and Transwell, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899963"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1024, "text": "Furthermore, the role of napabucasin on self-renewal and survival of PrCSCs was evaluated by their ability to grow spheres and cell viability assay, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899963"}]}, {"id": "590af75d70f9fc6f0f00001c", "body": "Which algorithm is used by the UCSC Genome Browser?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25348212", "http://www.ncbi.nlm.nih.gov/pubmed/22080555", "http://www.ncbi.nlm.nih.gov/pubmed/19957273", "http://www.ncbi.nlm.nih.gov/pubmed/18428780", "http://www.ncbi.nlm.nih.gov/pubmed/21975940", "http://www.ncbi.nlm.nih.gov/pubmed/23255150", "http://www.ncbi.nlm.nih.gov/pubmed/25766521", "http://www.ncbi.nlm.nih.gov/pubmed/19920125", "http://www.ncbi.nlm.nih.gov/pubmed/12519945", "http://www.ncbi.nlm.nih.gov/pubmed/17993665"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Navigating protected genomics data with UCSC Genome Browser in a Box.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "UNLABELLED: Genome Browser in a Box (GBiB) is a small virtual machine version of the popular University of California Santa Cruz (UCSC) Genome Browser that can be run on a researcher's own computer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 199, "offsetInEndSection": 336, "text": "Once GBiB is installed, a standard web browser is used to access the virtual server and add personal data files from the local hard disk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 483, "offsetInEndSection": 626, "text": "IMPLEMENTATION: Software downloads and installation instructions are freely available for non-commercial use at https://genome-store.ucsc.edu/.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 627, "offsetInEndSection": 819, "text": "GBiB requires the installation of open-source software VirtualBox, available for all major operating systems, and the UCSC Genome Browser, which is open source and free for non-commercial use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 820, "offsetInEndSection": 919, "text": "Commercial use of GBiB and the Genome Browser requires a license (http://genome.ucsc.edu/license/).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "The UCSC Archaeal Genome Browser: 2012 update.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22080555"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "The UCSC Archaeal Genome Browser (http://archaea.ucsc.edu) offers a graphical web-based resource for exploration and discovery within archaeal and other selected microbial genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22080555"}, {"offsetInBeginSection": 181, "offsetInEndSection": 426, "text": "By bringing together existing gene annotations, gene expression data, multiple-genome alignments, pre-computed sequence comparisons and other specialized analysis tracks, the genome browser is a powerful aggregator of varied genomic information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22080555"}, {"offsetInBeginSection": 427, "offsetInEndSection": 632, "text": "The genome browser environment maintains the current look-and-feel of the vertebrate UCSC Genome Browser, but also integrates archaeal and bacterial-specific tracks with a few graphic display enhancements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22080555"}]}, {"id": "5a76056983b0d9ea66000012", "body": "Does DDX54 play a role in DNA damage response?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28596291", "http://www.ncbi.nlm.nih.gov/pubmed/23239230", "http://www.ncbi.nlm.nih.gov/pubmed/27022404", "http://www.ncbi.nlm.nih.gov/pubmed/27074761", "http://www.ncbi.nlm.nih.gov/pubmed/19759019", "http://www.ncbi.nlm.nih.gov/pubmed/28525740", "http://www.ncbi.nlm.nih.gov/pubmed/22361354", "http://www.ncbi.nlm.nih.gov/pubmed/26884483", "http://www.ncbi.nlm.nih.gov/pubmed/16410768", "http://www.ncbi.nlm.nih.gov/pubmed/24795278"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "DDX54 regulates transcriptome dynamics during DNA damage response.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596291"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The cellular response to genotoxic stress is mediated by a well-characterized network of DNA surveillance pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596291"}, {"offsetInBeginSection": 116, "offsetInEndSection": 248, "text": "The contribution of post-transcriptional gene regulatory networks to the DNA damage response (DDR) has not been extensively studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596291"}, {"offsetInBeginSection": 326, "offsetInEndSection": 404, "text": "RNA:Ddx54, expressing a short hairpin RNA to silence endogenous Ddx54 protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239230"}, {"offsetInBeginSection": 1589, "offsetInEndSection": 1776, "text": "These results suggest that Ddx54 protein play an important role in central nervous system myelination, presumably in myelin sheath formation after the differentiation of oligodendrocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239230"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1286, "text": "The present study suggests that Ddx54 plays crucial role in remyelination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27022404"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "The dynamic behavior of Ect2 in response to DNA damage.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27074761"}, {"offsetInBeginSection": 140, "offsetInEndSection": 274, "text": "Since most BRCT-containing proteins are involved in DNA damage response and/or DNA repair, we tested whether Ect2 plays similar roles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27074761"}, {"offsetInBeginSection": 275, "offsetInEndSection": 436, "text": "We report that in primary mouse embryonic fibroblasts (MEFs), DNA damage quickly led to Ect2 relocalization to the chromatin and DNA damage foci-like structures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27074761"}, {"offsetInBeginSection": 697, "offsetInEndSection": 765, "text": "These results suggest that Ect2 plays a role in DNA damage response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27074761"}]}, {"id": "5a7d5033faa1ab7d2e000015", "body": "Is davunetide being considered for the treatment of progressive supranuclear palsy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22347799", "http://www.ncbi.nlm.nih.gov/pubmed/24873720", "http://www.ncbi.nlm.nih.gov/pubmed/23971871", "http://www.ncbi.nlm.nih.gov/pubmed/26459661", "http://www.ncbi.nlm.nih.gov/pubmed/21902667", "http://www.ncbi.nlm.nih.gov/pubmed/26227071", "http://www.ncbi.nlm.nih.gov/pubmed/26421389", "http://www.ncbi.nlm.nih.gov/pubmed/20678069", "http://www.ncbi.nlm.nih.gov/pubmed/26948290", "http://www.ncbi.nlm.nih.gov/pubmed/28436538"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease characterized by the accumulation of tau protein aggregates in the basal ganglia, brainstem and cerebral cortex leading to rapid disease progression and death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 111, "offsetInEndSection": 224, "text": "Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1223, "text": "FINDINGS: 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 1570, "offsetInEndSection": 1716, "text": "54 serious adverse events were reported in each of the treatment groups, including 11 deaths in the davunetide group and ten in the placebo group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 321, "offsetInEndSection": 626, "text": "Potential clinical uses of davunetide include neurodegenerative disorders such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or cognitive impairment in other diseases such as schizophrenia where microtubule structure and function is known to be impaired.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971871"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Interventions in progressive supranuclear palsy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26459661"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Progressive supranuclear palsy (PSP) an atypical parkinsonian with a common phenotype comprising early falls, the characteristic slowing of vertical saccades and a frontal syndrome with marked apathy (Richardson's syndrome).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26459661"}, {"offsetInBeginSection": 1515, "offsetInEndSection": 1707, "text": "Based on these extensive preclinical results, davunetide (NAP) is now being evaluated in a Phase II/III study of the tauopathy, progressive supranuclear palsy (PSP); (Allon Therapeutics Inc.).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}]}, {"id": "5a8941c5bc7bade53a000002", "body": "Which aminoacid position in the human CREB protein is phosphorylated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7554179", "http://www.ncbi.nlm.nih.gov/pubmed/1532242", "http://www.ncbi.nlm.nih.gov/pubmed/8065935", "http://www.ncbi.nlm.nih.gov/pubmed/2136830", "http://www.ncbi.nlm.nih.gov/pubmed/8627701", "http://www.ncbi.nlm.nih.gov/pubmed/8125987", "http://www.ncbi.nlm.nih.gov/pubmed/27816995", "http://www.ncbi.nlm.nih.gov/pubmed/8754745", "http://www.ncbi.nlm.nih.gov/pubmed/23143030", "http://www.ncbi.nlm.nih.gov/pubmed/7854055"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "cAMP response element binding protein is expressed and phosphorylated in the human heart.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7554179"}, {"offsetInBeginSection": 791, "offsetInEndSection": 941, "text": "CRE specific binding was found in competition studies, and CREB and its phosphorylated form were immunologically identified in supershift experiments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7554179"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1338, "text": "CONCLUSIONS: We conclude that in the failing and nonfailing human heart, CREB is expressed on the protein and mRNA levels and that CREB is phosphorylated and able to bind to CREs, indicating a functional role of CREB in the human heart.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7554179"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Direct interaction of CREB protein with 21 bp Tax-response elements of HTLV-ILTR.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}, {"offsetInBeginSection": 409, "offsetInEndSection": 505, "text": "Here we demonstrate that the 42 kDa protein is the cAMP-response element-binding (CREB) protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}, {"offsetInBeginSection": 506, "offsetInEndSection": 752, "text": "This is shown by phosphorylation of the proteins eluted from the DNA-affinity column with protein kinase A (PKA) in vitro and subsequent indirect immunoprecipitation with a CREB-specific antiserum raised against an internal CREB-specific peptide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}, {"offsetInBeginSection": 753, "offsetInEndSection": 888, "text": "This method allows detection of phosphorylated proteins by autoradiography with high sensitivity and is superior to metabolic labeling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}, {"offsetInBeginSection": 889, "offsetInEndSection": 1094, "text": "One of the phosphorylated proteins co-migrates with immuno-affinity-purified CREB protein--also phosphorylated in vitro--and competes with the peptide antigen, which proves the specificity of the reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1212, "text": "The purified CREB protein leads to specific DNA-protein complexes in DNA mobility-shift analyses with all three TREs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}, {"offsetInBeginSection": 1552, "offsetInEndSection": 1635, "text": "Antibodies against CREB but not Tax affect the mobility of the DNA-protein complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}]}, {"id": "5a737b483b9d13c70800000b", "body": "Which drugs were tested in the KEYNOTE-006 study?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28987768", "http://www.ncbi.nlm.nih.gov/pubmed/28822576", "http://www.ncbi.nlm.nih.gov/pubmed/26846323", "http://www.ncbi.nlm.nih.gov/pubmed/28125365", "http://www.ncbi.nlm.nih.gov/pubmed/27896938", "http://www.ncbi.nlm.nih.gov/pubmed/28964438", "http://www.ncbi.nlm.nih.gov/pubmed/28837405", "http://www.ncbi.nlm.nih.gov/pubmed/12942788", "http://www.ncbi.nlm.nih.gov/pubmed/6594234", "http://www.ncbi.nlm.nih.gov/pubmed/26034052"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "OBJECTIVE: Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768"}, {"offsetInBeginSection": 379, "offsetInEndSection": 546, "text": "The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was administered at baseline and throughout the study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 1739, "offsetInEndSection": 1974, "text": "Primary analysis was done on the intention-to-treat population (all randomly assigned patients) and safety analyses were done in the treated population (all randomly assigned patients who received at least one dose of study treatment).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 2540, "offsetInEndSection": 2610, "text": "A total of 811 patients received at least one dose of study treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 3063, "offsetInEndSection": 3284, "text": "INTERPRETATION: Substantiating the results of the interim analyses of KEYNOTE-006, pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between pembrolizumab dosing schedules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 209, "offsetInEndSection": 472, "text": "This intravenous drug is indicated for the treatment of advanced (unresectable or metastatic) melanoma, on the basis of its clinical benefit in this setting in the phase I KEYNOTE 001 trial (expansion cohorts) and the phase II and III trials, KEYNOTE 002 and 006.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846323"}, {"offsetInBeginSection": 720, "offsetInEndSection": 1197, "text": "In the trials with active comparator arms, pembrolizumab regimens significantly improved progression-free survival (PFS), overall survival (OS) and overall response rates (ORR) relative to ipilimumab in ipilimumab-na\u00efve patients (KEYNOTE 006), and significantly improved PFS and ORR, but not OS (although OS data are immature), relative to chemotherapy in ipilimumab-refractory patients, who had also received BRAF/MEK inhibitor therapy if BRAF-mutation positive (KEYNOTE 002).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846323"}]}, {"id": "590c740d70f9fc6f0f00001d", "body": "Which proteins are controlling sterol metabolism in S. cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28830344", "http://www.ncbi.nlm.nih.gov/pubmed/8474436", "http://www.ncbi.nlm.nih.gov/pubmed/20870767", "http://www.ncbi.nlm.nih.gov/pubmed/12006573", "http://www.ncbi.nlm.nih.gov/pubmed/7729765", "http://www.ncbi.nlm.nih.gov/pubmed/10929718", "http://www.ncbi.nlm.nih.gov/pubmed/7896706", "http://www.ncbi.nlm.nih.gov/pubmed/8067730", "http://www.ncbi.nlm.nih.gov/pubmed/8743048", "http://www.ncbi.nlm.nih.gov/pubmed/9090292"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Tum1 is involved in the metabolism of sterol esters in Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "BACKGROUND: The only hitherto known biological role of yeast Saccharomyces cerevisiae Tum1 protein is in the tRNA thiolation pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 1226, "offsetInEndSection": 1379, "text": "We further showed that the tRNA thiolation pathway is not involved in the regulation of sterol ester content in S. cerevisiae, as overexpression of the t", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 194, "offsetInEndSection": 373, "text": "We demonstrate structural and functional conservation between the enzymes from humans, a budding yeast (Saccharomyces cerevisiae), and a fission yeast (Schizosaccharomyces pombe).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 374, "offsetInEndSection": 518, "text": "The amino acid sequences of the human and S. pombe proteins deduced from cloned cDNAs were compared to those of the known S. cerevisiae protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 1011, "offsetInEndSection": 1273, "text": "Expression of cDNA clones encoding S. pombe or hybrid human-S. cerevisiae squalene synthetases reversed the ergosterol requirement of S. cerevisiae cells bearing ERG9 gene disruptions, showing that these enzymes can functionally replace the S. cerevisiae enzyme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1545, "text": "Inhibition of sterol synthesis in S. cerevisiae and S. pombe cells or in cultured human fibroblasts by treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor lovastatin resulted in elevated levels of squalene synthetase mRNA in all three cell types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 335, "offsetInEndSection": 500, "text": "The precise source(s) of PV membrane cholesterol is unknown, as is whether the bacterium actively diverts and/or modifies host cell cholesterol or sterol precursors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870767"}, {"offsetInBeginSection": 651, "offsetInEndSection": 808, "text": "Absent in other prokaryotes, this enzyme is predicted to reduce sterol double bonds at carbon 24 in the final step of cholesterol or ergosterol biosynthesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870767"}, {"offsetInBeginSection": 1017, "offsetInEndSection": 1167, "text": "CBU1206 activity was examined by expressing the protein in a Saccharomyces cerevisiae erg4 mutant under the control of a galactose-inducible promoter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870767"}]}, {"id": "5a7607f683b0d9ea66000014", "body": "Is Drk essential for anesthesia-resistant memory (ARM) in Drosophila?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28973902", "http://www.ncbi.nlm.nih.gov/pubmed/28416593", "http://www.ncbi.nlm.nih.gov/pubmed/21808003", "http://www.ncbi.nlm.nih.gov/pubmed/24239122", "http://www.ncbi.nlm.nih.gov/pubmed/14972677", "http://www.ncbi.nlm.nih.gov/pubmed/15143285", "http://www.ncbi.nlm.nih.gov/pubmed/27195782", "http://www.ncbi.nlm.nih.gov/pubmed/21530256", "http://www.ncbi.nlm.nih.gov/pubmed/10073459", "http://www.ncbi.nlm.nih.gov/pubmed/27466338"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Drk-mediated signaling to Rho kinase is required for anesthesia-resistant memory in", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973902"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Anesthesia-resistant memory (ARM) was described decades ago, but the mechanisms that underlie this protein synthesis-independent form of consolidated memory in", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973902"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Serotonin-mushroom body circuit modulating the formation of anesthesia-resistant memory in Drosophila.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Pavlovian olfactory learning in Drosophila produces two genetically distinct forms of intermediate-term memories: anesthesia-sensitive memory, which requires the amnesiac gene, and anesthesia-resistant memory (ARM), which requires the radish gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}, {"offsetInBeginSection": 601, "offsetInEndSection": 1154, "text": "Three supporting lines of evidence indicate that ARM formation requires 5HT released from only two dorsal paired medial (DPM) neurons onto the mushroom bodies (MBs), the olfactory learning and memory center in Drosophila: (i) DPM neurons were 5HT-antibody immunopositive; (ii) temporal inhibition of 5HT synthesis or release from DPM neurons, but not from other serotonergic neurons, impaired ARM formation; (iii) knocking down the expression of d5HT1A serotonin receptors in \u03b1/\u03b2 MB neurons, which are innervated by DPM neurons, inhibited ARM formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}, {"offsetInBeginSection": 1155, "offsetInEndSection": 1325, "text": "Thus, in addition to the Amnesiac peptide required for anesthesia-sensitive memory formation, the two DPM neurons also release 5HT acting on MB neurons for ARM formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "An octopamine-mushroom body circuit modulates the formation of anesthesia-resistant memory in Drosophila.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239122"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "BACKGROUND: Drosophila olfactory aversive conditioning produces two components of intermediate-term memory: anesthesia-sensitive memory (ASM) and anesthesia-resistant memory (ARM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239122"}, {"offsetInBeginSection": 364, "offsetInEndSection": 513, "text": "Octopamine (OA), an invertebrate analog of norepinephrine, is involved in appetitive conditioning, but its role in aversive memory remains uncertain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239122"}, {"offsetInBeginSection": 513, "offsetInEndSection": 668, "text": "RESULTS: Here, we show that chemical neurotransmission from the APL neuron, after conditioning but before testing, is necessary for aversive ARM formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239122"}]}, {"id": "5a7d50d0faa1ab7d2e000016", "body": "Is ACI-35 a passive vaccine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27485083", "http://www.ncbi.nlm.nih.gov/pubmed/6272472", "http://www.ncbi.nlm.nih.gov/pubmed/8041130", "http://www.ncbi.nlm.nih.gov/pubmed/26985884", "http://www.ncbi.nlm.nih.gov/pubmed/27079929", "http://www.ncbi.nlm.nih.gov/pubmed/12600748", "http://www.ncbi.nlm.nih.gov/pubmed/8613399", "http://www.ncbi.nlm.nih.gov/pubmed/20920572", "http://www.ncbi.nlm.nih.gov/pubmed/10431138", "http://www.ncbi.nlm.nih.gov/pubmed/6262995"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485083"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485083"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "[Use of the passive hemagglutination reaction to study Aujeszky's disease].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6272472"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Experiments were carried out with the use of the passive hemagglutination test to study Aujeszky's disease, the antigen employed being the avirulent MK-35 strain of the disease virus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6272472"}, {"offsetInBeginSection": 184, "offsetInEndSection": 341, "text": "It was established that the passive hemmagglutination reaction could be referred to as a specific and rapid method in the study and diagnosis of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6272472"}, {"offsetInBeginSection": 437, "offsetInEndSection": 566, "text": "In the treatment with an MK-25 vaccine there were predominantly antibodies detectable with the passive hemagglutination reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6272472"}, {"offsetInBeginSection": 395, "offsetInEndSection": 504, "text": "A rat model of passive immunization was used to test the role of anti-donor antibody in hyperacute rejection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041130"}, {"offsetInBeginSection": 1338, "offsetInEndSection": 1491, "text": "However, removal of RT1.Aa antigen from ACI serum prior to use in the passive transfer model did not abrogate the graft prolongation observed previously.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041130"}, {"offsetInBeginSection": 680, "offsetInEndSection": 799, "text": "Monoclonal antibodies for passive immunization or treatment show promise, with VRC01 entering advanced clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26985884"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Practical aspects in the use of passive immunization as an alternative to attenuated viral vaccines.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27079929"}]}, {"id": "5a894f6abc7bade53a000004", "body": "Which are the effects of ALDH2 deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25831092", "http://www.ncbi.nlm.nih.gov/pubmed/23689279", "http://www.ncbi.nlm.nih.gov/pubmed/12905081", "http://www.ncbi.nlm.nih.gov/pubmed/27186430", "http://www.ncbi.nlm.nih.gov/pubmed/26173414", "http://www.ncbi.nlm.nih.gov/pubmed/20515806", "http://www.ncbi.nlm.nih.gov/pubmed/17127431", "http://www.ncbi.nlm.nih.gov/pubmed/26734919", "http://www.ncbi.nlm.nih.gov/pubmed/27488451", "http://www.ncbi.nlm.nih.gov/pubmed/8290656"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intragastric alcohol administration.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 217, "offsetInEndSection": 371, "text": "In alcohol drinkers, ALDH2-deficiency is a well-known risk factor for upper aerodigestive tract cancers, i.e., head and neck cancer and esophageal cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 434, "offsetInEndSection": 627, "text": "In this study we demonstrated for the first time that ALDH2 deficiency results in markedly increased exposure of the gastric mucosa to acetaldehyde after intragastric administration of alcohol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1127, "text": "The gastric mucosa also possesses the acetaldehyde-eliminating ALDH2 enzyme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1286, "text": "Due to decreased mucosal ALDH2 activity, the elimination of ethanol-derived acetaldehyde is decreased, which results in its accumulation in the gastric juice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 1287, "offsetInEndSection": 1622, "text": "We also demonstrate that ALDH2 deficiency, proton pump inhibitor (PPI) treatment, and L-cysteine cause independent changes in gastric juice and salivary acetaldehyde levels, indicating that intragastric acetaldehyde is locally regulated by gastric mucosal ADH and ALDH2 enzymes, and by oral microbes colonizing an achlorhydric stomach.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 1832, "offsetInEndSection": 1990, "text": "A capsule that slowly releases L-cysteine effectively eliminated acetaldehyde from the gastric juice of PPI-treated ALDH2-active and ALDH2-deficient subjects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25831092"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that metabolizes ethanol and toxic aldehydes such as 4-hydroxy-2-nonenal (4-HNE).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689279"}, {"offsetInBeginSection": 141, "offsetInEndSection": 320, "text": "Using an unbiased proteomic search, we identified ALDH2 deficiency in stroke-prone spontaneously hypertensive rats (SHR-SP) as compared with spontaneously hypertensive rats (SHR).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689279"}, {"offsetInBeginSection": 321, "offsetInEndSection": 497, "text": "We concluded the causative role of ALDH2 deficiency in neuronal injury as overexpression or activation of ALDH2 conferred neuroprotection by clearing 4-HNE in in vitro studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689279"}]}, {"id": "5a7604de83b0d9ea66000011", "body": "What is mechanism of action of galunisertib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28691737", "http://www.ncbi.nlm.nih.gov/pubmed/27756784", "http://www.ncbi.nlm.nih.gov/pubmed/26057634", "http://www.ncbi.nlm.nih.gov/pubmed/28436712", "http://www.ncbi.nlm.nih.gov/pubmed/26902851", "http://www.ncbi.nlm.nih.gov/pubmed/26309397", "http://www.ncbi.nlm.nih.gov/pubmed/27509307", "http://www.ncbi.nlm.nih.gov/pubmed/25573078", "http://www.ncbi.nlm.nih.gov/pubmed/28481241", "http://www.ncbi.nlm.nih.gov/pubmed/26976322"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 141, "offsetInEndSection": 258, "text": "Galunisertib, a TGF-\u03b2 receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 259, "offsetInEndSection": 361, "text": "Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis.EXPERIMENTAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 508, "offsetInEndSection": 634, "text": "Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib.KEY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 1337, "offsetInEndSection": 1451, "text": "IMPLICATIONS: Galunisertib is a drug that deserves to be further investigated for the treatment of liver fibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 1452, "offsetInEndSection": 1530, "text": "Inhibition of SMAD2 phosphorylation is probably a central mechanism of action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 1531, "offsetInEndSection": 1683, "text": "In addition, blocking the production and maturation of collagens and promoting their degradation are related to the antifibrotic action of galunisertib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "TGF\u03b2R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784"}, {"offsetInBeginSection": 469, "offsetInEndSection": 619, "text": "The ability of galunisertib to inhibit SMAD activity induced by neuroblastoma patient blood and bone marrow plasmas in neuroblastoma cells was tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784"}, {"offsetInBeginSection": 620, "offsetInEndSection": 792, "text": "The impact of galunisertib on TGF\u03b21-induced inhibition of aNK cytotoxicity and ADCC in vitro and on anti-neuroblastoma activity in NOD-scid gamma (NSG) mice was determined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784"}]}, {"id": "590c74d170f9fc6f0f00001e", "body": "Which gene is the paralog of yeast UPC2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28986257", "http://www.ncbi.nlm.nih.gov/pubmed/24163365", "http://www.ncbi.nlm.nih.gov/pubmed/24453983", "http://www.ncbi.nlm.nih.gov/pubmed/11208779", "http://www.ncbi.nlm.nih.gov/pubmed/1885560", "http://www.ncbi.nlm.nih.gov/pubmed/26448198", "http://www.ncbi.nlm.nih.gov/pubmed/18487346", "http://www.ncbi.nlm.nih.gov/pubmed/17174052", "http://www.ncbi.nlm.nih.gov/pubmed/25385116", "http://www.ncbi.nlm.nih.gov/pubmed/9696767"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Ecm22 and Upc2 regulate yeast mating through control of expression of the mating genes PRM1 and PRM4.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986257"}, {"offsetInBeginSection": 185, "offsetInEndSection": 295, "text": "Cells lacking both ECM22 and UPC2 display strong mating defects whereas deletion of either gene has no effect.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986257"}, {"offsetInBeginSection": 366, "offsetInEndSection": 482, "text": "These genes are strongly induced in response to mating pheromone, which is also largely dependent on ECM22 and UPC2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "The yeast anaerobic response element AR1b regulates aerobic antifungal drug-dependent sterol gene expression.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 166, "offsetInEndSection": 386, "text": "Yeast studies defined a 7-bp consensus sterol-response element (SRE) common to genes involved in sterol biosynthesis and two transcription factors, Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 541, "offsetInEndSection": 760, "text": "We now show that it is two novel anaerobic AR1b elements in the UPC2 promoter that direct global ERG gene expression in response to a block in de novo ergosterol biosynthesis, brought about by antifungal drug treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 761, "offsetInEndSection": 898, "text": "The AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 1085, "offsetInEndSection": 1220, "text": "Recombinant endogenous promoter studies show that the UPC2 anaerobic AR1b elements act in trans to regulate ergosterol gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1340, "text": "Our results indicate that Upc2 must occupy UPC2 AR1b elements in order for ERG gene expression induction to take place.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 221, "offsetInEndSection": 404, "text": "However, in yeasts such as Saccharomyces cerevisiae and Candida albicans sterol synthesis is instead regulated by Upc2, an unrelated transcription factor with a Gal4-type zinc finger.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453983"}]}, {"id": "5a760c8483b0d9ea66000017", "body": "What is the FIRE (Functional Inference of Regulators of Expression) tool?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28961785", "http://www.ncbi.nlm.nih.gov/pubmed/28066488", "http://www.ncbi.nlm.nih.gov/pubmed/19442636", "http://www.ncbi.nlm.nih.gov/pubmed/24564496", "http://www.ncbi.nlm.nih.gov/pubmed/20418949", "http://www.ncbi.nlm.nih.gov/pubmed/18314574", "http://www.ncbi.nlm.nih.gov/pubmed/27794550", "http://www.ncbi.nlm.nih.gov/pubmed/22759573", "http://www.ncbi.nlm.nih.gov/pubmed/25910697", "http://www.ncbi.nlm.nih.gov/pubmed/17493254"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "FIRE: functional inference of genetic variants that regulate gene expression.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 134, "offsetInEndSection": 280, "text": "One mechanism by which noncoding single nucleotide variations (SNVs) influence downstream phenotypes is through the regulation of gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 281, "offsetInEndSection": 678, "text": "Methods to predict whether or not individual SNVs are likely to regulate gene expression would aid interpretation of variants of unknown significance identified in whole-genome sequencing studies.Results: We developed FIRE (Functional Inference of Regulators of Expression), a tool to score both noncoding and coding SNVs based on their potential to regulate the expression levels of nearby genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 679, "offsetInEndSection": 858, "text": "FIRE consists of 23 random forests trained to recognize SNVs in cis -expression quantitative trait loci ( cis -eQTLs) using a set of 92 genomic annotations as predictive features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 1157, "offsetInEndSection": 1473, "text": "FIRE scores are also predictive of cis -eQTL SNVs across a variety of tissue types.Availability: FIRE scores for genome-wide SNVs in hg19/GRCh37 are available for download at https://sites.google.com/site/fireregulatoryvariation/ .Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Gene regulatory networks (GRNs) provide a representation of relationships between regulators and their target genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28066488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Inference of active transcriptional networks by integration of gene expression kinetics modeling and multisource data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19442636"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Inference of gene expression networks has become one of the primary challenges in computational biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19442636"}, {"offsetInBeginSection": 105, "offsetInEndSection": 244, "text": "Analysis of microarray experiments using appropriate mathematical models can reveal interactions among protein regulators and target genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19442636"}, {"offsetInBeginSection": 245, "offsetInEndSection": 456, "text": "This paper presents a combined approach to the inference of gene expression networks from time series measurements, ChIP-on-chip experiments, analyses of promoter sequences, and protein-protein interaction data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19442636"}]}, {"id": "5a7d51dafaa1ab7d2e000017", "body": "What is the administration route of IVIG in Alzheimer's disease patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23735288", "http://www.ncbi.nlm.nih.gov/pubmed/25476011", "http://www.ncbi.nlm.nih.gov/pubmed/21138577", "http://www.ncbi.nlm.nih.gov/pubmed/20577707", "http://www.ncbi.nlm.nih.gov/pubmed/25392130", "http://www.ncbi.nlm.nih.gov/pubmed/24517534", "http://www.ncbi.nlm.nih.gov/pubmed/19620605", "http://www.ncbi.nlm.nih.gov/pubmed/16998751", "http://www.ncbi.nlm.nih.gov/pubmed/26330100", "http://www.ncbi.nlm.nih.gov/pubmed/18294736"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Intravenous immunoglobulin and Alzheimer's disease: what now?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Intravenous immunoglobulin (IVIG) products are prepared from purified plasma immunoglobulins from large numbers of healthy donors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 131, "offsetInEndSection": 386, "text": "Pilot studies with the IVIG preparations Octagam and Gammagard in individuals with mild-to-moderate Alzheimer's disease (AD) suggested stabilization of cognitive functioning in these patients, and a phase II trial with Gammagard reported similar findings.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 526, "offsetInEndSection": 753, "text": "Although these recent disappointing results have reduced enthusiasm for IVIG as a possible treatment for AD, it is premature to draw final conclusions; a phase III AD trial with the IVIG product Flebogamma is still in progress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 821, "offsetInEndSection": 992, "text": "This approach should be preferable to administration of single monoclonal antibodies in view of the multiple processes that are thought to contribute to AD neuropathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 1249, "offsetInEndSection": 1467, "text": "Such preparations, if generated with recombinant technology, could overcome the problems of high cost and limited supplies, which have been major concerns relating to the possible widespread use of IVIG in AD patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 1468, "offsetInEndSection": 1645, "text": "This review summarizes the recent AD IVIG trials and discusses the major issues relating to possible use of IVIG for treating AD, as well as the critical questions which remain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25476011"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer's disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25476011"}, {"offsetInBeginSection": 302, "offsetInEndSection": 528, "text": "If negative results are found, then further AD studies with IVIG are unlikely unless a manufacturer opts for a trial with high-dose IVIG, which would increase its anti-inflammatory effects but also the risk for adverse events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25476011"}]}, {"id": "5a89800efcd1d6a10c00000c", "body": "Where is the enzyme PM20D1 localized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27374330", "http://www.ncbi.nlm.nih.gov/pubmed/27378359", "http://www.ncbi.nlm.nih.gov/pubmed/24166889", "http://www.ncbi.nlm.nih.gov/pubmed/26999364", "http://www.ncbi.nlm.nih.gov/pubmed/25431941", "http://www.ncbi.nlm.nih.gov/pubmed/29143709", "http://www.ncbi.nlm.nih.gov/pubmed/25855069", "http://www.ncbi.nlm.nih.gov/pubmed/24618023", "http://www.ncbi.nlm.nih.gov/pubmed/7117251", "http://www.ncbi.nlm.nih.gov/pubmed/9307964"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 209, "offsetInEndSection": 344, "text": "Here, we identify a secreted enzyme, peptidase M20 domain containing 1 (PM20D1), that is enriched in UCP1(+) versus UCP1(-) adipocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 345, "offsetInEndSection": 544, "text": "We\u00a0demonstrate that PM20D1 is a bidirectional enzyme in\u00a0vitro, catalyzing both the condensation of fatty acids and amino acids to generate N-acyl amino acids and also the reverse hydrolytic reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 662, "offsetInEndSection": 770, "text": "Mice with increased circulating PM20D1 have augmented respiration and increased N-acyl amino acids in blood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 569, "offsetInEndSection": 707, "text": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378359"}, {"offsetInBeginSection": 818, "offsetInEndSection": 967, "text": "Administration of PM20D1 or its products, N-acyl amino acids, to diet-induced obese mice improves glucose tolerance by increasing energy expenditure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378359"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1342, "text": "Twelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hyper-methylated loci of FAM181A, MRI1, PIWIL1, CHFR, DEFA1, MRPL28, AURKA, and hypo-methylated loci of NALP1L5, MAP8KIP3, ACAT2, and PM20D1 in maternal asthma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166889"}, {"offsetInBeginSection": 1319, "offsetInEndSection": 1477, "text": "The absolute levels of methylation in blood and saliva were confirmed for 3 selected DMS in the PM20D1, STK32C, and FGFR2 genes using pyrosequencing analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999364"}, {"offsetInBeginSection": 1478, "offsetInEndSection": 1576, "text": "The differential methylation could only be confirmed for DMS in PM20D1 and STK32C genes in saliva.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999364"}, {"offsetInBeginSection": 474, "offsetInEndSection": 600, "text": "RESULTS: Array analysis identified 314 candidate genes associated with BWC extremes, four of which showed \u2265 4 BWC-linked CpGs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25431941"}]}, {"id": "5a760ed883b0d9ea66000019", "body": "Is dasatinib effective for treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19190119", "http://www.ncbi.nlm.nih.gov/pubmed/22891038", "http://www.ncbi.nlm.nih.gov/pubmed/21153679", "http://www.ncbi.nlm.nih.gov/pubmed/26517812", "http://www.ncbi.nlm.nih.gov/pubmed/23090987", "http://www.ncbi.nlm.nih.gov/pubmed/20664932", "http://www.ncbi.nlm.nih.gov/pubmed/20165690", "http://www.ncbi.nlm.nih.gov/pubmed/21226671", "http://www.ncbi.nlm.nih.gov/pubmed/19098899", "http://www.ncbi.nlm.nih.gov/pubmed/25758746"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Glioblastoma is defined by its aggressive invasion, microvascular proliferation, and central necrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 103, "offsetInEndSection": 358, "text": "BMS-354825 (dasatinib) is an ATP-competitive small-molecule inhibitor effective in treating drug-resistant tumors with mutant BCR-ABL, KIT, and epidermal growth factor receptor by blocking tyrosine phosphorylation sites that are critical in tumorigenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 359, "offsetInEndSection": 636, "text": "In studying the action of dasatinib in human glioblastoma, we found that levels of phospho-SRC, AKT, and ribosomal protein S6 were decreased in cell lines treated with low nanomolar concentrations of dasatinib at baseline and following stimulation with epidermal growth factor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 637, "offsetInEndSection": 735, "text": "Furthermore, an increased sensitivity to dasatinib was noted in glioma cells with functional PTEN.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 736, "offsetInEndSection": 1020, "text": "Reduction of invasive potential was observed in vitro at concentrations well below the IC(50) of dasatinib, which was corroborated by immunofluorescence staining showing disruption of paxillin localization to focal adhesions and decreases in focal adhesion kinase autophosphorylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 1021, "offsetInEndSection": 1271, "text": "Cell cycle analysis revealed minimal G(1) arrest but a significant increase in autophagic cell death in glioma cells treated with dasatinib as assessed by acridine orange staining and a concomitant increase in light chain 3 expression and processing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1428, "text": "Combination treatment of glioma cells with dasatinib and temozolomide resulted in a significant increase in cell cycle disruption and autophagic cell death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 1429, "offsetInEndSection": 1604, "text": "Dasatinib in combination with temozolomide more effectively increased the therapeutic efficacy of temozolomide than when dasatinib was combined with carboplatin or irinotecan.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1779, "text": "These results strongly support the clinical use of dasatinib in the treatment of glioblastoma and provide a rationale for combination therapy with dasatinib and temozolomide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}]}, {"id": "5916f14070f9fc6f0f00001f", "body": "What is the role of the positive effector of transcription (pet) in the hepatitis B virus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8107218", "http://www.ncbi.nlm.nih.gov/pubmed/9311882", "http://www.ncbi.nlm.nih.gov/pubmed/26983541", "http://www.ncbi.nlm.nih.gov/pubmed/18448976", "http://www.ncbi.nlm.nih.gov/pubmed/24769044", "http://www.ncbi.nlm.nih.gov/pubmed/8138254", "http://www.ncbi.nlm.nih.gov/pubmed/9013081", "http://www.ncbi.nlm.nih.gov/pubmed/9126788", "http://www.ncbi.nlm.nih.gov/pubmed/23422505", "http://www.ncbi.nlm.nih.gov/pubmed/8978357"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "pet, a small sequence distal to the pregenome cap site, is required for expression of the duck hepatitis B virus pregenome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "We have found that transcription of the pregenome of an avian hepadnavirus, duck hepatitis B virus (DHBV), is dependent on the presence of a small element in the 5' transcribed region of the pregenome-encoding sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 220, "offsetInEndSection": 445, "text": "This element, which we have named pet (positive effector of transcription), exerts its effect in cis in a position and orientation-dependent manner, suggesting that it may function as part of the nascent pregenome transcript.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 446, "offsetInEndSection": 664, "text": "The requirement for pet depends on the presence in the transcription unit of a region of the DHBV genome located upstream of the envelope promoters, which specifically suppresses transcription of templates lacking pet.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 665, "offsetInEndSection": 853, "text": "In the presence of this region, deletion of pet activates transcription from downstream promoters, suggesting that pregenome transcription complexes fail to reach the downstream promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 854, "offsetInEndSection": 978, "text": "In vitro transcription experiments support the model that pet is required for transcription elongation on the DHBV template.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1174, "text": "We speculate that pet is required to suppress transcription termination during the first passage of pregenome transcription complexes through a viral termination region on the circular viral DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "A novel transcriptional element in circular DNA monomers of the duck hepatitis B virus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9311882"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "We report the presence of two elements, pet and net, that are required for proper transcription of the duck hepatitis B virus (DHBV).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9311882"}, {"offsetInBeginSection": 134, "offsetInEndSection": 278, "text": "These regions were previously identified by using plasmid clones of the virus in transient expression assays (M. Huang and J. Summers, J. Virol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9311882"}]}, {"id": "5a774ce1faa1ab7d2e000006", "body": "Is there increased recombination rate in human regulatory domains?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29058599", "http://www.ncbi.nlm.nih.gov/pubmed/27503290", "http://www.ncbi.nlm.nih.gov/pubmed/20395511", "http://www.ncbi.nlm.nih.gov/pubmed/1324834", "http://www.ncbi.nlm.nih.gov/pubmed/8845024", "http://www.ncbi.nlm.nih.gov/pubmed/11074256", "http://www.ncbi.nlm.nih.gov/pubmed/12821945", "http://www.ncbi.nlm.nih.gov/pubmed/24225854", "http://www.ncbi.nlm.nih.gov/pubmed/1318616", "http://www.ncbi.nlm.nih.gov/pubmed/21949720"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Evidence of reduced recombination rate in human regulatory domains.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "BACKGROUND: Recombination rate is non-uniformly distributed across the human genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 85, "offsetInEndSection": 200, "text": "The variation of recombination rate at both fine and large scales cannot be fully explained by DNA sequences alone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 201, "offsetInEndSection": 328, "text": "Epigenetic factors, particularly DNA methylation, have recently been proposed to influence the variation in recombination rate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 328, "offsetInEndSection": 469, "text": "RESULTS: We study the relationship between recombination rate and gene regulatory domains, defined by a gene and its linked control elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 728, "offsetInEndSection": 859, "text": "Each link type shows a \"recombination rate\u00a0valley\" of significantly reduced recombination rate compared to matched control regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 860, "offsetInEndSection": 1107, "text": "This recombination rate\u00a0valley is most pronounced for gene regulatory domains of early embryonic development genes, housekeeping genes, and constitutive regulatory elements, which are known to show increased evolutionary constraint across species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 1108, "offsetInEndSection": 1294, "text": "Recombination rate\u00a0valleys show increased DNA methylation, reduced doublestranded break initiation, and increased repair efficiency, specifically in the lineage leading to the germ line.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 1295, "offsetInEndSection": 1451, "text": "Moreover, by using only the overlap of functional links and DNA methylation in germ cells, we are able to predict the recombination rate with high accuracy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 1451, "offsetInEndSection": 1664, "text": "CONCLUSIONS: Our results suggest the existence of a recombination rate valley at regulatory domains and provide a potential molecular mechanism to interpret the interplay between genetic and epigenetic variations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}]}, {"id": "5a7d54adfaa1ab7d2e000019", "body": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24760112", "http://www.ncbi.nlm.nih.gov/pubmed/20329802", "http://www.ncbi.nlm.nih.gov/pubmed/25561275", "http://www.ncbi.nlm.nih.gov/pubmed/21180569", "http://www.ncbi.nlm.nih.gov/pubmed/19883422", "http://www.ncbi.nlm.nih.gov/pubmed/28381506", "http://www.ncbi.nlm.nih.gov/pubmed/18685921", "http://www.ncbi.nlm.nih.gov/pubmed/25826319", "http://www.ncbi.nlm.nih.gov/pubmed/25115544", "http://www.ncbi.nlm.nih.gov/pubmed/17330405"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Clinical trials of intravenous immunoglobulin for Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer's disease (AD) since 2002.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 176, "offsetInEndSection": 329, "text": "Preclinical and clinical studies have shown that IVIG has anti-amyloid and immune modulatory properties relevant to treating neurodegenerative disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 330, "offsetInEndSection": 446, "text": "In early stage AD clinical trials, IVIG was found to reduce cognitive decline and increase brain glucose metabolism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 447, "offsetInEndSection": 577, "text": "Unfortunately, IVIG failed to meet primary outcome objectives in the North American Phase 3 clinical trial in mild to moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 848, "offsetInEndSection": 914, "text": "In addition, IVIG treatment was generally safe and well-tolerated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 1070, "offsetInEndSection": 1324, "text": "While the results of clinical trials to date do not provide support for the use of IVIG to treat AD at the doses tested, additional studies of IVIG's mechanisms are warranted and may guide the development of more effective therapies for AD in the future.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20329802"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Current treatment options for Alzheimer's disease (AD) exert only a short-lived effect on disease symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20329802"}, {"offsetInBeginSection": 277, "offsetInEndSection": 459, "text": "Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20329802"}]}, {"id": "5a8a9f18fcd1d6a10c00001a", "body": "Is NEMO a zinc finger protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21309033", "http://www.ncbi.nlm.nih.gov/pubmed/26224629", "http://www.ncbi.nlm.nih.gov/pubmed/19033441", "http://www.ncbi.nlm.nih.gov/pubmed/18313693", "http://www.ncbi.nlm.nih.gov/pubmed/12867425", "http://www.ncbi.nlm.nih.gov/pubmed/24100029", "http://www.ncbi.nlm.nih.gov/pubmed/28814200", "http://www.ncbi.nlm.nih.gov/pubmed/28035815", "http://www.ncbi.nlm.nih.gov/pubmed/20345847", "http://www.ncbi.nlm.nih.gov/pubmed/16794254"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The covalent attachment of lysine 63-linked polyubiquitin to the zinc-finger domain of IKBKG/NEMO (also known as IKK\u03b3) is necessary for full activation of NF-\u03baB.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 371, "offsetInEndSection": 531, "text": "Nevertheless, the biological function of the NEMO zinc-finger domain in the regulation of mitogen-activated protein kinase (MAPK) activity is poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 532, "offsetInEndSection": 739, "text": "Here we show that dendritic cells from patients with EDI caused by a C-terminal E391X deletion of the zinc finger of NEMO exhibit impaired MAPK activation in response to lipopolysaccharide (LPS) stimulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 740, "offsetInEndSection": 956, "text": "Interestingly, DCs from patients with a C417R missense mutation within the zinc finger domain of NEMO in which ubiquitination of NEMO is preserved are also defective in JNK and ERK activity following LPS stimulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 1110, "offsetInEndSection": 1378, "text": "Furthermore, phosphorylation and polyubiquitination of upstream TAK1 were significantly reduced in the E391X zinc-finger deleted patients, indicating that the NEMO zinc finger may play an important role in assembling the proximal signaling complex for MAPK activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "CYLD and the NEMO Zinc Finger Regulate Tumor Necrosis Factor Signaling and Early Embryogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629"}, {"offsetInBeginSection": 138, "offsetInEndSection": 426, "text": "Although mice with either CYLD deficiency or an alteration in the zinc finger domain of NEMO (K392R) are born healthy, we found that the combination of these two gene defects in double mutant (DM) mice is early embryonic lethal but can be rescued by the absence of TNF receptor 1 (TNFR1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629"}, {"offsetInBeginSection": 845, "offsetInEndSection": 1055, "text": "Therefore, our data demonstrate an unexpected non-catalytic function for CYLD as an adapter protein between TRAF2 and the NEMO zinc finger that is important for TNF-induced NF-\u03baB signaling during embryogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "The zinc finger of NEMO is a functional ubiquitin-binding domain.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033441"}, {"offsetInBeginSection": 200, "offsetInEndSection": 340, "text": "Here, we report that the zinc finger (ZF) motif, located in the regulatory C-terminal half of NEMO, forms a specific complex with ubiquitin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033441"}]}, {"id": "5a7612b483b0d9ea6600001d", "body": "Is enzastaurin effective treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20156802", "http://www.ncbi.nlm.nih.gov/pubmed/20124186", "http://www.ncbi.nlm.nih.gov/pubmed/16103100", "http://www.ncbi.nlm.nih.gov/pubmed/25398844", "http://www.ncbi.nlm.nih.gov/pubmed/23911595", "http://www.ncbi.nlm.nih.gov/pubmed/20934407", "http://www.ncbi.nlm.nih.gov/pubmed/22291006", "http://www.ncbi.nlm.nih.gov/pubmed/20971826", "http://www.ncbi.nlm.nih.gov/pubmed/19098118", "http://www.ncbi.nlm.nih.gov/pubmed/22413865"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20156802"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1313, "offsetInEndSection": 1412, "text": "Eleven patients treated with enzastaurin died on study (four because of AEs; one was drug-related).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1497, "offsetInEndSection": 1621, "text": "Grade 3 to 4 hematologic toxicities were significantly higher with lomustine (46 events) than with enzastaurin (one event; P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1622, "offsetInEndSection": 1810, "text": "CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"}, {"offsetInBeginSection": 107, "offsetInEndSection": 274, "text": "The PKCbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses angiogenesis and was advanced for clinical development based upon this antiangiogenic activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"}, {"offsetInBeginSection": 390, "offsetInEndSection": 542, "text": "Herein, we show that Enzastaurin has a direct effect on human tumor cells, inducing apoptosis and suppressing the proliferation of cultured tumor cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"}, {"offsetInBeginSection": 543, "offsetInEndSection": 666, "text": "Enzastaurin treatment also suppresses the phosphorylation of GSK3betaser9, ribosomal protein S6(S240/244), and AKT(Thr308).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"}]}, {"id": "5925227670f9fc6f0f000020", "body": "Which enzymes are responsible for base J creation in Trypanosoma brucei?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25064607", "http://www.ncbi.nlm.nih.gov/pubmed/18729733", "http://www.ncbi.nlm.nih.gov/pubmed/8692684", "http://www.ncbi.nlm.nih.gov/pubmed/20724435", "http://www.ncbi.nlm.nih.gov/pubmed/12235375", "http://www.ncbi.nlm.nih.gov/pubmed/12366829", "http://www.ncbi.nlm.nih.gov/pubmed/9742081", "http://www.ncbi.nlm.nih.gov/pubmed/24891501", "http://www.ncbi.nlm.nih.gov/pubmed/20215442", "http://www.ncbi.nlm.nih.gov/pubmed/17706299"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Tb927.10.6900 encodes the glucosyltransferase involved in synthesis of base J in Trypanosoma brucei.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064607"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Base J is a DNA modification found in the genome of Trypanosoma brucei and all other kinetoplastids analyzed, where it replaces a small fraction of Ts, mainly in telomeric and chromosome-internal transcription initiation and termination regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064607"}, {"offsetInBeginSection": 246, "offsetInEndSection": 408, "text": "The synthesis of base J is a two-step process whereby a specific T is converted to HOMedU (hydroxymethyldeoxyuridine) and subsequently glucosylated to generate J.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064607"}, {"offsetInBeginSection": 642, "offsetInEndSection": 797, "text": "(Nucleic Acids Res 2013;41:7635) suggested that Tb927.10.6900 encodes the glucosyltransferase (HmdUGT) responsible for converting HOMedU to J in T. brucei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064607"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "In 1993, a new base, beta-d-glucopyranosyloxymethyluracil (base J), was identified in the nuclear DNA of Trypanosoma brucei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18729733"}, {"offsetInBeginSection": 449, "offsetInEndSection": 622, "text": "Whereas in Leishmania nearly all J is telomeric, there are other repetitive DNA sequences containing J in T. brucei and T. cruzi, and most J is outside telomeres in Euglena.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18729733"}, {"offsetInBeginSection": 623, "offsetInEndSection": 802, "text": "The biosynthesis of J occurs in two steps: First, a specific thymidine in DNA is converted into hydroxymethyldeoxyuridine (HOMedU), and then this HOMedU is glycosylated to form J.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18729733"}, {"offsetInBeginSection": 803, "offsetInEndSection": 1062, "text": "This review discusses the identification and localization of base J in the genome of kinetoplastids, the enzymes involved in J biosynthesis, possible biological functions of J, and J as a potential target for chemotherapy of diseases caused by kinetoplastids.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18729733"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The telomeric GGGTTA repeats of Trypanosoma brucei contain the hypermodified base J in both strands.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8692684"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "We have previously shown that nuclear DNA of bloodstream from Trypanosoma brucei contains a novel base beta-glucosyl-hydroxymethyluracil, called J.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8692684"}]}, {"id": "5a80d6cbfaa1ab7d2e000024", "body": "What is the role of Kmt5a in liver?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28899750", "http://www.ncbi.nlm.nih.gov/pubmed/28746875", "http://www.ncbi.nlm.nih.gov/pubmed/25554733", "http://www.ncbi.nlm.nih.gov/pubmed/23419719", "http://www.ncbi.nlm.nih.gov/pubmed/20953199", "http://www.ncbi.nlm.nih.gov/pubmed/23575530", "http://www.ncbi.nlm.nih.gov/pubmed/18581285", "http://www.ncbi.nlm.nih.gov/pubmed/17620307", "http://www.ncbi.nlm.nih.gov/pubmed/16193099", "http://www.ncbi.nlm.nih.gov/pubmed/23410872"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Downregulation of UBE2E2 in rat liver cells after hepatocarcinogen treatment facilitates cell proliferation and slowing down of DNA damage response in GST-P-expressing preneoplastic lesions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899750"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Kmt5a Controls Hepatic Metabolic Pathways by Facilitating RNA Pol II Release from Promoter-Proximal Regions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28746875"}, {"offsetInBeginSection": 140, "offsetInEndSection": 341, "text": "Here, we show that, in non-dividing hepatic cells, H4K20Me1 is specifically enriched in active gene bodies and dynamically regulated by the antagonistic action of Kmt5a methylase and Kdm7b demethylase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28746875"}, {"offsetInBeginSection": 342, "offsetInEndSection": 407, "text": "In liver-specific Kmt5a-deficient mice, reduced levels of H4K20Me", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28746875"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "SETD8 (also known as SET8, PR-SET7, or KMT5A (lysine methyltransferase 5A)) is the only known lysine methyltransferase that catalyzes monomethylation of histone H4 lysine 20 (H4K20).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25554733"}, {"offsetInBeginSection": 0, "offsetInEndSection": 350, "text": "SET8 (also known as PR-Set7/9, SETD8, KMT5A), a member of the SET domain containing methyltransferase family, which specifically catalyzes mono-methylation of K20 on histone H4 (H4K20me1), has been implicated in multiple biological processes, such as gene transcriptional regulation, cell cycle control, genomic integrity maintenance and development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419719"}, {"offsetInBeginSection": 370, "offsetInEndSection": 592, "text": "Here, we show that the onset of licensing in mammalian cells coincides with an increase in histone H4 Lys 20 monomethylation (H4K20me1) at replication origins by the methyltransferase PR-Set7 (also known as Set8 or KMT5A).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20953199"}, {"offsetInBeginSection": 653, "offsetInEndSection": 785, "text": "Within the past few years, several studies have established that protein methylation is a novel mechanism by which p53 is regulated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18581285"}, {"offsetInBeginSection": 786, "offsetInEndSection": 918, "text": "Indeed, histone lysine methyltransferases KMT5 (Set9), KMT3C (Smyd2), and KMT5A (Set8) methylate p53 at specific C-terminal lysines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18581285"}, {"offsetInBeginSection": 182, "offsetInEndSection": 325, "text": "Previous studies using p27 knockout mice on mixed C57BL/6J x 129/Sv strain background did not find a tumor suppressor role of p27 in the liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17620307"}]}, {"id": "5a7d5ce0faa1ab7d2e00001b", "body": "How does increased GDF15 affect body weight?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28846097", "http://www.ncbi.nlm.nih.gov/pubmed/26672741", "http://www.ncbi.nlm.nih.gov/pubmed/28846098", "http://www.ncbi.nlm.nih.gov/pubmed/28953886", "http://www.ncbi.nlm.nih.gov/pubmed/28846099", "http://www.ncbi.nlm.nih.gov/pubmed/29046435", "http://www.ncbi.nlm.nih.gov/pubmed/27239403", "http://www.ncbi.nlm.nih.gov/pubmed/27986797", "http://www.ncbi.nlm.nih.gov/pubmed/29144449", "http://www.ncbi.nlm.nih.gov/pubmed/28898507"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 166, "offsetInEndSection": 339, "text": "In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 340, "offsetInEndSection": 471, "text": "The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 472, "offsetInEndSection": 606, "text": "Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 791, "offsetInEndSection": 1012, "text": "Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 1291, "offsetInEndSection": 1531, "text": "Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "BACKGROUND: Cancer-related weight loss is associated with increased inflammation and decreased survival.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26672741"}, {"offsetInBeginSection": 455, "offsetInEndSection": 734, "text": "METHODS: We measured body weight, appetite, plasma GDF15, and other inflammatory markers in men with cancer-related weight loss (C-WL, n\u2009=\u200958), weight stable patients with cancer (C-WS, n\u2009=\u200972), and non-cancer controls (Co, n\u2009=\u200959) matched by age and pre-illness body mass index.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26672741"}, {"offsetInBeginSection": 1394, "offsetInEndSection": 1530, "text": "GDF15, IL-6, and IL-8 significantly correlated with weight loss; GDF15 negatively correlated with aLBM, handgrip strength, and fat mass.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26672741"}, {"offsetInBeginSection": 1686, "offsetInEndSection": 1839, "text": "CONCLUSION: GDF15 and other inflammatory markers are associated with weight loss, decreased aLBM and strength, and poor survival in patients with cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26672741"}]}, {"id": "5a7617b183b0d9ea66000022", "body": "What is inhibited by a drug rilotumumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23454250", "http://www.ncbi.nlm.nih.gov/pubmed/19649990", "http://www.ncbi.nlm.nih.gov/pubmed/25912961", "http://www.ncbi.nlm.nih.gov/pubmed/27966237", "http://www.ncbi.nlm.nih.gov/pubmed/25185191", "http://www.ncbi.nlm.nih.gov/pubmed/25712685", "http://www.ncbi.nlm.nih.gov/pubmed/24965569", "http://www.ncbi.nlm.nih.gov/pubmed/25584489", "http://www.ncbi.nlm.nih.gov/pubmed/26750997", "http://www.ncbi.nlm.nih.gov/pubmed/28958504"], "snippets": [{"offsetInBeginSection": 1521, "offsetInEndSection": 1635, "text": "Further studies to evaluate (18)F-FDG PET imaging as an early tumor response marker for rilotumumab are warranted.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454250"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1331, "text": "Which tumor types might benefit most from treatment with rilotumumab remains to be determined, and the identification of candidate patients will be a critical issue for the further development of this drug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649990"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25912961"}, {"offsetInBeginSection": 118, "offsetInEndSection": 299, "text": "The aim of this study was to evaluate the potential pharmacokinetic (PK)-based drug-drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27966237"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "Patients with gastric or esophagogastric cancer treated with combination chemotherapy and rilotumumab, an anti-HGF monoclonal antibody, had longer progression-free survival than patients treated with chemotherapy alone, according to results from a phase II clinical trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25185191"}, {"offsetInBeginSection": 273, "offsetInEndSection": 446, "text": "The survival benefit was greatest in patients with MET-positive disease; a phase III trial testing the drug combination's effect on this patient population is now under way.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25185191"}, {"offsetInBeginSection": 1770, "offsetInEndSection": 1912, "text": "These findings support the phase II testing of rilotumumab 15 mg/kg every 3 weeks in MET-positive gastric/GEJ cancer (RILOMET-1; NCT01697072).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712685"}, {"offsetInBeginSection": 1044, "offsetInEndSection": 1275, "text": "The phase 1b primary endpoint was the incidence of dose-limiting toxicities in all phase 1b patients who received at least one dose of rilotumumab and completed the dose-limiting toxicity assessment window (first cycle of therapy).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965569"}, {"offsetInBeginSection": 1965, "offsetInEndSection": 2086, "text": "In phase 2, 121 patients were randomly assigned (40 to rilotumumab 15 mg/kg; 42 to rilotumumab 7\u00b75 mg/kg; 39 to placebo).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965569"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25584489"}]}, {"id": "593fe5c270f9fc6f0f000021", "body": "How many PML isoforms exist in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23135708", "http://www.ncbi.nlm.nih.gov/pubmed/15107834", "http://www.ncbi.nlm.nih.gov/pubmed/20664248", "http://www.ncbi.nlm.nih.gov/pubmed/21092142", "http://www.ncbi.nlm.nih.gov/pubmed/24036361", "http://www.ncbi.nlm.nih.gov/pubmed/7535592", "http://www.ncbi.nlm.nih.gov/pubmed/16778193", "http://www.ncbi.nlm.nih.gov/pubmed/20205709", "http://www.ncbi.nlm.nih.gov/pubmed/27860076", "http://www.ncbi.nlm.nih.gov/pubmed/18509536"], "snippets": [{"offsetInBeginSection": 446, "offsetInEndSection": 627, "text": "Paradoxically, the genomes of various DNA viruses become associated with PML NBs, and initial sites of viral transcription/replication centers are often juxtaposed to these domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1169, "text": "Coimmunoprecipitation assays showed that E1A-13S preferentially interacts with only one (PML-II) of at least six nuclear human PML isoforms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Mucosal human papillomaviruses (HPVs) are the causative agents of a number of human pathologies, including benign condylomas, as well as of the majority of cervical cancers and their high-grade precursor lesions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 665, "offsetInEndSection": 828, "text": "Using a panel of different PML isoforms, we demonstrate specific co-localization between the E6 proteins and PML isoforms I-IV, but not with PML isoforms V and VI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 829, "offsetInEndSection": 913, "text": "We also demonstrate the interaction between E6 and a subset of PML isoforms in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1292, "text": "These results show separable functions for different PML isoforms that are specifically targeted by the HPV E6 oncoproteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 112, "offsetInEndSection": 249, "text": "It is not known whether the PML gene is transcribed and expressed as PML nuclear bodies in gamete cells or in the early mammalian embryo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664248"}, {"offsetInBeginSection": 250, "offsetInEndSection": 438, "text": "In this study using reverse transcription-polymerase chain reaction and immunocytochemistry we show the presence of PML transcripts and identify their variants in the mature mouse gametes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664248"}, {"offsetInBeginSection": 439, "offsetInEndSection": 568, "text": "Mature sperm contains isoform II; however, oocyte contains transcript isoforms I, II, and possibly other unknown isoforms of PML.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664248"}]}, {"id": "5a80d965faa1ab7d2e000025", "body": "What is metaSPAdes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28298430", "http://www.ncbi.nlm.nih.gov/pubmed/28407798", "http://www.ncbi.nlm.nih.gov/pubmed/28693474", "http://www.ncbi.nlm.nih.gov/pubmed/28948103", "http://www.ncbi.nlm.nih.gov/pubmed/29036597"], "snippets": [{"offsetInBeginSection": 564, "offsetInEndSection": 725, "text": "We benchmark metaSPAdes against other state-of-the-art metagenome assemblers and demonstrate that it results in high-quality assemblies across diverse data sets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298430"}, {"offsetInBeginSection": 1383, "offsetInEndSection": 1527, "text": "RESULTS: We tested five metagenomic assemblers: Omega, metaSPAdes, IDBA-UD, metaVelvet and MEGAHIT on known and synthetic metagenomic data sets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407798"}, {"offsetInBeginSection": 655, "offsetInEndSection": 814, "text": "Overall, we found that SPAdes provided the largest contigs and highest N50 values across 6 of the 9 environmental datasets, followed by MEGAHIT and metaSPAdes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28693474"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1165, "text": "CONCLUSIONS: These simulations provide benchmarks for selecting analysis cut-offs and establish that an optimized sample-to-ecological-inference viromics pipeline is robust for making ecological inferences from natural viral communities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1312, "text": "Faucet used orders of magnitude less time and disk space than the specialized metagenome assemblers MetaSPAdes and Megahit, while also improving on their memory use; this broadly matched performance of other assemblers optimizing resource efficiency-namely, Minia and LightAssembler.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036597"}, {"offsetInBeginSection": 340, "offsetInEndSection": 487, "text": "RESULTS: Tools specifically designed for metagenomes, specifically metaSPAdes, MEGAHIT, and IDBA-UD, were the most effective at assembling viromes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 95, "offsetInEndSection": 167, "text": "Faucet builds an assembly graph incrementally as each read is processed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036597"}, {"offsetInBeginSection": 488, "offsetInEndSection": 618, "text": "Read pre-processing, such as partitioning, had virtually no impact on assembly output, but may be useful when hardware is limited.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 1745, "offsetInEndSection": 1875, "text": "At the ORF level, metaSPAdes and MEGAHIT had the least number of missing ORFs within diverse and similar communities respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407798"}, {"offsetInBeginSection": 561, "offsetInEndSection": 669, "text": "However, in order to obtain the best metagenomic assemblies, it is important to choose the proper assembler.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407798"}]}, {"id": "5a7d6287faa1ab7d2e00001c", "body": "Which receptor does GDF15 bind?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28846097", "http://www.ncbi.nlm.nih.gov/pubmed/28846099", "http://www.ncbi.nlm.nih.gov/pubmed/28846098", "http://www.ncbi.nlm.nih.gov/pubmed/21803025", "http://www.ncbi.nlm.nih.gov/pubmed/26497212", "http://www.ncbi.nlm.nih.gov/pubmed/24597762", "http://www.ncbi.nlm.nih.gov/pubmed/28953886", "http://www.ncbi.nlm.nih.gov/pubmed/28847729", "http://www.ncbi.nlm.nih.gov/pubmed/27093475", "http://www.ncbi.nlm.nih.gov/pubmed/24191265"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 166, "offsetInEndSection": 339, "text": "In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 340, "offsetInEndSection": 471, "text": "The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 472, "offsetInEndSection": 606, "text": "Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 607, "offsetInEndSection": 790, "text": "Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 791, "offsetInEndSection": 1012, "text": "Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1290, "text": "Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 1291, "offsetInEndSection": 1531, "text": "Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846099"}]}, {"id": "5a76196faacfb9cd4c000001", "body": "List the two most important hematological features of the Evans syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21088621", "http://www.ncbi.nlm.nih.gov/pubmed/17179698", "http://www.ncbi.nlm.nih.gov/pubmed/2095900", "http://www.ncbi.nlm.nih.gov/pubmed/25548448", "http://www.ncbi.nlm.nih.gov/pubmed/17943645", "http://www.ncbi.nlm.nih.gov/pubmed/28055149", "http://www.ncbi.nlm.nih.gov/pubmed/27082565", "http://www.ncbi.nlm.nih.gov/pubmed/12554529", "http://www.ncbi.nlm.nih.gov/pubmed/15495242", "http://www.ncbi.nlm.nih.gov/pubmed/22796025"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Massive hemoperitoneum with splenic infarction in Evans syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21088621"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Evans syndrome is a very rare hematologic autoimmune disease, characterized by a direct Coombs' positive hemolytic anemia and immune thrombocytopenic purpura without a known underlying etiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21088621"}, {"offsetInBeginSection": 275, "offsetInEndSection": 355, "text": "Evans syndrome usually is complicated by hemolytic or thrombocytopenic symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21088621"}, {"offsetInBeginSection": 413, "offsetInEndSection": 601, "text": "Reported here is a case with massive hemoperitoneum because of splenic infarction with rupture, in an 18-month-old male patient with Evans syndrome, and the embolization of splenic artery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21088621"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "A patient with mixed type Evans syndrome: efficacy of rituximab treatment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Mixed type Evans syndrome is a very rare hematologic disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}, {"offsetInBeginSection": 62, "offsetInEndSection": 212, "text": "Although mixed type Evans syndrome may initially respond well to steroids, this disease usually runs a chronic course with intermittent exacerbations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}, {"offsetInBeginSection": 213, "offsetInEndSection": 348, "text": "We describe here a 46-yr-old female with the steroid-refractory, mixed type Evans syndrome, and she had a prompt response to rituximab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}, {"offsetInBeginSection": 349, "offsetInEndSection": 487, "text": "She was diagnosed as having the mixed type Evans syndrome with the clinical features of symptomatic anemia, jaundice and thrombocytopenia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}, {"offsetInBeginSection": 269, "offsetInEndSection": 391, "text": "No correlation was found between iron deficiency and severity of the hematological or non-hematological clinical features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2095900"}]}, {"id": "593fe7f970f9fc6f0f000022", "body": "How many of the human PML isoforms are cytosolic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15107834", "http://www.ncbi.nlm.nih.gov/pubmed/23135708", "http://www.ncbi.nlm.nih.gov/pubmed/7535592", "http://www.ncbi.nlm.nih.gov/pubmed/24036361", "http://www.ncbi.nlm.nih.gov/pubmed/20205709", "http://www.ncbi.nlm.nih.gov/pubmed/16778193", "http://www.ncbi.nlm.nih.gov/pubmed/19279115", "http://www.ncbi.nlm.nih.gov/pubmed/16501113", "http://www.ncbi.nlm.nih.gov/pubmed/23734343", "http://www.ncbi.nlm.nih.gov/pubmed/21115099"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Mucosal human papillomaviruses (HPVs) are the causative agents of a number of human pathologies, including benign condylomas, as well as of the majority of cervical cancers and their high-grade precursor lesions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 213, "offsetInEndSection": 385, "text": "Although the viral E6 protein is known to be essential for driving malignant progression of HPV-infected cells, there are still many uncertainties about its mode of action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 523, "offsetInEndSection": 664, "text": "We show that both E6 proteins localize within the nucleus in nuclear bodies that are confocal with the promyelocytic leukaemia (PML) protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 665, "offsetInEndSection": 828, "text": "Using a panel of different PML isoforms, we demonstrate specific co-localization between the E6 proteins and PML isoforms I-IV, but not with PML isoforms V and VI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 829, "offsetInEndSection": 913, "text": "We also demonstrate the interaction between E6 and a subset of PML isoforms in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1292, "text": "These results show separable functions for different PML isoforms that are specifically targeted by the HPV E6 oncoproteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15107834"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "PML nuclear bodies (PML NBs), also called ND10, are matrix-bound nuclear structures that have been implicated in a variety of functions, including DNA repair, transcriptional regulation, protein degradation, and tumor suppression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}, {"offsetInBeginSection": 231, "offsetInEndSection": 351, "text": "These domains are also known for their potential to mediate an intracellular defense mechanism against many virus types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}, {"offsetInBeginSection": 446, "offsetInEndSection": 627, "text": "Paradoxically, the genomes of various DNA viruses become associated with PML NBs, and initial sites of viral transcription/replication centers are often juxtaposed to these domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}]}, {"id": "593ff22b70f9fc6f0f000023", "body": "How many Groucho-related genes (GRG) are contained in the mouse genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8892234", "http://www.ncbi.nlm.nih.gov/pubmed/8369224", "http://www.ncbi.nlm.nih.gov/pubmed/8989517", "http://www.ncbi.nlm.nih.gov/pubmed/8573724", "http://www.ncbi.nlm.nih.gov/pubmed/7916324", "http://www.ncbi.nlm.nih.gov/pubmed/12666196", "http://www.ncbi.nlm.nih.gov/pubmed/8955148", "http://www.ncbi.nlm.nih.gov/pubmed/10512199", "http://www.ncbi.nlm.nih.gov/pubmed/11266540", "http://www.ncbi.nlm.nih.gov/pubmed/15923151"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Transcripts of Grg4, a murine groucho-related gene, are detected in adjacent tissues to other murine neurogenic gene homologues during embryonic development.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8892234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "The groucho-related genes (Grg) of the mouse comprise at least four family members.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8892234"}, {"offsetInBeginSection": 322, "offsetInEndSection": 523, "text": "Thus, by analogy to the Drosophila proteins, murine Grg proteins may interact with mammalian Hairy and E(spl) homologues (Hes proteins) and take part in a signalling pathway downstream of murine Notch.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8892234"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1053, "text": "This distinct pattern of expression suggests a role for Grg4 in later stages of cell differentiation than for the other mouse neurogenic gene homologues.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8892234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Cloning and developmental expression of Grg, a mouse gene related to the groucho transcript of the Drosophila Enhancer of split complex.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}, {"offsetInBeginSection": 323, "offsetInEndSection": 489, "text": "Here we describe the cloning and RNA expression analysis of a mouse gene, designated Grg, that is homologous to just the amino-terminal region of the groucho product.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}, {"offsetInBeginSection": 490, "offsetInEndSection": 639, "text": "Grg encodes a 197 amino acid protein that shares 53% amino acid identity with the corresponding region of the product of the Drosophila groucho gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}, {"offsetInBeginSection": 640, "offsetInEndSection": 737, "text": "However, the mouse Grg protein does not contain the region homologous to G-protein beta-subunits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}, {"offsetInBeginSection": 738, "offsetInEndSection": 995, "text": "An analysis by in situ hybridization of the spatial and temporal localization of Grg RNA expression revealed that, while the initial pattern of Grg expression was quite restricted, by midgestation Grg RNA was ubiquitously expressed in the developing embryo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}, {"offsetInBeginSection": 1056, "offsetInEndSection": 1250, "text": "The implications of these results for the existence of separable functional domains of the Drosophila groucho product, and possible roles of the Grg gene during mouse development, are discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}]}, {"id": "59bf823b542ba3824b000001", "body": "Does a tonsillectomy affect the patient's voice?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26846544", "http://www.ncbi.nlm.nih.gov/pubmed/21074280", "http://www.ncbi.nlm.nih.gov/pubmed/18468843", "http://www.ncbi.nlm.nih.gov/pubmed/20926254", "http://www.ncbi.nlm.nih.gov/pubmed/19841332", "http://www.ncbi.nlm.nih.gov/pubmed/25704470", "http://www.ncbi.nlm.nih.gov/pubmed/22803405", "http://www.ncbi.nlm.nih.gov/pubmed/16966154", "http://www.ncbi.nlm.nih.gov/pubmed/12161728", "http://www.ncbi.nlm.nih.gov/pubmed/22242470"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Does Tonsillectomy Affect Voice in Early or Late Postoperative Periods in Adults?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "OBJECTIVE: The aim of our study was to investigate the short- and long-term effects of tonsillectomy on voice performance in adults.STUDY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 255, "offsetInEndSection": 383, "text": "A total of 26 adults who had tonsillectomy due to chronic tonsillitis or recurrent acute tonsillitis were included in the study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 384, "offsetInEndSection": 528, "text": "The voice performances of the participants were analyzed with objective and subjective methods before surgery, and 1 and 3 months after surgery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 529, "offsetInEndSection": 722, "text": "An acoustic voice analysis (fundamental frequency [F0], jitter %, shimmer %) was performed for objective analysis, and Voice Handicap Index survey was used for subjective analysis of the voice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 723, "offsetInEndSection": 861, "text": "Preoperative F0, jitter %, shimmer %, and Voice Handicap Index values were compared with the values obtained 1 and 3 months after surgery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 861, "offsetInEndSection": 1014, "text": "RESULTS: Impairment of voice performance was determined when preoperative and postoperative first month F0, jitter %, and shimmer % values were compared.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1263, "text": "CONCLUSION: Tonsillectomy affects voice performance negatively in adults in short term; however, it does not affect voice performance in long term after surgery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Thermal welding vs. cold knife tonsillectomy: a comparison of voice and speech.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21074280"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "OBJECTIVE: To compare acoustic, aerodynamic and perceptual voice and speech parameters in thermal welding system tonsillectomy and cold knife tonsillectomy patients in order to determine the impact of operation technique on voice and speech.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21074280"}]}, {"id": "59d09a0cbc32f93e6d000001", "body": "What is the difference between ganglion mother cells (GMC) and intermediate neural precursor cells (INP) in Drosophila?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23376107", "http://www.ncbi.nlm.nih.gov/pubmed/15704126", "http://www.ncbi.nlm.nih.gov/pubmed/21996673", "http://www.ncbi.nlm.nih.gov/pubmed/14973280", "http://www.ncbi.nlm.nih.gov/pubmed/29158446", "http://www.ncbi.nlm.nih.gov/pubmed/28325554", "http://www.ncbi.nlm.nih.gov/pubmed/25285448", "http://www.ncbi.nlm.nih.gov/pubmed/11688564", "http://www.ncbi.nlm.nih.gov/pubmed/8095484", "http://www.ncbi.nlm.nih.gov/pubmed/18342578"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The Drosophila SERTAD protein Taranis determines lineage-specific neural progenitor proliferation patterns.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Neural progenitors of the Drosophila larval brain, called neuroblasts, can be divided into distinct populations based on patterns of proliferation and differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 168, "offsetInEndSection": 419, "text": "Type I neuroblasts produce ganglion mother cells (GMCs) that divide once to produce differentiated progeny, while type II neuroblasts produce self-renewing intermediate neural progenitors (INPs) and thus generate lineages containing many more progeny.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 646, "offsetInEndSection": 822, "text": "Tara is differentially-expressed in neural progenitors, with high levels of expression in proliferating type I neuroblasts but no detectable expression in type II lineage INPs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 1108, "offsetInEndSection": 1241, "text": "Mis-expression of tara in type II lineages delays INP cell cycle progression and induces premature differentiation of INPs into GMCs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 1242, "offsetInEndSection": 1396, "text": "Premature INP differentiation can also be induced by loss of E2F1/Dp function and elevated E2F1/Dp expression suppresses Tara-induced INP differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 1397, "offsetInEndSection": 1603, "text": "Our results show that lineage-specific Tara expression is necessary for proper brain development and suggest that distinct cell cycle regulatory mechanisms exist in type I versus type II neural progenitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Generating neuronal diversity in the Drosophila central nervous system: a view from the ganglion mother cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15704126"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "The generation of cellular diversity in the developing embryonic central nervous system of Drosophila melanogaster requires the precise orchestration of several convergent molecular and cellular mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15704126"}, {"offsetInBeginSection": 207, "offsetInEndSection": 361, "text": "Most reviews have focused on the formation and specification of neuroblasts (NBs), the putative neural stem cell in the Drosophila central nervous system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15704126"}]}, {"id": "5a003e0a966455904c000001", "body": "What is the function of the TFIIS transcriptional factor (Dst1) in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/28521214", "http://www.ncbi.nlm.nih.gov/pubmed/16492753", "http://www.ncbi.nlm.nih.gov/pubmed/15082542", "http://www.ncbi.nlm.nih.gov/pubmed/18628399", "http://www.ncbi.nlm.nih.gov/pubmed/15359273", "http://www.ncbi.nlm.nih.gov/pubmed/10811649", "http://www.ncbi.nlm.nih.gov/pubmed/21761155", "http://www.ncbi.nlm.nih.gov/pubmed/20179968", "http://www.ncbi.nlm.nih.gov/pubmed/9712888"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Stimulation of RNA polymerase II transcript cleavage activity contributes to maintain transcriptional fidelity in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The transcription elongation factor S-II, also designated TFIIS, stimulates the nascent transcript cleavage activity intrinsic to RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 245, "offsetInEndSection": 384, "text": "Here, we investigated the role of nascent transcript cleavage stimulation activity on the maintenance of transcriptional fidelity in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 385, "offsetInEndSection": 428, "text": "In yeast, S-II is encoded by the DST1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 459, "offsetInEndSection": 632, "text": "Previous reports indicate that Rad26, a yeast homolog of transcription-repair coupling factor CSB, partly mediates strand-specific repair of UV-dimers as well as AP lesions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1102, "text": "We additionally show that Dst1, a homolog of mammalian transcription elongation factor TFIIS, interferes with NER-dependent repair of AP lesions while suppressing homologous recombination pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1205, "text": "Overall, Def1 and Dst1 mediate very different outcomes in response to AP-induced transcription arrest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "The fidelity of yeast RNA polymerase II (Pol II) was assessed in vivo with an assay in which errors in transcription of can1-100, a nonsense allele of CAN1, result in enhanced sensitivity to the toxic arginine analog canavanine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16492753"}, {"offsetInBeginSection": 229, "offsetInEndSection": 387, "text": "The Pol II accessory factor TFIIS has been proposed to play a role in transcript editing by stimulating the intrinsic nuclease activity of the RNA polymerase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16492753"}, {"offsetInBeginSection": 388, "offsetInEndSection": 542, "text": "However, deletion of DST1, the gene encoding the yeast homolog of TFIIS, had only a small effect on transcriptional fidelity, as determined by this assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16492753"}]}, {"id": "5a3566bb966455904c000003", "body": "Does TFIIS affect nucleosome positioning?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21177855", "http://www.ncbi.nlm.nih.gov/pubmed/12765535", "http://www.ncbi.nlm.nih.gov/pubmed/19140324", "http://www.ncbi.nlm.nih.gov/pubmed/19856965", "http://www.ncbi.nlm.nih.gov/pubmed/22019336", "http://www.ncbi.nlm.nih.gov/pubmed/15808512", "http://www.ncbi.nlm.nih.gov/pubmed/23032292", "http://www.ncbi.nlm.nih.gov/pubmed/17081995", "http://www.ncbi.nlm.nih.gov/pubmed/24733939", "http://www.ncbi.nlm.nih.gov/pubmed/19527704"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Efficient and rapid nucleosome traversal by RNA polymerase II depends on a combination of transcript elongation factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 122, "offsetInEndSection": 271, "text": "The elongation factors TFIIF and TFIIS have been shown to cooperate in maintaining pol II in the catalytically competent state on pure DNA templates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 272, "offsetInEndSection": 458, "text": "We now show that although TFIIF or TFIIS alone is modestly stimulatory for nucleosome traversal, both factors together increase transcription through nucleosomes in a synergistic manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 459, "offsetInEndSection": 569, "text": "We also studied the effect of TFIIF and TFIIS on transcription of nucleosomes containing a Sin mutant histone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 570, "offsetInEndSection": 665, "text": "The Sin point mutations reduce critical histone-DNA contacts near the center of the nucleosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 666, "offsetInEndSection": 863, "text": "Significantly, we found that nucleosomes with a Sin mutant histone are traversed to the same extent and at nearly the same rate as equivalent pure DNA templates if both TFIIS and TFIIF are present.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 864, "offsetInEndSection": 965, "text": "Thus, the nucleosome is not necessarily an insurmountable barrier to transcript elongation by pol II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1170, "text": "If unfolding of template DNA from the nucleosome surface is facilitated and the tendency of pol II to retreat from barriers is countered, transcription of nucleosomal templates can be rapid and efficient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177855"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Nucleosome positioning on yeast plasmids is determined only by the internal signal of DNA sequence occupied by the nucleosome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765535"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The possible role of border factors in determining the nucleosome positioning on a DNA sequence was investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765535"}]}, {"id": "5a37df1c966455904c000004", "body": "How does Dst1 knock-out affect transcription in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/28521214", "http://www.ncbi.nlm.nih.gov/pubmed/18823333", "http://www.ncbi.nlm.nih.gov/pubmed/24780862", "http://www.ncbi.nlm.nih.gov/pubmed/15082542", "http://www.ncbi.nlm.nih.gov/pubmed/16492753", "http://www.ncbi.nlm.nih.gov/pubmed/14690608", "http://www.ncbi.nlm.nih.gov/pubmed/19197357", "http://www.ncbi.nlm.nih.gov/pubmed/15956671", "http://www.ncbi.nlm.nih.gov/pubmed/11296232"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Stimulation of RNA polymerase II transcript cleavage activity contributes to maintain transcriptional fidelity in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 245, "offsetInEndSection": 384, "text": "Here, we investigated the role of nascent transcript cleavage stimulation activity on the maintenance of transcriptional fidelity in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 385, "offsetInEndSection": 428, "text": "In yeast, S-II is encoded by the DST1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 459, "offsetInEndSection": 632, "text": "Previous reports indicate that Rad26, a yeast homolog of transcription-repair coupling factor CSB, partly mediates strand-specific repair of UV-dimers as well as AP lesions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1102, "text": "We additionally show that Dst1, a homolog of mammalian transcription elongation factor TFIIS, interferes with NER-dependent repair of AP lesions while suppressing homologous recombination pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1205, "text": "Overall, Def1 and Dst1 mediate very different outcomes in response to AP-induced transcription arrest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 205, "offsetInEndSection": 302, "text": "The present study reveals a novel function of Sub1 as a transcription repressor in budding yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823333"}, {"offsetInBeginSection": 406, "offsetInEndSection": 544, "text": "First, we examined the genetic interaction of Sub1 with the transcription elongation factor S-II/TFIIS, which is encoded by the DST1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823333"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Involvement of S. cerevisiae Rpb4 in subset of pathways related to transcription elongation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24780862"}, {"offsetInBeginSection": 510, "offsetInEndSection": 652, "text": "Yet we find strong genetic interaction of rpb4\u2206 with mutants in many transcription elongation factors such as Paf1, Spt4, Dst1, Elp3 and Rpb9.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24780862"}]}, {"id": "5a39453d966455904c000006", "body": "Which method for subsampling of NGS reads requires only gene counts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26130573", "http://www.ncbi.nlm.nih.gov/pubmed/24708854", "http://www.ncbi.nlm.nih.gov/pubmed/26253000", "http://www.ncbi.nlm.nih.gov/pubmed/23565205", "http://www.ncbi.nlm.nih.gov/pubmed/28419628", "http://www.ncbi.nlm.nih.gov/pubmed/26558903", "http://www.ncbi.nlm.nih.gov/pubmed/25894390", "http://www.ncbi.nlm.nih.gov/pubmed/25349885", "http://www.ncbi.nlm.nih.gov/pubmed/23441149", "http://www.ncbi.nlm.nih.gov/pubmed/25183223"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Inference of Markovian properties of molecular sequences from NGS data and applications to comparative genomics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 130, "offsetInEndSection": 262, "text": "The fact that NGS reads are generally short makes it challenging to assemble the reads and reconstruct the original genome sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 263, "offsetInEndSection": 589, "text": "For clustering genomes using such NGS data, word-count based alignment-free sequence comparison is a promising approach, but for this approach, the underlying expected word counts are essential.A plausible model for this underlying distribution of word counts is given through modeling the DNA sequence as a Markov chain (MC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 738, "offsetInEndSection": 923, "text": "As NGS data do not provide a single long sequence, inference methods on Markovian properties of sequences based on single long sequences cannot be directly used for NGS short read data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 923, "offsetInEndSection": 991, "text": "RESULTS: Here we derive a normal approximation for such word counts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1257, "text": "We propose several methods to estimate the order of the MC based on NGS reads and evaluate those using simulations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1447, "text": "We illustrate the applications of our results by clustering genomic sequences of several vertebrate and tree species based on NGS reads using alignment-free sequence dissimilarity measures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 1678, "offsetInEndSection": 1840, "text": "IMPLEMENTATION: Our implementation of the statistics developed here is available as R package 'NGS.MC' at http://www-rcf.usc.edu/\u223cfsun/Programs/NGS-MC/NGS-MC.html", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "BACKGROUND: Next generation sequencing (NGS) is a state of the art technology for microRNA (miRNA) analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24708854"}, {"offsetInBeginSection": 109, "offsetInEndSection": 174, "text": "The quantitative interpretation of the primary output of NGS i.e.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24708854"}]}, {"id": "5a3e8683966455904c000007", "body": "Which test is used to diagnose colour synesthesia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25734257", "http://www.ncbi.nlm.nih.gov/pubmed/22073035", "http://www.ncbi.nlm.nih.gov/pubmed/21531581", "http://www.ncbi.nlm.nih.gov/pubmed/23458658", "http://www.ncbi.nlm.nih.gov/pubmed/19739904", "http://www.ncbi.nlm.nih.gov/pubmed/16083418", "http://www.ncbi.nlm.nih.gov/pubmed/1584615", "http://www.ncbi.nlm.nih.gov/pubmed/3876538", "http://www.ncbi.nlm.nih.gov/pubmed/24367321", "http://www.ncbi.nlm.nih.gov/pubmed/23279836"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Validating a standardised test battery for synesthesia: Does the Synesthesia Battery reliably detect synesthesia?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Synesthesia is a neurological condition that gives rise to unusual secondary sensations (e.g., reading letters might trigger the experience of colour).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 330, "offsetInEndSection": 513, "text": "In 2007 however, Eagleman and colleagues presented an online 'Synesthesia Battery' of tests aimed at identifying synesthesia by assessing consistency but within a single test session.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 696, "offsetInEndSection": 856, "text": "We recruited 2847 participants to complete The Synesthesia Battery and found the prevalence of grapheme-colour synesthesia in the general population to be 1.2%.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1152, "text": "This reproduction of similar prevalence rates suggests that the Synesthesia Battery is indeed a valid methodology for assessing synesthesia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Colour-grapheme synesthesia affects binocular vision.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073035"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "In colour-grapheme synesthesia, non-coloured graphemes are perceived as being inherently coloured.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073035"}, {"offsetInBeginSection": 99, "offsetInEndSection": 243, "text": "In recent years, it is debated whether visual processing of synesthesia-inducing achromatic graphemes is similar to that of chromatic graphemes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073035"}, {"offsetInBeginSection": 568, "offsetInEndSection": 749, "text": "We show that achromatic digits that induce synesthetic colour percepts increase the incidence of binocular rivalry compared to achromatic non-digits that do not evoke such percepts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073035"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1089, "text": "This finding shows that the synesthetic colour experience can provide the conditions for promoting binocular rivalry, much like stimulus features that induce rivalry in normal vision.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073035"}]}, {"id": "5a43a139966455904c000008", "body": "What is measured through the NOMe-Seq methodology?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28035030", "http://www.ncbi.nlm.nih.gov/pubmed/26484155", "http://www.ncbi.nlm.nih.gov/pubmed/27899623", "http://www.ncbi.nlm.nih.gov/pubmed/22960375", "http://www.ncbi.nlm.nih.gov/pubmed/28653622", "http://www.ncbi.nlm.nih.gov/pubmed/22479200", "http://www.ncbi.nlm.nih.gov/pubmed/21835883", "http://www.ncbi.nlm.nih.gov/pubmed/28222791", "http://www.ncbi.nlm.nih.gov/pubmed/25747664", "http://www.ncbi.nlm.nih.gov/pubmed/28413449"], "snippets": [{"offsetInBeginSection": 317, "offsetInEndSection": 607, "text": "Recently, Methyltransferase Accessibility Protocol for individual templates-Bisulfite Genome Sequencing (MAPit-BGS) and nucleosome occupancy and methylome sequencing (NOMe-seq) have been developed for simultaneously profiling chromatin accessibility and DNA methylation on single molecules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035030"}, {"offsetInBeginSection": 608, "offsetInEndSection": 914, "text": "Therefore, there is a great demand in developing computational methods to identify chromatin accessibility from MAPit-BGS and NOMe-seq.Results: In this article, we present CAME (Chromatin Accessibility and Methylation), a seed-extension based approach that identifies chromatin accessibility from NOMe-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035030"}, {"offsetInBeginSection": 467, "offsetInEndSection": 697, "text": "To address this we used Nucleosome Occupancy and Methylation sequencing (NOMe-seq) to compare the genome-wide DNA methylation and nucleosome occupancy profiles between normal and cancer cell line models of the breast and prostate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484155"}, {"offsetInBeginSection": 698, "offsetInEndSection": 935, "text": "Here we describe the bioinformatic pipeline and methods that we developed for the processing and analysis of the NOMe-seq data published by (Taberlay et al., 2014 [1]) and deposited in the Gene Expression Omnibus with accession GSE57498.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484155"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The binding and contribution of transcription factors (TF) to cell specific gene expression is often deduced from open-chromatin measurements to avoid costly TF ChIP-seq assays.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899623"}, {"offsetInBeginSection": 497, "offsetInEndSection": 521, "text": "DNaseI-seq and NOMe-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899623"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1197, "text": "In our application, gene-based scores computed by TEPIC with one open-chromatin assay nearly reach the quality of several TF ChIP-seq data sets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899623"}, {"offsetInBeginSection": 1198, "offsetInEndSection": 1404, "text": "Finally, these scores correctly predict known transcriptional regulators as illustrated by the application to novel DNaseI-seq and NOMe-seq data for primary human hepatocytes and CD4+ T-cells, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899623"}, {"offsetInBeginSection": 256, "offsetInEndSection": 559, "text": "We have developed a method (NOMe-seq) that uses a GpC methyltransferase (M.CviPI) and next generation sequencing to generate a high resolution footprint of nucleosome positioning genome-wide using less than 1 million cells while retaining endogenous DNA methylation information from the same DNA strand.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960375"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1307, "text": "Importantly, NOMe-seq obtains DNA methylation and nucleosome positioning information from the same DNA molecule, giving the first genome-wide DNA methylation and nucleosome positioning correlation at the single molecule, and thus, single cell level, that can be used to monitor disease progression and response to therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960375"}]}, {"id": "5a43a214966455904c000009", "body": "Is DNA methylation correlated with nucleosome occupancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28413449", "http://www.ncbi.nlm.nih.gov/pubmed/23839233", "http://www.ncbi.nlm.nih.gov/pubmed/23686312", "http://www.ncbi.nlm.nih.gov/pubmed/25437056", "http://www.ncbi.nlm.nih.gov/pubmed/22960375", "http://www.ncbi.nlm.nih.gov/pubmed/24733939", "http://www.ncbi.nlm.nih.gov/pubmed/26484155", "http://www.ncbi.nlm.nih.gov/pubmed/21835883", "http://www.ncbi.nlm.nih.gov/pubmed/20602769", "http://www.ncbi.nlm.nih.gov/pubmed/25578963"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Links between DNA methylation and nucleosome occupancy in the human genome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "BACKGROUND: DNA methylation is an epigenetic modification that is enriched in heterochromatin but depleted at active promoters and enhancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 142, "offsetInEndSection": 270, "text": "However, the debate on whether or not DNA methylation is a reliable indicator of high nucleosome occupancy has not been settled.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 271, "offsetInEndSection": 477, "text": "For example, the methylation levels of DNA flanking CTCF sites are higher in linker DNA than in nucleosomal DNA, while other studies have shown that the nucleosome core is the preferred site of methylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 478, "offsetInEndSection": 745, "text": "In this study, we make progress toward understanding these conflicting phenomena by implementing a bioinformatics approach that combines MNase-seq and NOMe-seq data and by comprehensively profiling DNA methylation and nucleosome occupancy throughout the human genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 745, "offsetInEndSection": 919, "text": "RESULTS: The results demonstrated that increasing methylated CpG density is correlated with nucleosome occupancy in the total genome and within nearly all subgenomic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 920, "offsetInEndSection": 1252, "text": "Features with elevated methylated CpG density such as exons, SINE-Alu sequences, H3K36-trimethylated peaks, and methylated CpG islands are among the highest nucleosome occupied elements in the genome, while some of the lowest occupancies are displayed by unmethylated CpG islands and unmethylated transcription factor binding sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 1253, "offsetInEndSection": 1517, "text": "Additionally, outside of CpG islands, the density of CpGs within nucleosomes was shown to be important for the nucleosomal location of DNA methylation with low CpG frequencies favoring linker methylation and high CpG frequencies favoring core particle methylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 1518, "offsetInEndSection": 1821, "text": "Prominent exceptions to the correlations between methylated CpG density and nucleosome occupancy include CpG islands marked by H3K27me3 and CpG-poor heterochromatin marked by H3K9me3, and these modifications, along with DNA methylation, distinguish the major silencing mechanisms of the human epigenome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 1821, "offsetInEndSection": 2015, "text": "CONCLUSIONS: Thus, the relationship between DNA methylation and nucleosome occupancy is influenced by the density of methylated CpG dinucleotides and by other epigenomic components in chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}]}, {"id": "5a43a581966455904c00000a", "body": "Which are the properties of mammalian GA-sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19043592", "http://www.ncbi.nlm.nih.gov/pubmed/19270754", "http://www.ncbi.nlm.nih.gov/pubmed/22626543", "http://www.ncbi.nlm.nih.gov/pubmed/1463824", "http://www.ncbi.nlm.nih.gov/pubmed/9545369", "http://www.ncbi.nlm.nih.gov/pubmed/19845643", "http://www.ncbi.nlm.nih.gov/pubmed/2558055", "http://www.ncbi.nlm.nih.gov/pubmed/11884146", "http://www.ncbi.nlm.nih.gov/pubmed/10037452", "http://www.ncbi.nlm.nih.gov/pubmed/6301150"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Properties and distribution of pure GA-sequences of mammalian genomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The article describes DNA sequences of mammalian genomes that are longer than 50 bases, but consist exclusively of G's and A's ('pure GA-sequences').", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043592"}, {"offsetInBeginSection": 433, "offsetInEndSection": 534, "text": "With the exception of a small number of poly-A-, poly-G-, poly-GA-, and poly-GAAA-sequences (combined", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Outline of a genome navigation system based on the properties of GA-sequences and their flanks.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Introducing a new method to visualize large stretches of genomic DNA (see Appendix S1) the article reports that most GA-sequences [1] shared chains of tetra-GA-motifs and contained upstream poly(A)-segments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 208, "offsetInEndSection": 364, "text": "Although not integral parts of them, Alu-elements were found immediately upstream of all human and chimpanzee GA-sequences with an upstream poly(A)-segment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 365, "offsetInEndSection": 472, "text": "The article hypothesizes that genome navigation uses these properties of GA-sequences in the following way.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 473, "offsetInEndSection": 701, "text": "(1) Poly(A) binding proteins interact with the upstream poly(A)-segments and arrange adjacent GA-sequences side-by-side ('GA-ribbon'), while folding the intervening DNA sequences between them into loops ('associated DNA-loops').", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 702, "offsetInEndSection": 849, "text": "(2) Genome navigation uses the GA-ribbon as a search path for specific target genes that is up to 730-fold shorter than the full-length chromosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 850, "offsetInEndSection": 1051, "text": "(3) As to the specificity of the search, each molecule of a target protein is assumed to catalyze the formation of specific oligomers from a set of transcription factors that recognize tetra-GA-motifs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}]}, {"id": "5a43a933966455904c00000b", "body": "How may CTCF mediate splicing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26711177", "http://www.ncbi.nlm.nih.gov/pubmed/21964334", "http://www.ncbi.nlm.nih.gov/pubmed/25934638", "http://www.ncbi.nlm.nih.gov/pubmed/27083996", "http://www.ncbi.nlm.nih.gov/pubmed/24657531", "http://www.ncbi.nlm.nih.gov/pubmed/28594324", "http://www.ncbi.nlm.nih.gov/pubmed/28150704", "http://www.ncbi.nlm.nih.gov/pubmed/26938874", "http://www.ncbi.nlm.nih.gov/pubmed/20020479", "http://www.ncbi.nlm.nih.gov/pubmed/26154016"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Intragenic 5-methylcytosine and CTCF mediate opposing effects on pre-mRNA splicing: CTCF promotes inclusion of weak upstream exons through RNA polymerase II pausing, whereas 5-methylcytosine evicts CTCF, leading to exon exclusion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 231, "offsetInEndSection": 324, "text": "However, the mechanisms governing dynamic DNA methylation at CTCF-binding sites were unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 325, "offsetInEndSection": 514, "text": "Here, we reveal the methylcytosine dioxygenases TET1 and TET2 as active regulators of CTCF-mediated alternative splicing through conversion of 5-methylcytosine to its oxidation derivatives.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 515, "offsetInEndSection": 685, "text": "5-hydroxymethylcytosine and 5-carboxylcytosine are enriched at an intragenic CTCF-binding sites in the CD45 model gene and are associated with alternative exon inclusion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 686, "offsetInEndSection": 792, "text": "Reduced TET levels culminate in increased 5-methylcytosine, resulting in CTCF eviction and exon exclusion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 793, "offsetInEndSection": 930, "text": "In vitro analyses establish the oxidation derivatives are not sufficient to stimulate splicing, but efficiently promote CTCF association.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1147, "text": "We further show genomewide that reciprocal exchange of 5-hydroxymethylcytosine and 5-methylcytosine at downstream CTCF-binding sites is a general feature of alternative splicing in na\u00efve and activated CD4(+) T cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334"}, {"offsetInBeginSection": 148, "offsetInEndSection": 285, "text": "Spliceosome assembly occurs co-transcriptionally, raising the possibility that DNA structure may directly influence alternative splicing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334"}]}, {"id": "5a43b2d7966455904c00000c", "body": "Which are the best methods for the prediction of circular RNA (circRNA)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26846540", "http://www.ncbi.nlm.nih.gov/pubmed/29165116", "http://www.ncbi.nlm.nih.gov/pubmed/27493192", "http://www.ncbi.nlm.nih.gov/pubmed/28346469", "http://www.ncbi.nlm.nih.gov/pubmed/27241756", "http://www.ncbi.nlm.nih.gov/pubmed/27097056", "http://www.ncbi.nlm.nih.gov/pubmed/28744405", "http://www.ncbi.nlm.nih.gov/pubmed/28977896", "http://www.ncbi.nlm.nih.gov/pubmed/28082450", "http://www.ncbi.nlm.nih.gov/pubmed/28265491"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "OBJECTIVE: To determine the expression of circular RNA (circRNA) in blood corpuscles of pregnant women before 20\u00a0weeks of pregnancy and to create a new model to identify the performance of circRNA combined with protein factors for the early diagnosis of pre-eclampsia (PE).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}, {"offsetInBeginSection": 613, "offsetInEndSection": 782, "text": "METHODS: The samples were analysed using a human circRNA microarray in the discovery phase, then the circRNA and the plasma protein factor endoglin (ENG) were validated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}, {"offsetInBeginSection": 783, "offsetInEndSection": 878, "text": "Finally we combined ENG with circRNA to create a new early prediction model for PE.MAIN OUTCOME", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}, {"offsetInBeginSection": 879, "offsetInEndSection": 928, "text": "MEASURES: Early changes of circRNA and ENG in PE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1299, "text": "The performance of each of these factors may be strengthened when plasma proteins are used in combination with circRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}, {"offsetInBeginSection": 109, "offsetInEndSection": 268, "text": "Recently, circular RNA (circRNA), a class of endogenous non-protein coding RNAs that contain a circular loop, was found to exhibit multiple biological effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29165116"}, {"offsetInBeginSection": 578, "offsetInEndSection": 804, "text": "Microarray screening revealed 107 up-regulated and 83 down-regulated circRNAs, among which top 30 circRNAs with the highest fold changes were chosen for further analysis, with 5 microRNAs binding sites listed for each circRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29165116"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "MOTIVATION: Recent studies reveal an important role of non-coding circular RNA (circRNA) in the control of cellular processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493192"}, {"offsetInBeginSection": 335, "offsetInEndSection": 765, "text": "RESULTS: A circRNA prediction software for plants (termed PcircRNA_finder) was developed that is more sensitive in detecting circRNAs than other frequently used programs (such as find_circ and CIRCexplorer), Based on analysis of simulated and real rRNA-/RNAase R RNA-Seq data from Arabidopsis thaliana and rice PcircRNA_finder provides a more comprehensive sensitive, precise prediction method for plants circRNAs.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493192"}, {"offsetInBeginSection": 832, "offsetInEndSection": 942, "text": "CONTACT: fanlj@zju.edu.cnSupplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493192"}]}, {"id": "5a468785966455904c00000d", "body": "Does RNA polymerase II have RNA cleavage activity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1371280", "http://www.ncbi.nlm.nih.gov/pubmed/1379232", "http://www.ncbi.nlm.nih.gov/pubmed/8312968", "http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/9869639", "http://www.ncbi.nlm.nih.gov/pubmed/8090778", "http://www.ncbi.nlm.nih.gov/pubmed/7503982", "http://www.ncbi.nlm.nih.gov/pubmed/12692127", "http://www.ncbi.nlm.nih.gov/pubmed/9037112", "http://www.ncbi.nlm.nih.gov/pubmed/25764335"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Elongation factor-dependent transcript shortening by template-engaged RNA polymerase II.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280"}, {"offsetInBeginSection": 164, "offsetInEndSection": 263, "text": "For DNA polymerases this activity is an important factor in establishing fidelity in DNA synthesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280"}, {"offsetInBeginSection": 264, "offsetInEndSection": 411, "text": "This report describes a novel in vitro activity of RNA polymerase II whereby it cleaves an RNA chain contained within an active elongation complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280"}, {"offsetInBeginSection": 544, "offsetInEndSection": 692, "text": "The new 3'-end revealed by this cleavage remains associated with an active elongation complex and is capable of being extended by RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280"}, {"offsetInBeginSection": 693, "offsetInEndSection": 845, "text": "Nascent RNA cleavage is evident after removal of free nucleotides and is dependent upon a divalent metal cation and transcription elongation factor SII.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280"}, {"offsetInBeginSection": 947, "offsetInEndSection": 1075, "text": "It is also possible that the transcript cleavage activity of RNA polymerase II represents a proofreading function of the enzyme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "The RNA polymerase II elongation complex.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232"}, {"offsetInBeginSection": 42, "offsetInEndSection": 114, "text": "Factor-dependent transcription elongation involves nascent RNA cleavage.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232"}, {"offsetInBeginSection": 108, "offsetInEndSection": 321, "text": "SII is an RNA polymerase II-binding protein that stimulates transcription elongation and also activates nascent transcript cleavage by RNA polymerase II in elongation complexes in vitro (Reines, D. (1992) J. Biol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232"}, {"offsetInBeginSection": 345, "offsetInEndSection": 482, "text": "Here we show that SII-dependent in vitro transcription through an arrest site in a human gene is preceded by nascent transcript cleavage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232"}]}, {"id": "5a4df811966455904c00000e", "body": "Which RNA polymerase II subunit carries RNA cleavage activity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9869639", "http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/21454497", "http://www.ncbi.nlm.nih.gov/pubmed/22396529", "http://www.ncbi.nlm.nih.gov/pubmed/8090778", "http://www.ncbi.nlm.nih.gov/pubmed/23847103", "http://www.ncbi.nlm.nih.gov/pubmed/7678416", "http://www.ncbi.nlm.nih.gov/pubmed/9037112", "http://www.ncbi.nlm.nih.gov/pubmed/9150890", "http://www.ncbi.nlm.nih.gov/pubmed/10777522"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The RNA cleavage activity of RNA polymerase III is mediated by an essential TFIIS-like subunit and is important for transcription termination.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Budding yeast RNA polymerase III (Pol III) contains a small, essential subunit, named C11, that is conserved in humans and shows a strong homology to TFIIS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 430, "offsetInEndSection": 519, "text": "Remarkably, Pol III Delta lacked the intrinsic RNA cleavage activity of complete Pol III.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 520, "offsetInEndSection": 623, "text": "In vitro reconstitution experiments demonstrated that Pol III RNA cleavage activity is mediated by C11.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 624, "offsetInEndSection": 752, "text": "Mutagenesis in C11 of two conserved residues, which are critical for the TFIIS-dependent cleavage activity of Pol II, is lethal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 866, "offsetInEndSection": 1088, "text": "We propose that C11 allows the enzyme to switch between an RNA elongation and RNA cleavage mode and that the essential role of the Pol III RNA cleavage activity is to remove the kinetic barriers to the termination process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 1089, "offsetInEndSection": 1274, "text": "The integration of TFIIS function into a specific Pol III subunit may stem from the opposite requirements of Pol III and Pol II in terms of transcript length and termination efficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Stimulation of RNA polymerase II transcript cleavage activity contributes to maintain transcriptional fidelity in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The transcription elongation factor S-II, also designated TFIIS, stimulates the nascent transcript cleavage activity intrinsic to RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 149, "offsetInEndSection": 244, "text": "Rpb9, a small subunit of RNA polymerase II, enhances the cleavage stimulation activity of S-II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}]}, {"id": "5a4e1882966455904c00000f", "body": "Is there a sequence bias in MNase digestion patterns?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21206756", "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "http://www.ncbi.nlm.nih.gov/pubmed/22559821", "http://www.ncbi.nlm.nih.gov/pubmed/23458408", "http://www.ncbi.nlm.nih.gov/pubmed/29073207", "http://www.ncbi.nlm.nih.gov/pubmed/22310051", "http://www.ncbi.nlm.nih.gov/pubmed/27185945", "http://www.ncbi.nlm.nih.gov/pubmed/22183607", "http://www.ncbi.nlm.nih.gov/pubmed/1988681", "http://www.ncbi.nlm.nih.gov/pubmed/29052192"], "snippets": [{"offsetInBeginSection": 144, "offsetInEndSection": 259, "text": "A common experimental procedure to determine nucleosome positions involves the use of micrococcal nuclease (MNase).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206756"}, {"offsetInBeginSection": 260, "offsetInEndSection": 409, "text": "Here, we show that the cutting preference of MNase in combination with size selection generates a sequence-dependent bias in the resulting fragments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206756"}, {"offsetInBeginSection": 658, "offsetInEndSection": 827, "text": "More generally, our results show that data generated after MNase digestion of chromatin requires a matched control experiment in order to determine nucleosome positions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206756"}, {"offsetInBeginSection": 116, "offsetInEndSection": 330, "text": "Here we describe methidiumpropyl-EDTA sequencing (MPE-seq), a method for the genome-wide characterization of chromatin that involves the digestion of nuclei withMPE-Fe(II) followed by massively parallel sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}, {"offsetInBeginSection": 331, "offsetInEndSection": 435, "text": "Like micrococcal nuclease (MNase), MPE-Fe(II) preferentially cleaves the linker DNA between nucleosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}, {"offsetInBeginSection": 436, "offsetInEndSection": 536, "text": "However, there are differences in the cleavage of nuclear chromatin by MPE-Fe(II) relative to MNase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}, {"offsetInBeginSection": 1127, "offsetInEndSection": 1211, "text": "In addition, unlike MNase, MPE-Fe(II) cleaves nuclear DNA with little sequence bias.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1339, "text": "In this regard, we found that DNA sequences at RNA splice sites are hypersensitive to digestion by MNase but not by MPE-Fe(II).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1600, "text": "These findings collectively indicate that MPE-seq provides a unique and straightforward means for the genome-wide analysis of chromatin structure with minimal DNA sequence bias.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}, {"offsetInBeginSection": 1601, "offsetInEndSection": 1792, "text": "In particular, the combined use of MPE-seq and MNase-seq enables the identification of noncanonical chromatin structures that are likely to be important for the regulation of gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409"}]}, {"id": "5a4e50b242878bf97d000001", "body": "Which topoisomerase is essential in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10497270", "http://www.ncbi.nlm.nih.gov/pubmed/2842762", "http://www.ncbi.nlm.nih.gov/pubmed/1332607", "http://www.ncbi.nlm.nih.gov/pubmed/11350066", "http://www.ncbi.nlm.nih.gov/pubmed/11353773", "http://www.ncbi.nlm.nih.gov/pubmed/10075939", "http://www.ncbi.nlm.nih.gov/pubmed/2989818", "http://www.ncbi.nlm.nih.gov/pubmed/2840207", "http://www.ncbi.nlm.nih.gov/pubmed/6323017", "http://www.ncbi.nlm.nih.gov/pubmed/18570880"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 117, "offsetInEndSection": 253, "text": "While the functions of topoisomerases I and II in eukaryotes are well established, the role of topoisomerase III remains poorly defined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 254, "offsetInEndSection": 465, "text": "We have identified a gene in the fission yeast Schizosaccharomyces pombe, designated top3 (+), which shows significant sequence similarity to genes encoding topoisomerase III enzymes in other eukaryotic species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 466, "offsetInEndSection": 617, "text": "In common with murine TOP3 alpha, but in contrast to Saccharomyces cerevisiae TOP3, the S.pombe top3 (+)gene is essential for long-term cell viability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1222, "text": "Consistent with the existence of an intimate association (originally identified in S.cerevisiae ) between topoisomerase III and DNA helicases of the RecQ family, deletion of the rqh1 (+)gene encoding the only known RecQ helicase in S.pombe suppresses lethality in top3 mutants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 1223, "offsetInEndSection": 1466, "text": "This conservation of genetic interaction between two widely diverged yeasts suggests that the RecQ family helicases encoded by the Bloom's and Werner's syndrome genes are likely to act in concert with topoisomerase III isozymes in human cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1695, "text": "Our data are consistent with a model in which the association of a RecQ helicase and topoisomerase III is important for facilitating decatenation of late stage replicons to permit faithful chromosome segregation during anaphase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Functional expression of a Drosophila gene in yeast: genetic complementation of DNA topoisomerase II.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2842762"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "Since DNA topoisomerase II (EC 5.99.1.3) is an essential enzyme in yeast, heterologous topoisomerase II gene expression in yeast cells can provide a system for analyzing the structure and function of topoisomerase II genes from other species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2842762"}, {"offsetInBeginSection": 243, "offsetInEndSection": 449, "text": "A series of yeast expression plasmids was constructed in which segments of the cDNA sequences encoding Drosophila DNA topoisomerase II were inserted under the transcriptional control of yeast GAL1 promoter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2842762"}]}, {"id": "5a82fc89faa1ab7d2e000028", "body": "Which yeast nucleosomes are preferentially marked by H2A.Z?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24613878", "http://www.ncbi.nlm.nih.gov/pubmed/18268003", "http://www.ncbi.nlm.nih.gov/pubmed/17671089", "http://www.ncbi.nlm.nih.gov/pubmed/21266479", "http://www.ncbi.nlm.nih.gov/pubmed/21187892", "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "http://www.ncbi.nlm.nih.gov/pubmed/22393239", "http://www.ncbi.nlm.nih.gov/pubmed/16543223", "http://www.ncbi.nlm.nih.gov/pubmed/16248679", "http://www.ncbi.nlm.nih.gov/pubmed/26974124"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Anp32e, a higher eukaryotic histone chaperone directs preferential recognition for H2A.Z.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "H2A.Z is a highly conserved histone variant in all species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 60, "offsetInEndSection": 203, "text": "The chromatin deposition of H2A.Z is specifically catalyzed by the yeast chromatin remodeling complex SWR1 and its mammalian counterpart SRCAP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 204, "offsetInEndSection": 311, "text": "However, the mechanism by which H2A.Z is preferentially recognized by non-histone proteins remains elusive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 312, "offsetInEndSection": 401, "text": "Here we identified Anp32e, a novel higher eukaryote-specific histone chaperone for H2A.Z.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 402, "offsetInEndSection": 574, "text": "Anp32e preferentially associates with H2A.Z-H2B dimers rather than H2A-H2B dimers in vitro and in vivo and dissociates non-nucleosomal aggregates formed by DNA and H2A-H2B.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 575, "offsetInEndSection": 688, "text": "We determined the crystal structure of the Anp32e chaperone domain (186-232) in complex with the H2A.Z-H2B dimer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 689, "offsetInEndSection": 911, "text": "In this structure, the region containing Anp32e residues 214-224, which is absent in other Anp32 family proteins, specifically interacts with the extended H2A.Z \u03b1C helix, which exhibits an unexpected conformational change.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1004, "text": "Genome-wide profiling of Anp32e revealed a remarkable co-occupancy between Anp32e and H2A.Z.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 1005, "offsetInEndSection": 1191, "text": "Cells overexpressing Anp32e displayed a strong global H2A.Z loss at the +1 nucleosomes, whereas cells depleted of Anp32e displayed a moderate global H2A.Z increase at the +1 nucleosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}]}, {"id": "5a855585faa1ab7d2e000029", "body": "What is the origin of XUT transcripts in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26805575", "http://www.ncbi.nlm.nih.gov/pubmed/21697827", "http://www.ncbi.nlm.nih.gov/pubmed/29114019", "http://www.ncbi.nlm.nih.gov/pubmed/20962350", "http://www.ncbi.nlm.nih.gov/pubmed/26184436", "http://www.ncbi.nlm.nih.gov/pubmed/28557013", "http://www.ncbi.nlm.nih.gov/pubmed/21421781", "http://www.ncbi.nlm.nih.gov/pubmed/28981695", "http://www.ncbi.nlm.nih.gov/pubmed/6270142", "http://www.ncbi.nlm.nih.gov/pubmed/12844360"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Nonsense-Mediated Decay Restricts LncRNA Levels in Yeast Unless Blocked by Double-Stranded RNA Structure.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Antisense long non-coding (aslnc)RNAs represent a\u00a0substantial part of eukaryotic transcriptomes that are, in yeast, controlled by the Xrn1 exonuclease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 152, "offsetInEndSection": 285, "text": "Nonsense-Mediated Decay (NMD) destabilizes the Xrn1-sensitive aslncRNAs (XUT), but what determines their sensitivity remains unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 286, "offsetInEndSection": 412, "text": "We report that 3' single-stranded (3'-ss) extension mediates XUTs degradation by NMD, assisted by the Mtr4 and Dbp2 helicases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 413, "offsetInEndSection": 588, "text": "Single-gene investigation, genome-wide RNA analyses, and double-stranded (ds)RNA mapping revealed that 3'-ss extensions discriminate the NMD-targeted XUTs from stable lncRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 589, "offsetInEndSection": 670, "text": "Ribosome profiling showed that XUT are translated, locking them for NMD activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 671, "offsetInEndSection": 810, "text": "Interestingly, mutants of the Mtr4 and Dbp2 helicases accumulated XUTs, suggesting that dsRNA unwinding is a\u00a0critical step for degradation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 909, "offsetInEndSection": 1033, "text": "Our results indicate that aslncRNAs form dsRNA that are only translated\u00a0and targeted to NMD if dissociated by Mtr4 and Dbp2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 1034, "offsetInEndSection": 1127, "text": "We propose that NMD buffers genome expression by discarding pervasive regulatory transcripts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "XUTs are a class of Xrn1-sensitive antisense regulatory non-coding RNA in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697827"}]}, {"id": "5a859184faa1ab7d2e000031", "body": "How are cryptic unstable transcripts (CUTs) defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19169244", "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "http://www.ncbi.nlm.nih.gov/pubmed/16973437", "http://www.ncbi.nlm.nih.gov/pubmed/27113450", "http://www.ncbi.nlm.nih.gov/pubmed/21863483", "http://www.ncbi.nlm.nih.gov/pubmed/18022358", "http://www.ncbi.nlm.nih.gov/pubmed/22567365", "http://www.ncbi.nlm.nih.gov/pubmed/18775327", "http://www.ncbi.nlm.nih.gov/pubmed/18660821", "http://www.ncbi.nlm.nih.gov/pubmed/18316478"], "snippets": [{"offsetInBeginSection": 171, "offsetInEndSection": 313, "text": "Cryptic unstable transcripts (CUTs) were recently described as a principal class of RNA polymerase II transcripts in Saccharomyces cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 440, "offsetInEndSection": 603, "text": "Although CUT degradation mechanisms have been analysed in detail, the genome-wide distribution at the nucleotide resolution and the prevalence of CUTs are unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 604, "offsetInEndSection": 787, "text": "Here we report the first high-resolution genomic map of CUTs in yeast, revealing a class of potentially functional CUTs and the intrinsic bidirectional nature of eukaryotic promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 788, "offsetInEndSection": 932, "text": "An RNA fraction highly enriched in CUTs was analysed by a 3' Long-SAGE (serial analysis of gene expression) approach adapted to deep sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 933, "offsetInEndSection": 1126, "text": "The resulting detailed genomic map of CUTs revealed that they derive from extremely widespread and very well defined transcription units and do not result from unspecific transcriptional noise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 1127, "offsetInEndSection": 1280, "text": "Moreover, the transcription of CUTs predominantly arises within nucleosome-free regions, most of which correspond to promoter regions of bona fide genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 1281, "offsetInEndSection": 1358, "text": "Some of the CUTs start upstream from messenger RNAs and overlap their 5' end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1607, "text": "Our data reveal numerous new CUTs with such a potential regulatory role.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 1608, "offsetInEndSection": 1835, "text": "However, most of the identified CUTs corresponded to transcripts divergent from the promoter regions of genes, indicating that they represent by-products of divergent transcription occurring at many and possibly most promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 1836, "offsetInEndSection": 2085, "text": "Eukaryotic promoter regions are thus intrinsically bidirectional, a fundamental property that escaped previous analyses because in most cases divergent transcription generates short-lived unstable transcripts present at very low steady-state levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}]}]}